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Abstract 
The aims of the PhD were to synthesize deuterium labelled epicatechin in a 
microreactor, discover if theaflavin and epicatechin possess antibacterial action 
against important hospital pathogens and to determine if synergy exists 
between polyphenols and between polyphenol and current antibiotics. Other 
aims were to determine the minimum inhibitory concentrations of theaflavin and 
a theaflavin:epicatechin combination against the bacteria Stenotrophomonas 
maltophilia, to synthesize theaflavin and deuterium labelled theaflavin in a 
microreactor and to link the continuous flow process to antimicrobial testing for 
future mode of action analysis.  
A 2-step microreactor synthesis using in a T-shaped microreactor successfully 
produced deuterium labelled epicatechin in position 8. Mass spectrometry and 
H-NMR confirmed deuterium labelled epicatechin had been produced. The 2-
step synthesis produced a yield in excess of 90%. A 4-step micro reactor 
synthesis of deuterium labelled epicatechin, was found to be unsuccessful after 
step 2 of the synthesis. A 1-step method for the microreactor production of 
planar epicatechin was also shown to be unsuccessful in a microreactor. 
Antimicrobial testing of theaflavin, epicatechin and a 2:1 combination of 
theaflavin and epicatechin was performed against 4 clinical isolates of MRSA, 6 
clinical isolates of Acinetobacter baumannii and 6 clinical isolates of 
Stenotrophomonas maltophilia. Results from the disc diffusion assay confirmed 
that epicatechin produced no antibacterial action and theaflavin produced 
strong antibacterial action. The combination of theaflavin and epicatechin 
produced higher antibacterial activity than theaflavin alone indicating synergy 
between the two polyphenols. Minimum inhibitory concentrations (MICs) of 
theaflavin and the theaflavin:epicatechin combination (2:1) were determined 
against 9 clinical isolates and one control isolate of Stenotrophomonas 
maltophilia using a microtiter assay. Results from the microtiter assay used 
indicated that the MIC for theaflavin was between 400 and 800 µg/mL. The MIC 
for the theaflavin:epicatechin combination (2:1) was between 200 and 400 
µg/mL.  
A 1-step microreactor synthesis of theaflavin from epicatechin and 
epigallocatechin using extracted polyphenol oxidase was shown to be 
successful, producing high yields. Using the same methodology, the synthesis 
of deuterium labelled theaflavin was undertaken using epigallocatechin and the 
deuterium labelled epicatechin. However, this reaction was shown to be 
unsuccessful. The antibacterial action of microreactor synthesized theaflavin 
against Acinetobacter baumannii in a continuous flow process was investigated. 
Bacterial viability was tested using the resazurin indicator method. No viable 
cells were observed from bacterial samples exposed to ≥ 4 hours of the 
continuous flow of theaflavin products. This indicated that the theaflavin 
produced antibacterial action after this time of exposure. At exposure times less 
than 4 hours, viable cells were detected. 
	  
	  
v	  
Table of contents 
 
Declaration            I 
Acknowledgements           ii 
Dedication            iii 
Abstract            iv 
Contents            v 
Table of figures           xii 
List of tables            xviii 
List of equations           xx 
Publications            xxi 
Abbreviations           xxii 
 
Chapter 1. Introduction to polyphenols, synthesis and 
microfluidics                   1 
1.1 Introduction                   2 
1.1.1 Tea and its contents            3 
1.1.2 Bioavailability and stability of polyphenols               8 
1.1.3 Benefits of tea polyphenols         10 
1.1.3.1 General benefits of polyphenols            10 
1.1.3.2 Polyphenols as antioxidants            10 
1.1.3.3 Antibacterial activity of polyphenols and infection          14 
1.1.4 Stable isotopic Labelling              18 
1.1.5 Microfluidics                20 
1.1.5.1 Flow of fluids in a microfluidic device           20 
1.1.5.2 Manufacturing microfluidic devices          24 
1.1.5.3 Advantages and uses of microfluidics           25 
1.2 General aims                 26 
1.3 References                 27 
 
	  
	  
vi	  
 
Chapter 2. Organic synthesis of deuterium labelled  
(-)-epicatechin in a microreactor         44 
 
2.1 Introduction                 45 
2.1.1 Synthesis of deuterium labelled epicatechin and       45 
theaflavin  
2.1.2 Synthesis of modified catechins               47 
2.2 Aims                  49 
2.3 Materials and methods             50 
2.3.1 Methods for testing the stability of EC           50 
2.3.1.1 Production of EC solution             50 
2.3.1.2 Analysis of EC solutions            50 
2.3.2 Synthesis of deuterium labelled epicatechin – Method 1           50 
2.3.2.1 Microfluidic reactor design and preparation          51 
2.3.2.2 Production and optimisation of 3,3’,4’,5,7-O        52 
-pentaacetyl-(-)-epicatechin in a microreactor 
 
2.3.2.3 Bromination of 3,3’,4’,5,7-O-              53 
pentaacetyl-(-)-epicatechin in a microreactor 
2.3.2.4 Substitution of bromine with deuterium       54 
2.3.3 Microreactor synthesis of deuterium labelled         55 
epicatechin – Method 2 
2.3.3.1 Microreactor synthesis of 6-iodoepicatechin          55 
2.3.3.2 Microreactor synthesis of deuterated epicatechin          56 
2.3.4 Microreactor synthesis of double deuterium        57 
labelled epicatechin 
2.3.4.1 Microreactor synthesis of double iodinated           57 
epicatechin 
2.3.4.2 Microreactor synthesis of double deuterated      57 
epicatechin 
2.3.5 Microreactor synthesis of deuterium labelled epicatechin      58 
 – Method 3 
2.3.5.1 Microreactor synthesis of tert-         59 
butyldimethylsilyl protected epicatechin  
 
 
	  
	  
vii	  
 
2.3.5.2 Microreactor synthesis of 3,3’,4’,7-O-       60 
tetraacetyl-(-)-epicatechin  
2.3.5.3 Microreactor synthesis of oxidised 3,3’,4’,7- O      61 
-tetraaacetyl-(-)-epicatechin 
2.3.6 Synthesis of planar epicatechin in a microreactor           62 
2.3.6.1 Microreactor synthesis of planar epicatechin      62 
– Method 1 
2.3.6.2 Microreactor synthesis of planar         63 
epicatechin – Method 2 
2.4 Results and discussion             64 
2.4.1 Results for the stability of EC              64 
2.4.2 Results for microreactor synthesis of labelled of        66 
epicatechin - Method 1 
2.4.2.1 Optimization and production 3,3’,4’,5,7-O-       68 
pentaacetyl-(-)-epicatechin in a microreactor 
2.4.2.2 Bromination of 3,3’,4’,5,7-O-pentaacetyl-(-)-         74 
epicatechin in a microreactor 
2.4.2.3 Substitution reaction          75 
2.4.3 Results for microreactor synthesis of deuterium labelled       75 
epicatechin – Method 2 
2.4.3.1 Iodination of epicatechin in a microreactor              76 
2.4.3.2 Deuteration of 6-iodoepicatechin in a microreactor           77 
2.4.4 Results for Double deuteration of epicatechin           78 
2.4.4.1 Double iodination of epicatechin           79 
2.4.4.2 Deuteration of 6,8 –iodoepicatechin               80 
2.4.5 Results for the synthesis of deuterium labelled        81 
epicatechin – Methodology 3  
2.4.5.1 Results for tert-butyldimethylsilyl protection      82 
2.4.5.2 Results for the production of 3,3’,4’,7-O-         82 
tetraacetyl-(-)-epicatechin 
2.4.5.3 Results for Dess-Martin reaction        83 
2.4.6.1 Results for microreactor synthesis of        84 
planar epicatechin - Method 1 
 
 
	  
	  
viii	  
 
2.4.6.2 Results for the microreactor synthesis of        85 
planar epicatechin - Method 2 
2.5 Conclusions             86 
2.6 References             87 
 
Chapter 3. Antimicrobial and synergistic effects of  
tea polyphenols against problematic hospital pathogens    89 
 
3.1 Introduction              90 
3.1.1 Hospital pathogens, antibiotics and resistance       90 
3.1.1.1 Antibiotic groups          90 
3.1.1.2 Hospital pathogens and resistance            93 
3.1.2 The use of natural compounds in antimicrobial drug       97 
discovery 
3.1.3 Susceptibility testing and determining minimum        98 
inhibitionary concentrations (MICs) 
3.2 Aims               99 
3.3 Preliminary antimicrobial testing against MRSA, VRE and      99 
A. baumannii 
3.3.1 Microbiology methodologies          99 
3.3.1.1 Preparing stock cultures         99 
3.3.1.2 Method of inoculating ISO plates from      100 
stock cultures 
3.3.1.3 Preparation of polyphenol stock solutions            100 
3.3.1.4 Production of impregnated susceptibility discs    101 
3.3.1.5 Antibiotic susceptibility testing      101 
3.3.1.6 Susceptibility testing with tea compounds       102 
3.4 Results and discussion for preliminary antibacterial testing       103 
3.4.1 Antibiotic susceptibility testing       103 
3.4.2 Theaflavin, epicatechin and epigallocatechin gallate     107 
susceptibility testing 
3.5 Antimicrobial and synergistic testing against hospital isolates    123 
of MRSA, Acinetobacter baumannii and Stenotrophomonas 
maltophilia 
	  
	  
ix	  
 
3.5.1 Clinical isolates           123 
3.5.2 Tea polyphenols          123 
3.5.3 Culture media, antibiotics and other materials     123 
3.5.4 Methodologies for hospital isolate testing      124 
3.5.4.1 Microbiology methodologies         124 
3.5.4.2 Gram stains         124 
3.5.4.3 Stock culture preparation       124 
3.5.4.4 Method inoculating ISO plates from stock        125 
cultures  
3.5.4.5 Preparation of polyphenol stock solutions            125 
3.5.4.6 Production of impregnated susceptibility discs      125 
3.5.5 Determination of minimum inhibitory concentrations (MICs)     126 
3.5.6 Production of polyphenol impregnated         128 
antibiotic susceptibility discs 
3.5.7 Statistical analysis           130 
3.6 Results and discussion for hospital isolates       131 
3.6.1 Gram staining results         131 
3.6.2 Results for antimicrobial and polyphenol synergy testing     133 
3.6.3 Results for the minimum inhibitory concentration      150   
testing against clinical isolates of S. maltophilia 
3.6.4 Results and discussion for antibiotic synergy testing      151 
3.7 Conclusions           180 
3.8 References             182	  
 
Chapter 4. Production of theaflavin in a microreactor and  
the road to integrated antimicrobial testing     191 
 
4.1 Introduction           192 
4.1.1 Synthesis of theaflavin           192 
4.1.2 Synthesis of deuterium labelled theaflavin      195 
4.1.3 Enzymatic synthesis in a microreactor       196 
 
	  
	  
x	  
4.1.4 Antibacterial testing and monitoring cell viability        197 
and metabolites 
4.1.4.1 Polyphenol metabolites       197 
4.1.4.2 Antibacterial testing         198 
4.1.5 Monitoring cell viability         199 
4.1.6 Links between synthesis and antimicrobial testing       200 
4.2 Aims             202 
4.3 Methods            202 
4.3.1 Method 1 for the microreactor synthesis of theaflavin       202 
4.3.1.1 Preparation of substrates       202 
4.3.1.2 Tea leaf catalyst preparation       202 
4.3.1.3 Microfluidic reactor design and preparation     203 
4.3.1.4 Experimental setup        204 
4.3.2 Method 2 for the microreactor synthesis of theaflavin    205 
4.3.2.1 Preparation of substrates       205 
4.3.2.2 Crude polyphenol oxidase preparation     205 
4.3.2.3 Experimental setup for method 2       205 
4.3.3 The microreactor synthesis of deuterium labelled theaflavin    206 
4.3.4 Method for linking microreactor synthesis products        207 
to a method for antibacterial testing  
4.3.4.1 Experimental setup        207 
4.3.4.2 Cell viability testing        209 
4.4 Results and discussion          209 
4.4.1 Results of method 1 for the microreactor synthesis of    209 
theaflavin  
4.4.2 Results method 2 for the microreactor synthesis of  theaflavin   210 
4.4.3 Results for the microreactor synthesis of d-labelled theaflavin   212 
4.4.4 Results for monitoring bacterial metabolites from deuterated   213 
theaflavin 
4.4.5 Results for linked microreactor theaflavin synthesis-cell    213 
viability testing 
4.5 Conclusions           219 
	  
	  
xi	  
4.6 References           220	  
 
Chapter 5. Overall conclusions and future research    225 
 
5.1 Overall PhD conclusions         226 
5.2 Future work           227 
 
  
	  
	  
xii	  
Table of figures 
 
Figure 1. The leaves and white flowers of Camellia sinensis.         2 
 
Figure 2. Methods of tea processing (teazonline, 2011)         3 
 
Figure 3. The change in colour of tea leaves which relates to         5 
flavonoid content.     
        
Figure 4. The structure of the black tea flavanoids, theaflavin,         6 
theaflavin-3’-monogallate and theaflavin-3-3’-digallate and their  
molecular weights 
 
Figure 5. The structures of the green tea catechins, epigallocatechin        7 
gallate, epicatechin, epigallocatechin, epicatechin gallate, catechin  
and their molecular weights 
 
Figure 6. An overview of the environmental and biological causes of      11 
free radical formation (Lifeinnovate, 2008). 
 
Figure 7. An example of a comet assay (Rowland, 2008)       12 
 
Figure 8. New antimicrobial agents between 1983 and 2002        15 
(Spellberg et al., 2004) 
 
Figure 9. The differences of laminar and turbulent flow in a microfluidic      21 
device (Cambridge, 2011) 
 
Figure 10. A representation of diffusion and the movement of particles     22 
from a high to a low concentration (Tabeling, 2005) 
 
Figure 11. The Taylor dispersion problem (Bruus, 2008).        24 
 
Figure 12. The steps involved in the fabrication of a glass microreactor      25 
taken from Fletcher et al., (2002). 
 
Figure 13. Reaction scheme adapted from Kohri et al., (2001) by Peng      46 
and Yao (2009) showing steps for 2 synthetic routes of producing a  
deuterium labelled epicatechin and theaflavin in batch reactions. 
 
Figure 14. Positions of deuterium labelling in catechin        47 
(Kiehlmann et al., 1988) 
 
Figure 15. Showing planar epicatechin and planar catechin       48 
 
Figure 16. Microreactor design used in the multi step synthesis      51 
 
Figure 17. The reaction scheme for the production of 3,3’,4’,5,7-O-         52 
pentaacetyl-(-)-epicatechin 
 
Figure 18. The reaction scheme for the bromination of 3,3’,4’,5,7-O-           53 
pentaacetyl-(-)-epicatechin with NBS 
	  
	  
xiii	  
Figure 19. The reaction scheme for the substitution of bromine using      54 
NaBD4 
 
Figure 20. The reaction scheme for the iodination of epicatechin      55 
 
Figure 21. Showing the deuteration of 6-iodoepicatechin        56 
 
Figure 22. The reaction scheme for the double iodination of epicatechin     57 
 
Figure 23. The reaction scheme for the double deuteration of       58 
6,8-iodoepicatechin 
 
Figure 24. Method 3 for deuterating epicatechin        59 
 
Figure 25. The reaction scheme for the addition of tert-       60 
butyldimethylsilyl  protecting groups 
 
Figure 26. The reaction scheme for the production of 3,3’,4’,7-O-      61 
tetraacetyl-(-)-epicatechin 
 
Figure 27. Showing the reaction scheme for the Dess-Martin reaction     62 
 
Figure 28. Showing the reaction scheme for method 1 of planar       63 
epicatechin production.  
 
Figure 29. Showing the reaction scheme for method 2 of planar       64 
epicatechin production.  
 
Figure 30. Colour change of epicatechin solutions over time       65 
Figure 31. Graph to show the reduction in epicatechin concentration               66 
over time 
Figure 32. Reaction scheme adapted from Kohri et al., (2001) by Peng      67 
and Yao (2009) showing steps for 2 synthetic routes of producing a  
deuterium labelled epicatechin and theaflavin in batch reactions. 
 
Figure 33. Graph showing the correlation between flow rate and yield      73 
obtained for the synthesis of 3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin 
 
Figure 34. 6-bromo and 8-bromo 3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin      74 
 
Figure 35. Reaction scheme for method 2 of the microreactor       76 
synthesis of deuterium labelled epicatechin. 
 
Figure 36. Reaction scheme for the microreactor synthesis of double      79 
deuterium labelled epicatechin. 
 
Figure 37. Method 3 for the microreactor synthesis of deuterated       82 
epicatechin  
 
 
 
	  
	  
xiv	  
Figure 38. The reaction scheme for method 1 of the microreactor       84 
synthesis of planar epicatechin. 
 
Figure 39. Reaction scheme for method 2 of planar epicatechin production     85 
 
Figure 40. Distribution of Costs incurred from resistant infections      93 
(Rowland et al., 1999) 
 
Figure 41. A scanning electron micrograph of Acinetobacter        94 
baumannii magnified 13331x (CDC, 2004) 
 
Figure 42. A scanning electron micrograph of MRSA magnified 9560x      95 
(CDC, 2005) 
 
Figure 43. A Scanning electron micrograph of VRE magnified 12000x      96 
(CDC, 2005) 
 
Figure 44. A Scanning electron micrograph of S. maltophilia        97 
(Nangia et al., 2009) 
 
Figure 45.  Antibiotic disc susceptibility testing for A. baumannii on  
ISO-agar.            104 
Figure 46. Antibiotic disc susceptibility testing for MRSA on ISO-agar.   105 
Figure 47. Antibiotic disc susceptibility testing for VRE on ISO-agar              106 
 
Figure 48. A. baumannii susceptibility testing with epicatechin (EC).              108 
Figure 49. MRSA susceptibility testing with epicatechin (EC).               109 
Figure 50. VRE susceptibility testing with epicatechin.      110 
 
Figure 51. A. baumannii susceptibility testing with epigallocatechin gallate.   112 
 
Figure 52. MRSA susceptibility testing with epigallocatechin gallate.    113 
 
Figure 53 Showing VRE susceptibility testing with epigallocatechin gallate.   114 
 
Figure 53. A. baumannii susceptibility testing with theaflavin.     116 
 
Figure 54. VRE susceptibility testing with theaflavin.      117 
 
Figure 55. A. baumannii susceptibility testing with mixed theaflavins.   119 
 
Figure 56. MRSA susceptibility testing with mixed theaflavins.    120 
 
Figure 57. VRE susceptibility testing with mixed theaflavins.     121 
 
Figure 58. Organisation of a 96 well cell culture plate for MIC testing   127 
 
Figure 59. An example of a gram stain undertaken for a MRSA clinical   131 
isolate 
	  
	  
xv	  
Figure 60. An example of a gram stain undertaken for a clinical     132 
isolate of A. baumannii  
 
Figure 61. An example of a gram stain undertaken for a clinical     132 
isolate of S. maltophilia  
 
Figure 62. Figure 62. Mean zones of inhibition of theaflavin, 
theaflavin:epicatechin combination and epicatechin against  the MRSA  
isolate 1. Zones include the 6 mm disc diameter.            134 
 
Figure 63. Mean zones of inhibition for the MRSA isolate 2. Zones include   135 
the 6 mm disc diameter. 
 
Figure 64. Mean zones of inhibition for the MRSA isolate 3. Zones include   136 
the 6 mm disc diameter. 
 
Figure 65. Mean zones of inhibition for the MRSA isolate 4. Zones include   137 
the 6 mm disc diameter. 
 
Figure 66. Mean zones of inhibition for the A. baumannii isolate 1.     138 
Zones include the 6 mm disc diameter. 
 
Figure 67. Mean zones of inhibition for the A. baumannii isolate 2.     139 
Zones include the 6 mm disc diameter. 
 
Figure 68. Mean zones of inhibition for the A. baumannii isolate 3.     140 
Zones include the 6 mm disc diameter. 
 
Figure 69. Mean zones of inhibition for the A. baumannii isolate 4.     141 
Zones include the 6 mm disc diameter. 
 
Figure 70. Mean zones of inhibition for the S. maltophilia isolate 1.     142 
Zones include the 6 mm disc diameter. 
 
Figure 71. Mean zones of inhibition for the S. maltophilia isolate 2.     143 
Zones include the 6 mm disc diameter. 
 
Figure 72. Mean zones of inhibition for the S. maltophilia isolate 3.     144 
Zones include the 6 mm disc diameter. 
 
Figure 73. Mean zones of inhibition for the S. maltophilia isolate 4.     145 
Zones include the 6 mm disc diameter. 
 
Figure 74. Graphs representing the percentage of isolate MICs for     150 
theaflavin (TF) and theaflavin:epicatechin combination (TF:EC) 
 
Figure 75. Graph showing the synergistic and antagonistic effects                 155        155   
of polyphenols with antibiotics against isolate 1 of MRSA.   
 
Figure 76. Graph showing the synergistic and antagonistic effects of             156 
polyphenols with antibiotics against isolate 2 of MRSA.   
 
	  
	  
xvi	  
Figure 77. Graph showing the synergistic and antagonistic effects of             157 
polyphenols with antibiotics against isolate 3 of MRSA.   
 
Figure 78. Graph showing the synergistic and antagonistic effects               158 
of polyphenols with antibiotics against isolate 4 of MRSA.   
 
Figure 79. Graph showing the synergistic and antagonistic effects                 159 
of polyphenols with antibiotics against isolate 1 of A. baumannii. 
Figure 80. Graph showing the synergistic and antagonistic effects                 160 
of polyphenols with antibiotics against isolate 2 of A. baumannii. 	  
Figure 81. Graph showing the synergistic and antagonistic effects                 161 
of polyphenols with antibiotics against isolate 3 of A. baumannii.  
Figure 82. Graph showing the synergistic and antagonistic effects                 162 
of polyphenols with antibiotics against isolate 4 of A. baumannii.  
 
Figure 83. Graph showing the synergistic and antagonistic effects                 163 
of polyphenols with antibiotics against isolate 5 of A. baumannii.  
 
Figure 84. Graph showing the synergistic and antagonistic effects                 164 
of polyphenols with antibiotics against isolate 6 of A. baumannii.  
 
Figure 85. Graph showing the synergistic and antagonistic effects                 165 
of polyphenols with antibiotics against the control strain  
(NCTC 13485) of A.	  baumannii. Zones include the 6 mm disc diameter. 
 
Figure 86. Graph showing the synergistic and antagonistic effects                 166 
of polyphenols with antibiotics against isolate 1 of S. maltophilia.  
Figure 87. Graph showing the synergistic and antagonistic effects                 167 
of polyphenols with antibiotics against isolate 2 of S. maltophilia.  
Figure 88. Graph showing the synergistic and antagonistic effects                 168 
of polyphenols with antibiotics against isolate 3 of S. maltophilia.  
 
Figure 89. S Graph showing the synergistic and antagonistic effects             169 
of polyphenols with antibiotics against isolate 4 of S. maltophilia.  
 
Figure 90. Graph showing the synergistic and antagonistic effects                 170 
of polyphenols with antibiotics against isolate 5 of S. maltophilia.  
 
Figure 91. Graph showing the synergistic and antagonistic effects     171 
of polyphenols with antibiotics against isolate 6 of S. maltophilia.  
 
Figure 92. Graph showing the synergistic and antagonistic effects     172 
of polyphenols with antibiotics against the control strain (NCTC 13014)  
of S. maltophilia.  
 
Figure 93. Enzyme coupling of epicatechin and epigallocatechin to     192 
form theaflavin 
 
	  
	  
xvii	  
Figure 94. Example of the structure of catechol oxidase     194 
 
Figure 95. Enzyme coupling of deuterated epicatechin and      195 
epigallocatechin to form deuterated theaflavin 
 
Figure 96. Breakdown of resazurin to resorufin       200 
 
Figure 97. Proposed integration between microreactor synthesis     201 
and antimicrobial testing/monitoring of bacterial metabolites  
 
Figure 98. Microreactor design used for the synthesis of theaflavin    203 
 
Figure 99. Experimental setup for the microreactor synthesis of theaflavin    204 
 
Figure 100. Microreactor - microbial filter setup       208 
 
Figure 101. MS spectra for method 1 products of microreactor     210 
theaflavin synthesis 
 
Figure 102. MS spectra for method 2 products of microreactor     211 
theaflavin synthesis 
 
Figure 103. Resazurin assay to test for cell viability for A. baumannii    215 
treated for 20 minutes with synthesized theaflavin. 
 
Figure 104. Resazurin assay to test for cell viability for A. baumannii    216 
treated for 60 minutes with synthesized theaflavin 
 
Figure 105. Resazurin assay to test for cell viability for A. baumannii    217 
treated for 30 minutes with synthesized theaflavin. 
 
Figure 106. Resazurin assay to test for cell viability for A. baumannii    218 
treated for 40 minutes with synthesized theaflavin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
	  
xviii	  
List of tables 
 
Table 1. Showing elemental analysis from 3,3’,4’,5,7-O-       68 
pentaacetyl-(-)-epicatechin produced from a reaction at 20 µL/min 
 
Table 2. Showing elemental analysis from 3,3’,4’,5,7-O-       69 
pentaacetyl-(-)-epicatechin produced from a reaction at 15 µL/min 
 
Table 3. Showing elemental analysis from 3,3’,4’,5,7-O-       70 
pentaacetyl-(-)-epicatechin produced from a reaction at 10 µL/min 
 
Table 4. Showing elemental analysis from 3,3’,4’,5,7-O-       71 
pentaacetyl-(-)-epicatechin produced from a reaction at 5 µL/min 
 
Table 5. Showing elemental analysis from 3,3’,4’,5,7-O-       72 
pentaacetyl-(-)-epicatechin produced from a reaction at 2.5 µL/min  
 
Table 6. Important antibiotics and their modes of action and bacterial      90 
targets (Madigan et al., 2009) 
 
Table 7. Showing the zones of inhibition for a variety of antibiotics     104 
against the bacterium A. baumannii 
 
Table 8. Zones of inhibition for a variety of antibiotics against MRSA   106 
 
Table 9. Zones of inhibition for a variety of antibiotics against VRE    107 
 
Table 10. Mean zones of inhibition for EC at various concentrations    108 
against A. baumannii 
 
Table 11. Mean zones of inhibition for EC at various concentrations    110 
against MRSA 
 
Table 12. Mean zones of inhibition for EC at various concentrations    111 
against VRE 
 
Table 13. Mean zones of inhibition for EGCG at various concentrations    112 
A. baumannii 
 
Table 14. Mean zones of inhibition for EGCG at various concentrations    114 
against MRSA 
 
Figure 15. Mean zones of inhibition for EGCG at various concentrations    115 
against VRE 
 
Table 16. Mean zones of inhibition for theaflavin at various      116 
concentrations against A. baumannii 
 
Table 17. Mean zones of inhibition for theaflavin at various        118 
concentrations against VRE 
 
 
	  
	  
xix	  
Figure 18. Mean zones of inhibition for mixed theaflavins at      119 
various concentrations against A. baumannii 
 
Table 19. Showing the mean zones of inhibition for mixed theaflavins at    120 
various concentrations against MRSA 
 
Table 20. Mean zones of inhibition for mixed theaflavins at      122 
various concentrations against VRE 
 
Table 21. Experimental organisation of inoculated discs on plates 1-6 for    126 
MRSA, A. baumannii and S. maltophilia 
 
Table 22. Final compound concentrations in the 96 well plate     128 
 
Table 23. Experimental organisation of inoculated discs and antibiotic disc   127 
 on plates 1-7 for A. baumannii and S. maltophilia. 
 
Table 24. Results of a student T-test (paired, 2 tailed) to show     146 
significant difference between antibacterial effects of polyphenols  
and polyphenol combinations against isolates of MRSA. 
Table 25. Results of a student T-test (paired, 2 tailed) to show     147 
significant difference between antibacterial effects of polyphenols   
and polyphenol combinations against isolates of A. baumannii. 
Table 26. Results of a student T-test (paired, 2 tailed) to show     148 
significant difference between antibacterial effects of polyphenols  
and polyphenol combinations against isolates of S. maltophilia. 
 
Table 27. Results of a student T-test (paired, 2 tailed) to show     173 
significant difference between antibacterial effects of antibiotics and  
antibiotic-polyphenol combinations against MRSA isolates. 
 
Table 28. Results of a student T-test (paired, 2 tailed) to show     174 
significant difference between antibacterial effects of antibiotics and  
antibiotic-polyphenol combinations against A. baumannii isolates. 
 
Table 29. Results of a student T-test (paired, 2 tailed) to show     175 
significant difference between antibacterial effects of antibiotics and  
antibiotic-polyphenol combinations against S. maltophilia isolates. 
 
 
 
 
 
 
 
 
 
 
 
 
	  
	  
xx	  
List of equations 
 
Equation 1. The equation to determine the Reynolds number (deMello, 2006)      24 
Re =  ρvd/η 
 
Equation 2. The equation for Flick’s first law           25 
! 
J = "D#$
#x  
 
Equation 3. Showing the equation for Flick’s second law         25 
! 
"#
"t = D
" 2#
"x 2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
	  
xxi	  
Publications 
 
Published papers 
 
J. W. Betts., S. P. Kitney., Y. Fu., W. Peng., S. M. Kelly and S. J. Haswell (2010) 
Production of deuterium labelled (-)-epicatechin in a microreactor. Chemical 
Engineering Journal. 167(2-3). 545-547. 
 
J. W. Betts., S. M. Kelly and S. J. Haswell (2011) Antibacterial effects of 
theaflavin and its synergy with epicatechin against clinical isolates of 
Acinetobacter baumannii and Stenotrophomonas maltophilia. International 
Journal of Antimicrobial Agents. 38. 421-425. 
 
 
Papers in preparation 
 
Enzymatic synthesis of theaflavin in a continuous flow microreactor.	  
 
Minimum inhibitory concentrations of theaflavin and combinations with 
epicatechin and quercetin against clinical isolates of Stenotrophomonas 
maltophilia. 	  	  
Antagonistic and synergistic antibacterial effects of polyphenols combined with 
clinical antibiotics against hospital isolates of Stenotrophomonas maltophilia 
and Acinetobacter baumannii.	  
 
 
Conference presentations 
 
J. W. Betts, S. P. Kitney, S. M. Kelly and S. J. Haswell (2010) Production of 
deuterium labelled (-)-epicatechin in a microreactor – a route to toxicological 
studies. Poster presented at IMRET 2010 conference in Kyoto, Japan. 
 
J. W. Betts, W. Peng, Y. Fu, S. M. Kelly and S. J. Haswell (2008) Chemical 
synthesis of theaflavin in a microreactor. Poster presented at SES conference 
(2008) at Lancaster University. 
 
J. W. Betts, W. Peng, Y. Fu, S. M. Kelly and S. J. Haswell (2008) Chemical 
synthesis and biological activity of theaflavin in a microreactor. Poster 
presented at ARF student conference (2008) at Hull University. 
 
 
 
 
 
 
  
	  
	  
xxii	  
Abbreviations 
 
EC  -  Epicatechin 
TF  - Theaflavin 
EGC  - Epigallocatechin 
EGCG - Epigallocatechin gallate 
MS  - Mass spectrometry 
1H-NMR - Proton nuclear magnetic resonance 
13C-NMR - Carbon 13 nuclear magnetic resonance 
PBS  - Phosphate buffered saline 
DMSO - Dimethyl sulfoxide 
MIC  - Minimum inhibitory concentration 
LDL  - Low-density lipoprotein 
DNA  - Deoxyribonucleic acid 
RNA  - Ribonucleic acid 
SCLC  - Small cell lung carcinoma 
FDA  - Food and drug administration (US) 
CDC  - Centre for disease control 
WHO  - World heath organisation 
ICU  - Intensive care unit 
MRSA  - Methicillin-resistant Staphylococcus aureus 
VRE  - Vancomycin-resistant enterococci 
PDMS  - Polydimethyl siloxane 
PMMA - Polymethyl methacrylate 
HF  - Hydrogen fluoride 
D-labelling - Deuterium labelling 
THF  - Trifluoromethanesulfonate 
HPLC  - High performance liquid chromatography 
UV  - Ultraviolet 
HCL  - Hydrochloric acid 
NBS  - N-bromosuccinimide 
CCl4  - Carbon tetrachloride 
DCM  - Dichloromethane 
NaBD4 - Sodium borodeuteride 
NIS  - N-iodosuccinimide 
TFA  - Trifluoroacetic acid 
TBDMS - Tert-butyldimethylsilyl 
DMF  - Dimethylformamide 
MgSO4 - Magnesium sulphate 
TLC  - Thin layer chromatography 
NaSO4 - Sodium sulphate 
MW  - Molecular weight 
spp  - Species 
HIV  - Human immunodeficiency virus 
CBA  - Columbia blood agar 
ISO  - Iso-sensitive 
BSAC  - British society for antimicrobial chemotherapy 
NCTC  - National collection of type cultures 
AMP  - Ampicillin 
CN  - Gentamycin 
IPM  - Imipenem 
TE  - Tetracycline 
	  
	  
xxiii	  
FOX  - Cefoxitin 
CIP  - Ciprofloxacin 
CLM  - Clarithromycin 
P  - Penicillin G 
PPO  - Polyphenol oxidase  
NADPH - Nicotinamide adenine dinucleotide phosphate 
rpm  - Rotations per minute 
 
 1 
 
 
 
 
 
 
Chapter 1 
Introduction to polyphenols, synthesis and 
microfluidics 
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1.1 Introduction 
1.1.1 Tea and its contents 
Green tea like black tea is produced from the plant Camellia sinensis (Zaveri, 
2006). Camellia sinensis is an evergreen shrub with leaves between 3 and 10 
inches long (Taylor, 1998), which grows in over 30 countries (Gupta et al., 
2002). These tea trees often produce fragrant white flowers (figure 1) and are 
typically grown in conditions such as in acidic soils, high or low altitude and high 
humidity (Dufresne and Farnworth, 2001) and therefore can be cultivated in 
many regions of the world including China, Japan, Kenya, India, Brazil and 
Argentina (Mitscher and Dolby Toews, 2008). 
 
Figure 1. The leaves and white flowers of Camellia sinensis. 
 
 
Although there is only one tree/shrub from which tea is produced, there are 
many of different varieties of tea including black tea, green tea, oolong tea and 
white tea Sharangi (2009). The main difference between them is their oxidation 
state, with the most oxidation occurring in black tea (Jhoo et al., 2004). 
Accordingly teas can be processed in a variety of ways depending on the 
product required (See figure 2).  
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Figure 2. Methods of tea processing (teazonline, 2011) 
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Tea is the second most consumed beverage in the world, of this 72% is black 
tea and 26% is green tea and 2 % other varieties (Katiyar and Mukhtar, 1996). 
The consumption of tea has occurred for over five thousand years and was 
thought of as a highly prized tonic to keep the body in a healthy condition 
(Mitscher and Dolby Toews, 2008). Archaeological data suggests that infusions 
from tea and other wild pants, was practiced by our ancestors up to five 
hundred thousand years ago (Jelinek, 1978). Although it was thought to have 
originated as a beverage in Japan, the earliest evidence of tea comes from 
China where traditional healers such as Sheg Nung lived in 2730 BC (Kuroda 
and Hara, 2004). In Japan for hundreds of years a tradition called the tea 
ceremony has existed. Tea ceremonies where originally conducted by warriors 
and were thought of as spiritual events.  
 
Although for many years green tea has been consumed more in the eastern 
world it has in more recent years become very popular in the west due to its link 
with health benefits (Marion et al., 2003).  However, black tea is still the most 
popular choice as it makes up 72% of the worlds total tea production (Sharangi, 
2009). 
 
The health benefits of tea are linked to their active ingredients called 
polyphenols (Marion et al., 2003). These polyphenolic compounds are part of 
the flavonoid group, which are also found in red wine, black grapes, cocoa, 
beans and Chinese rhubarb (Rein et al., 2000). It is estimated that in the US 
500-1000mg of flavonoids including those found in tea are consumed everyday 
(Cushnie and Lamb, 2005). Catechins are the most common polyphenolic 
compounds in green tea whereas theaflavins are more common in black tea 
(Matsuo, Tanaka and Kouno, 2009) and inpart the reddish brown colour to the 
tea from the theaflavins. This colour difference between black and green tea 
can be seen in figure 3.   
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Figure 3. The change in colour of tea leaves which relates to flavonoid content. 
 
 
Theaflavins represent 0.4-1.8% of the dry weight of black tea (Sharma, bari and 
Singh, 2009). Catechins form 80% of the polyphenolic content of green tea and 
represent 20-30% of the dry weight of the tea leafs. Catechins in green tea leafs 
include epicatechin, catechin, epigallocatechin and epigallocatechin gallate 
(Lorenz et al., 2004). Examples of the structures of catechins and theaflavins 
can be seen in figures 4 and 5. The leaves contain other compounds including 
caffeine, amino acids, minerals (fluoride), aromatic oils, vitamins, proteins and 
carbohydrates (Khan and Mukhtar, 2007). The quantities of these compounds 
vary between types of tea and can affect its smell, taste and colour (Mitscher 
and Dolby Toews, 2008). 
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Figure 4. The structure of the black tea flavanoids, theaflavin, theaflavin-3’-
monogallate and theaflavin-3-3’-digallate and their molecular weights 
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Figure 5. The structures of the green tea catechins, epigallocatechin gallate, 
epicatechin, epigallocatechin, epicatechin gallate, catechin and their molecular 
weights 
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1.1.2 Bioavailability and stability of polyphenols  
In humans, polyphenol concentrations in plasma often do not exceed 1 µM even 
after the consumption of 10–100 mg of an individual polyphenol (Scalbert and 
Williamson, 2000). However, due to polyphenol metabolites formed in the 
body’s tissues, the total polyphenol concentration in plasma is likely to be 
higher. Many studies focus on polyphenol activity in vitro that do not take factors 
such as metabolism or bioavailability into consideration that could affect their 
activity in vivo (Williamson and Manach, 2005). However, there have been 
demonstrations that tea polyphenols have strong in vivo activity in humans 
(Serafini, Ghiselli and Ferro-Luzzi, 1996). It was suggested that polyphenol 
absorption took place in the upper gastrointestinal system due to the speed of 
the in vivo response after any tea was consumed.  
 
Catechins have been shown to have short half-lives in plasma often forming 
conjugates with sulfate or methyl groups after 2-3 hours (Bell et al., 2000). An 
exception to this is with epigallocatechin gallate where research has 
demonstrated that up to 100% of the polyphenol remains unconjugated after 1 
hour (Lee et al., 2002). 
 
There are various factors including those biochemical and chemical that can 
affect polyphenol absorption and polyphenol bioavailability can also be linked to 
stability. 
 
As many of the benefits of green and black tea are thought to come from their 
active components there stability is the environment is very important. A 
number of research groups have investigated the stability of catechins on 
several occasions, with some having described an effect called “browning” 
(Lopez-Toledano et al., 2002) whereby phenolic compounds degrade. The 
“browning” of these phenolics can be caused by enzymatic and non-enzymatic 
oxidation reactions. These reactions can be seen in a variety of products for 
example, in damaged fruit where a red/brown “bruise” is produced (Tanaka et 
al., 2002). The bruise is the result of surface damage to the fruit, which allows 
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oxygen below the surface of the skin resulting in an oxidation reaction of 
phenolics contained in the fruit. The stability of catechins has a great impact on 
their usage especially in the food/beverage market and also in their applications 
in the medical industry. 
 
Temperature has been shown to have an effect on the stability of catechins. 
Results from various studies have shown that boiling catechins at 98°C for 7 
hours contributes to 15-20% of their degradation (Chen et al., 2001 and Zhu et 
al., 1997). It was noted by Chen et al., (2001) that autoclaving catechins at 
120°C for 20 minutes reduces their stability by 24%, although this was thought 
to be partially pH dependant.  
 
Research groups have also invested pH and its contribution to the 
stability/degradation of catechins (Zhu et al., 1997). In this study it was noted 
that in green tea catechins, the lower the pH the more stable the catechins 
were.  It was also noted that in alkaline solutions the catechins were less stable 
and therefore more easily absorbed in the intestine. Another issue that has 
been raised is the effect of mixing flavanols with milk. In 2007 Lorenz et al., 
discovered that when adding milk to a solution containing flavanols the 
protective health effects are prevented. A possible reason the investigation 
gave for this was that the protein in the milk led to the formation of complexes 
with catechins in the tea. 
 
A study by Hatano et al., (2008) discovered that the addition of ascorbic acid to 
polyphenolic solutions prolonged its usage. This was a very useful discovery in 
terms of the potential storage lifespan of polyphenols for food or medicinal uses. 
Synergy has also been seen in other research, where the cholesterol-lowering 
effects of green tea extracts were increased by the addition of theaflavin (Maron 
et al., 2003).   
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1.1.3 Benefits of tea polyphenols 
1.1.3.1 General benefits of polyphenols 
There have been many investigations to determine the health benefits of 
flavanols, which include anticancer (Cooper, Morre and Morre, 2005; Sadava et 
al., 2007), anti- inflammatory (Sang et al., 2004), antioxidant (Dobashi et al., 
2008), antiviral (Williamson et al., 2006) and antibacterial effects (Navarro-
Martinez et al, 2005; Vijaya et al., 1995). Other benefits of green and black tea 
components include stroke prevention (Fraser, Mok and Lee, 2007), a 
protective effect from liver damage that can be caused by anticancer drugs (El-
Beshbishy, 2005) and its use as a food preservative (Yilmaz, 2006). It has been 
proposed that flavanols, including theaflavin, improve vascular function 
(Schewe, Steffen and Sies, 2008).  Epicatechin has been particularly noted to 
have positive effects, with its metabolites having a protective effect against 
oxidized low-density lipoprotein (LDL) that would otherwise cause oxidative 
stress to endothelial cells. However, there are doubts about the positive effect 
of flavanols on cardiovascular health, with some researchers stating that there 
is inconclusive evidence and the need for further controlled studies in this area 
(Riemersma et al., 2001). Recent research has also proposed that polyphenols 
could be used in the preservation of mammalian tissue without the need for 
cryopreservation Han et al., 2006). Previous studies have also demonstrated 
that tea polyphenols can increase that rate of fat oxidation, leading to weight 
loss (Dulloo et al., 1999). However, another study using green tea found that it 
had no effect on weight maintenance following a low energy diet in obese 
subjects (Kovacs et al., 2004). 
 
1.1.3.2 Polyphenols as antioxidants 
The basis for many of their reported benefits are thought to be the flavanols role 
as antioxidants (Almajano et al., 2008). Antioxidants are defined as materials 
that are able to neutalize the effects of free radicals and thus prevent the 
oxidative damage they cause to biological systems (Azzi et al., 2004). 
Antioxidants are classified into two groups: enzymatic and non-enzymatic 
antioxidants (Ratnam et al., 2006). Green and black tea polyphenols are 
classed as non-enzymatic antioxidants. Previous research has shown that 
 11 
consumption of antioxidants in the human diet has fallen over thousands of 
years and is now far less than that of our ancestors (Benzie, 2003) possibly due 
to higher processing of food. Antioxidants including ascorbic acid (vitamin C) 
and catechins have been proposed to have a protective affect against free 
radicals and other oxidative agents (Collins et al., 1996; Frei and Higdon, 2003).  
 
Free radicals are molecules with an unpaired electron making them highly 
reactive (Bettelheim and March, 1998). One very important example of a free 
radical is the reactive oxygen species (ROS) ∙O -H (hydroxyl radical) that can be 
formed when high energy such as radiation reacts with H2O. Free radicals are 
produced naturally in mitochondria to aid energy production (Del Prete et al., 
2008), but they also can be generated by a variety of environmental factors 
including pollution, radiation, ingested chemicals (see figure 6) and can 
contribute to diseases such as heart disease, cancer and diabetes (Ratnam et 
al., 2006). 
 
Figure 6. An overview of the environmental and biological causes of free radical 
formation (Lifeinnovate, 2008). 
 
 12 
Reactive oxygen species are also used by neutrophil granulocytes to destroy 
infectious agents such as bacteria when engulfed (Ligeti and Mocsai, 1999). 
Although free radicals have benefits, if uncontrolled they can also disrupt DNA 
replication, transcription and translation (Riso et al., 2002). These disruptions 
can cause mutations, cancers or even lead to cell death (Labieniec and 
Gabryelak, 2005). It is therefore crucial that the integrity of DNA in cells remains 
and replication of healthy DNA can therefore continue (Riso et al., 2002).  
 
DNA damage can be monitored using various methods including the Comet 
assay (Plazar et al., 2007). Using a Comet assay, damage to the DNA caused 
by any oxidative damage can be detected. A Comet assay involves single cell 
electrophoresis and produces a fluorescent Comet style image when DNA 
damage has occurred (Plazar et al., 2008). If no DNA damage has occurred, an 
intact circle of DNA will be seen. This is due to fragments of DNA travelling 
further through the electrophoresis gel than intact DNA. An example of a comet 
assay can be seen in Figure 7 showing undamaged DNA on the left and 
damaged DNA on the right giving the classic Comet tail. 
 
Figure 7. An example of a comet assay (Rowland, 2008) 
 
 13 
The green tea catechins epigallocatcechin gallate and epicatechin have been 
shown to have a free radical scavenging ability (Li et al., 2007), which can have 
a great impact on DNA damage and lipid oxidation (Yumiko, Takeshi and 
Hiroshi, 1998). However, theaflavin from black tea has been shown to have an 
equal or greater antioxidant ability than epigallocatechin gallate (Leung et al., 
2001 and Luczaj and Skrzydlewska, 2005). Polyphenolic compounds related to 
theaflavin found in black tea have also been found to inhibit oxidative DNA 
damage (Lodovici et al., 2000). In this study DNA damage in colon mucosa in 
rats was prevented by the ingestion of black tea polyphenols. One study also 
found that due to its antioxidant properties, epicatechin gave antidegenerative 
effects in rats with induced Alzheimer’s disease (De Ruvo et al., 2000).  
 
Many also agree with the role of antioxidants in the prevention or even 
treatment for cancers. An example of this was reported by Sadava et al., in 
2007 where it was shown that green tea extracts do have anticancer effects and 
could be used as a treatment of drug resistant Small-cell lung carcinoma 
(SCLC). However, previously in 2005 the U.S Food and Drug Administration 
(FDA) dismissed anticancer effects of green tea claiming “it is highly unlikely”. 
Other research groups suggest the catechin epigallocatechin gallate in green 
tea actually causes oxidative damage, which may lead to carcinogenesis 
(Furukawa et al., 2003). Other research suggested that taking high doses of 
antioxidants may cause harm and that the benefits of pro-oxidnants such be 
investigated (Gutteridge and Halliwell, 2010). However, in 2008 a study found 
theaflaivin-3,3’-digallate, inhibited the growth of tumour cells due to the 
compound generating reactive oxygen species (Schuck et al., 2008). It was 
proven in one study that the antioxidant abilities of epigallocatechin gallate 
came from the trihydroxyphenyl B ring (Valcic et al., 1999). The study also 
proposed that the epigallocatechin gallate phenoxyl radical that is initially 
formed in an antioxidant reaction, could be used as a novel marker for 
epigallocatechin gallate reactions in living systems. 
 
Alternative or additional research into flavanols and their interaction and ability 
to inhibit various enzymes and other types of proteins has been reported 
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(Cushnie and Lamb, 2005). Although very little research has been undertaken 
to discover the exact structural relationship and proposed activity, some groups 
(Tsuchiya et al., 1996) have found that 5,7-dihydroxylation of the A ring and 
2',4'- or 2',6'-dihydroxylation of the B ring of specific flavanones are very 
important in there antibacterial activity.  
 
1.1.3.3 Antibacterial activity of polyphenols and infection 
An area where polyphenols have significant benefits is in microbiological 
diseases and antimicrobial action. Microbiology is defined as the study of 
microscopic multicellular and unicellular organisms and covers areas including 
bacteriology, medical microbiology, virology and mycology (Madigan et 
al.,2009). Microbial disease is a vastly important area and affects human 
populations on every continent. Figures from the World Health Organisation 
(WHO) in 2004 showed that over 16.8% of deaths in the world are as a result of 
an infection (WHO, 2004) and in low income countries it increases to over 34%.  
 
Areas of particular concern are hospital-acquired infections, opportunistic 
pathogens and drug resistance.  Hospital-acquired infections often affect the 
elderly, individuals with a suppressed or poor immune system and patients who 
have had surgery and are often very costly to treat (Sheng et al., 2005). Data 
suggests that patients staying on an intensive care unit (ICU) increases their 
risk of developing a nosocomial infection by up to 10 times that of general 
wards (Weber et al. 1999). However, hospital-acquired infections can cause 
additional problems when the infection is caused by a resistant strain of 
bacteria. For example infections caused by methicillin resistant Staphylococcus 
aureus (MRSA) and vancomycin resistant enterococci (VRE) can result in 
patient mortality (Albrich et al., 1999).   
 
Opportunistic infections are often caused by bacteria, which naturally colonise 
the human body but do not usually cause harm in healthy individuals. However, 
they can cause serious infections in immunocompromised individuals (Madigan 
et al., 2009). An example of a opportunistic pathogen is Acinetobacter 
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baumannii which has been shown to cause serious infection in various 
individuals including wounded soldiers or victims of natural disasters (Joly-
Guillou, 2005). 
 
Antibiotic resistance can occur via several routes including over prescription of 
antibiotics, full courses of antibiotics not being taken by patients and bacterial 
mutation (Arias and Murray, 2009). Resistance is not a new topic, since the first 
antibiotics were used resistance has occurred, for example only one year after 
methicillin was introduced in 1960, resistant strains were seen (Maltezou and 
Giamarellou, 2006).  Since that time many more resistant strains have 
appeared and despite the reduction in the prescriptions of antibiotics such as 
fluoroquinolones, numbers of resistant strains to the drug including Escherichia 
coli, have increased (Soulsby, 2005).  
 
With production and approval of new antimicrobial drugs reducing in the last 30 
years (see figure 8), and further research indicating a reduction of 56% in 1998- 
2002 when compared to 1983-1987 (Spellberg et al., 2004), the drugs used to 
treat bacterial infections is rapidly reducing.  
 
Figure 8. New antimicrobial agents between 1983 and 2002 (Spellberg et al., 
2004) 
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Due to the increase in resistance and the decrease in the production of new 
antimicrobial drugs, using natural compounds such as polyphenols could be 
useful in creating new antimicrobial chemotherapies.  
 
Polyphenols have shown to have significant antibacterial activity against various 
bacterial species including MRSA and also reduce the resistance to certain 
antibiotics (Anderson et al., 2005). It has also been shown that green tea 
polyphenols inhibit Helicobacter growth in vivo and in vitro (Stoicov, Saffari and 
Houghton, 2009). This is a significant finding as Helicobacter has been linked to 
causing stomach cancer.  
 
Previous research has suggested that tea catechins can suppress the 
emergence of resistance due to their antimutagenic properties (Pillai et al., 
2001). It was discovered by Zhao et al., (2002) that epigallocatechin gallate 
inhibited penicilinase produced by penicillin resistant Staphylococcus aureus 
resulting in the restoration of the antibiotics effects. This is a major benefit as 
these synergistic effects could be used to restore the other antibiotics. Tea 
polyphenols have also been shown to have synergy with other antioxidants 
such as ascorbic acid where it was found to increase the antibacterial effect and 
stability of epigallocatechin gallate (Hatano et al., 2008).  
 
Black tea theaflavins have previously been shown to have strong antibacterial 
effects against Bacillus cereus with theaflavin-3, 3’-digallate having the greatest 
effect (Friedman et al., 2006). However, in a past study it was shown that when 
comparing the antimicrobial of tea with various degrees of fermentation, black 
tea showed the least activity (Chou, Lin and Chung, 1999). 
 
The consumption of tea has also been shown to significantly reduce caries in 
animals and humans (Wu and Wei, 2002). Research studies have shown that 
tea polyphenols inhibit the glucan produced by bacteria used to adhere to tooth 
enamel and cause plaque (Kuroda and Hara, 2004). Without this glucon 
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bacteria are no long able to proliferate and as a result acid induced tooth decay 
is reduced. It has been suggested that supplements of green tea in a diet would 
be advantageous in dental management (Sharma et al., 2007). 
 
Tea flavanoids have also been shown to block the harmful effects of bacterial 
toxins including the neurotoxin produces by Clostridium botulinum, which 
causes the disease botulism (Friedman, 2007). According to the research by 
Satoh et al., (2002) black tea flavanoids blocked the action of bolulinum 
neurotoxcins in mice.  
 
The mechanisms of the antibacterial action of polyphenols have been proposed 
and include inhibiting enzymes including DNA gyrase whereby epigallocatechin 
gallate has been shown to bind to the ATP binding site of the gyrase B subunit 
and disrupting activity (Gradisar et al., 2007). The study by Gradisar et al., 
(2007) also showed that it is the benzopryan ring of epigallocatechin gallate that 
blocks the active site. In previous research the mechanism was suggested to 
result from direct binding of the polyphenols the peptide structure of bacterial 
components (Shimamura, Zhao and Hu, 2007). A further previous study 
indicated that tea catechins, in particular, epigallocatechin gallate can cause 
leakage from bacterial cell membranes (Friedman, 2007). The study also stated 
that due to significant differences in human and bacterial cell membrane 
structures results in bacterial and not human cell death. Another proposed 
mode of action is the inhibition of bacterial energy metabolism in a similar to 
respiratory-inhibiting antibiotics (Cushnie and Lamb, 2005) 
 
Although there are proposed mechanisms of polyphenol antibacterial activity 
more research is needed to confirm the modes of action. To accurately 
understand the antimicrobial modes of action of compounds including 
polyphenols, isotopic labelling can be undertaken. Previous research had used 
deuterium labelling to identify the modes of action of compounds (Paaren et al., 
1981). By labelling a compound it could be possible to either trace where it is 
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having and effect or monitor metabolites (Kohri et al., 2001) to determine which 
part of the compound is giving the antimicrobial effects.  
 
1.1.4 Stable isotopic Labelling 
The use of stable isotope labelled compounds such as epicatechin can be a 
very useful way of identifying the potential health benefits of flavanols. Labelled 
compounds can for example be used in metabolic studies (Allen, Shachar-Hill 
and Ohlrogge, 2007). The synthesis of labelled compounds can be notoriously 
difficult, expensive and usually requires a number of synthetic steps (Hooper, 
Watts and Wiles, 2008). Compounds of interest can be labelled with a variety of 
markers, which include 13C, 14C, fluorescence fluophores and deuterium 
(Lundberg et al., 2007 and Zheng et al., 2008).  
 
Fluorescent fluorophore markers such as a protein, nucleic acid or reactive 
probe are bonded covalently to another molecule (Matthews, Van Holde and 
Ahern, 1999). The fluoropore emits part of its excitation energy by non-radiant 
transfer to surrounding molecules as a result of absorbing ambient energy 
(Reed, Holmes, Weyers and Jones, 2003) and fluorescence is produced. 
 
Fluorescent markers are very useful in biological studies such as cell sorting 
and microscopy (Stryer, 1998). However, they are very sensitive to 
environmental conditions such as temperature and pH (Parak, Pellegrino and 
Plank, 2005). Another problem with fluorescent labels is that they are often 
large and can alter the overall structure and potentially the properties of a 
compound, which in turn could bias results in a metabolic study.  
 
Using a carbon isotope represents an alternative option and a number of carbon 
isotopes can be used including 11C, 13C and 14C (Solomans and Fryhle, 2006). 
All carbon isotopes stable and unstable (radioactive) have the same atomic 
number and protons as carbon but they all have variations in their neutrons and 
therefore a different mass.  
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The use of a 13C marker has great benefits such as its stability and integration 
into the overall structure of the compound investigated (Flores et al., 2002). 
Using 14C has similar benefits in that it too can be integrated into the overall 
structure. Another benefit of using 14C is that it is detectable due to the radiation 
it omits (EVS, 2005). Using the carbon isotopes 13C or 14C in the molecular 
structure of a compound, effectively allows monitoring of the compounds 
metabolic pathway (Allen, Shachar-Hill and Ohlrogge, 2007). Carbon isotopes 
have also been found to be effective in nutrition studies where ingested plant 
material labelled with 13C (Svejcar, Judkins and Boutton, 1993). In this study 
changes in the isotope ratios were monitored by mass spectrometry. Although 
this is an effective method of labelling a compound and has been used in 
flavanoids in previous research, it often involves many reaction steps and more 
complicated stereochemistry (Nay, Arnaudinaud and Vercauteren, 2002). 
However, a simple method of producing 14C labelled epicatechin, was 
undertaken in 1974, by Eastmond and Gardner. In their proposed method 14C 
labelled epicatechin and 14C procyanidins were extracted from the seeds of 
Aesculus hippocastanum after the plant had been fed with sodium acetate-1-
14C. This methodology was effective in using the plants natural production 
system to yield 14C epicatechin. Theoretically this could be performed using the 
tea plant Camellia sinensis. Whereas 13C is a stable carbon isotope 14C is 
unstable (radioactive) and therefore there are associated risks when it is used 
including radiation exposure (CNSC, 2003).  
 
Deuterium labelling involves the substitution of hydrogen with deuterium atom. 
Deuterium is an isotope of hydrogen having the same atomic number but a 
different mass (Riley, 2000). This is due to the nucleus of hydrogen containing 
one proton, whereas the nucleus of deuterium contains a proton and a neutron 
(Solomons, T. W. G. and Fryhle, C. B. 2006). 
 
Deuterium labelling often involves multiple steps and has been used by many 
research groups to label compounds such as procyanidins (Pierre, Cheze and 
Vercauteren, 1997) and polyphenolic compounds (Buffnoir et al., 1998). This 
approach has been the chosen method for this study as similar reactions have 
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been proven to be successful in various batch reactions (Kohri et al., 2001 and 
Peng and Yao, 2009).  Due to the change in mass when substituting hydrogen 
with deuterium it is an excellent marker and can be used in a wide variety of 
research including monitoring the deep-water access of plants (Panuelas and 
Filella, 2003) and in metabolic studies. 
 
1.1.5 Microfluidics 
Microfluidics is a subject that deals with the manipulation of small volumes of 
fluids using channels with dimensions in the range of 10 to many hundreds of 
micrometres (Whitesides, 2006). Microfluidics encompasses a range of 
disciplines including chemistry, biology, fluid mechanics and surface science 
(Gomez, 2008). Other important disciplines are electronics and fabrication. 
Microfluidics, lab-on-chip or micro total analysis systems (µTAS) can be used to 
integrate processes including PCR, detection and analysis onto a chip in the 
micrometer scale (Ong et al., 2008). The first microfluidic systems were created 
in the mid-1970’s with the production of miniaturized gas chromatography 
system (Terry, 1979). Since then microfluidic systems have flourished and are 
an integral part of modern day research (Haswell, 2006). 
 
1.1.5.1 Flow of fluids in a microfluidic device 
The flow of fluids in a microfluidic device, have different characteristics than in 
larger (macro) devices, which can be altered using a variety of techniques, 
including the use of obstacles and/or micromixers (deMello, 2006 and Wong et 
al., 2003). A fluid can be defined as a material that can continually deform under 
any shear stress that is applied (Ong et al., 2008). There are three parameters 
that are important when characterizing a fluid. They are pressure, P, viscosity, 
η, and density, p (Tabeling, 2005).  If the viscosity gradient of a fluid is directly 
proportional to its shear stress it can be defined as a Newtonian fluid, whereas 
a fluid is defined as a non-Newtonian if viscosity is changed with shear stress 
(Nguyen and Wereley, 2002). The behaviour of fluids are dominated by factors 
such as, fluidic resistance, surface tension and energy dissipation and in 
microfluidics these factors are exploited (Kirby, 2010). Using obstacles in the 
flow channels of a microfluidic device can generate a mixture of turbulent and 
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laminar flows (Tabeling, 2005). These techniques can be used in chemical 
synthesis to mix reagents. Laminar flow is often seen in microfluidics and is 
described as streamlined flow, where parallel layers flow along side each other 
with no disruption (Ong et al., 2008). The difference between Laminar and 
turbulent flow can been seen in figure 9.  
 
Figure 9. The differences of laminar and turbulent flow in a microfluidic device 
(Cambridge, 2011) 
 
 
The type of flow in a system can be determined from the Reynolds number 
(deMello, 2006). An equation used to determine the Reynolds number can be 
seen in equation 1. 
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Equation 1. The equation to determine the Reynolds number (deMello, 2006) 
Re =  ρvd/η 
Where: 
Re = Reynolds number 
ρ = Density of fluid (Kg/m3) 
v = Velocity of flowing fluid (m/s) 
d = Diameter of channel (m) 
η = Vis cos ity of fluid (Ns /m2) 
 
If Re < 10, the flow will be laminar, if Re > 2000, the flow will be turbulent. In 
between Re < 10 and >2000 is classed as an intermediate regime. 
 
In microchannels Re is very small and as a result reagents mix via diffusion 
(deMello, 2006).  Diffusion is defined as the movement of particles from areas 
of higher concentration to those of a lower concentration (Isaacs, 1996) and 
relates to Flick’s law.  A representation of diffusion can be seen in figure 10. 
 
Figure 10. A representation of diffusion and the movement of particles from a 
high to a low concentration (Tabeling, 2005) 
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Flick’s law describes this movement of particles from high to low concentrations 
in his equation (Tabelling, 2005), which can be seen in equation 2, where J is 
the diffusion flux, D is the diffusion coefficient, φ is the concentration and x is the 
position. 
 
Equation 2. The equation for Flick’s first law 
 
 
Flick’s second law in concerned with the predicting how diffusion results in the 
concentration field to change over time (Tabelling, 2005). The equation for 
Flick’s second law can be seen in equation 3, where t is the time, D is the 
diffusion coefficient, φ is the concentration and x is the position. 
 
Equation 3. Showing the equation for Flick’s second law 
 
 
A very important requirement when diffusion is used for mixing of reagents in a 
microfluidic device, is the absence of convection (Heeren et al., 2006). As 
diffusion is not instantaneous, it can be predicted.  Therefore due to the short 
channel length in a microfluidic device it is important that reaction flow rates 
allow adequate time for total mixing of reagents by diffusion. Other transport 
mechanisms in microfluidic systems are convection, where heat transfer effects 
transport and migration, where molecules are transport due to a driving force 
such as an electric field (Ong et al., 2008). 
Another key factor when describing flow in microfluidics is Taylor dispersion, 
which Sir Geoffrey Taylor described in 1953 (Azer, 2005). This is a 
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phenomenon whereby a solution in a capillary tube or cylindrical microchannel 
with a Poiseuille flow (Bruus, 2008) has a initial flat concentration, but when 
diffusion is neglected friction on the sides of the solution results in a stretched 
paraboloid-shaped plug (see figure 11). However, with diffusion the profile of 
the solution is evened out. If diffusion did not come into play, the solution would 
become increasing stretched (Kirby, 2010).  
 
Figure 11. The Taylor dispersion problem (Bruus, 2008). V is poiseuille flow, a 
showing normal flow with a flat profile solute, b with no diffusion a paraboloid 
plug forms, c with diffusion profile evens out. 
 
The flow of cells and particles can also be manipulated in a microfluidic device 
by altering flow rates and by using acoustophoresis where acoustic force is 
used (Evander et al., 2008). 
 
1.1.5.2 Manufacturing microfluidic devices 
Microfluidic devices can be produced using different materials including glass, 
metals, polymers such as polydimethyl siloxane (PDMS) or polymethyl 
methacrylate (PMMA) and ceramics (Haswell and Skelton, 2000). The type of 
material used in the fabrication of a microfluidic device is dependant on various 
factors including reproducibility of the fabrication and the materials chemical 
compatibility (Fletcher et al., 2002). The fabrication methods used today for 
glass are based on those using photolithography and etching, which were 
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developed in the 1970s (Gravesen, Branebjerg and Jensen, 1993; McCreedy 
and Wilson 2001 and Tabeling, 2005). The fabrication of glass microreactors, 
which are preferable for chemical synthesis, involves using pre-produced mask 
(McCreedy, 2001) and hydrogen fluoride (HF) to etch channels in glass in 
series of steps (Fletcher et al., 2002), which can be seen in figure 12.  
 
Figure 12. The steps involved in the fabrication of a glass microreactor taken 
from Fletcher et al., (2002). 
 
 
 
1.1.5.3 Advantages and uses of microfluidics 
Microreactors have been shown to have many advantages in chemical 
synthesis (Janasek, Franzke and Manz, 2006). These advantages include a 
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greater level of reaction control, an increase in product yield and purity and a 
lower volume of reagents required (Haswell, 2006). Another benefit of 
microreactors is in the area of health and safety where due to reduced 
reactants, factors such as managing heat transfer are more easily and safely 
controlled (Haswell and Skelton, 2000). Reactions in microfluidic reactors can 
also be relatively easily optimized making them much more efficient than 
traditional batch reactions (Whitesides, 2006). Microreactors and MEMS 
(microelectro mechanical systems) have their uses in various fields including 
chemical analysis and biological screening (Pennemann et al., 2004). Various 
reactions have been performed in microreactors including multiple step 
chemical synthesis (Wiles et al., 2003) and labelling (Hooper, Watts and Wiles, 
2008).  
 
1.2 General aims 
The aims in chapter 2 of this project are to synthesis deuterium labelled 
epicatechin for the use in the synthesis of deuterium labelled theaflavin 
 
In chapter 3 the aim of the research will be to discover if there is any 
antibacterial effect of theaflavin against hospital isolates of MRSA, A. baumannii 
and S. maltophilia and to discover if any antibacterial synergy occurs between 
theaflavin and epicatechin against those isolates. 
 
The aims in chapter 4 are to enzymatically synthesize theaflavin and deuterium 
labelled theaflavin in a microreactor as a continuous flow process whereby the 
microreactor synthesis of theaflavin and the antimicrobial testing are combined 
in order to discover the antimicrobial modes of action. 
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Chapter 2  
Organic synthesis of deuterium labelled  
(-)-epicatechin in a microreactor 
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2.1 Introduction 
2.1.1 Synthesis of deuterium labelled epicatechin and theaflavin  
Producing theaflavin involves an oxidation reaction between epicatechin and 
epigallocatechin with an enzyme catalyst (Jhoo et al., 2004). This has been 
performed on several occasions in batch reactions using oxidative enzymes 
extracted from various fruits and plants (Tanaka et al., 2002). Producing a D-
labelled theaflavin molecule would require the same final reaction with the 
exception that the EC would have be previously D-labelled. One method for D-
labelling theaflavin is based the method reported by Kohri et al., (2001) to D-
label epigallocatechin gallate and involves 5 steps, which can be seen in figure 
13. This scheme was presented to us by our research partners at Unilever 
Shanghai who carried out the reactions in batch (Peng and Yao, 2009). 
 
Previous groups have performed a similar reaction to that of step 5 in figure 13 
(Jhoo et al., 2004). This was performed in a batch reaction with a crude enzyme 
extract to produce and unlabelled theaflavin. The reaction undertaken by Jhoo 
et al., (2004) only produced a yield of 15.2%. This is a very poor yield and if a 
similar reaction was used for the final step of producing labelled theaflavin, it 
was be very costly. However this was dramatically improved by Sharma, Bari 
and Singh (2009) who converted 85% of catechins to theaflavins using an 
immobilized polyphenol oxidase in their batch reaction. This result has never 
been achieved in a continuous flow system such that it could be used as 
method to manufacture labelled theaflavin. 
 
It is theoretically possible to perform the series of reactions shown in figure 13 
in a microfluidic reactor, with the potential benefit of a greater yield than in 
previous batch reactions. 
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Figure 13. Reaction scheme adapted from Kohri et al., (2001) by Peng and Yao 
(2009) showing steps for 2 synthetic routes of producing a deuterium labelled 
epicatechin and theaflavin in batch reactions. 
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Chemical synthesis has been performed on many occasions in a microfluidics 
reactor (Haswell, 2006). D-labelling has also been performed using a 
microreactor, more recently by Hooper, Watts and Wiles (2008) with great 
success. In their reactions phenol derivatives were labelled with deuterium 
giving yields in excess of 92%.   
 
When examining the structure of epicatechin another option of deuterium 
labelling is present. Previous research by Kiehlmann et al., (1988) shows that in 
epicatechins stereoisomer catechin, a deuterium label can be added in position 
6 or 8 (see figure 14).  
 
Figure 14. Positions of deuterium labelling in catechin (Kiehlmann et al., 1988) 
 
 
 
A rapid microreactor synthesis of labelling epicatechin using a scheme based 
on this work could also be achieved. However in the work by Kiehlmann et al., 
(1988), deuterium labelled catechin was easily converted back to catechin in 
acidic conditions 
 
2.1.2 Synthesis of modified catechins 
Various groups have attempted to synthesize modified catechins in order to 
increase their antioxidant capabilities. In 1990, Van der Western, Steenkamp 
and Ferreira showed what they called “an unusual reaction” where they reacted 
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various flavan-3-ols, including epicatechin, catechin and epigallocatechin with 
acetone and tetrabromomethane. The result was a simple acid catalysed 
reaction, where acetone was incorporated into the carbon framework of the 
flavan-3-ols, leading to the formation of a tetracyclic ring, which can be seen in 
figure 15. 
 
Figure 15. Showing planar epicatechin and planar catechin 
 
 
Unfortunately the yield of planar epicatechin and catechin in the method by Van 
der Western, Steenkamp and Ferreira (1990) was very low. The yield for planar 
epicatechin was 23% and for catechin it was only 24%. However, the yield for 
planar catechin was increased to 71% by Fukuhara et al., (2002) by utilizing a 
new method. This method involved the reaction of catechin with borontrifluoride 
diethyletherate and acetone at 0°C for 3 hours. The research group used a new 
method in 2006, which gave a 76.3% yield of planar catechin (Hakamata et al., 
2006). In this new method catechin was reacted with acetone and Trimethylsilyl 
trifluoromethanesulfonate in THF at -5°C for 12 hours. From the research 
carried out in 2002 and 2006 planar epicatechin was shown to have increased 
antioxidant capabilities. In a theoretical study (Wang and Zhang, 2005) it was 
proposed that the increased radical scavenging activity was due to an electron 
transfer mechanism and not hydrogen transfer as in the case of unmodified 
polyphenols. In 2009, Fukuhara et al., practically confirmed that planar catechin 
had a 5-fold increase in radical-scavenging activity in comparison to catechin. 
The extra activity was proposed to arise from the “modifications affecting O-H 
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bond dissociation enthalpy or stabilization of the phenoxyl radical” (Fukuhara et 
al., 2009). 
It is noticeable that since Van der Western, steenkamp and Ferreira (1990), 
there had been no further research conducted on the production of planar 
epicatechin. It is likely that planar epicatechin could show increased antioxidant 
capabilites comparable to planar catechin, and therefore would be beneficial to 
synthesize. Since the yield was so poor in batch a microfluidic approach may 
give better results due to enhanced mixing conditions. 
 
2.2 Aims  
The aims of this project are to produce deuterium labelled epicatechin in a 
microreactor by adapting batch methods by Kohri et al., (2001), Peng and Yao 
(2009) and Kiehlmann, Leto and Cherniwchan (1988). It is hoped that the stable 
deuterium labelled epicatechin produced will be be used in future metabolic 
studies and in the deuterium labelled theaflavin which will be used to determine 
its antimicrobial modes of action. Further aims of this project will be to 
synthesize planar epicatechin in a microreactor in order to test if like planar 
catechin it had increased antioxidant and antibacterial effects. 
 
2.3 Materials and methods 
General: All chemicals were used as supplied and were purchased from 
Sigma-Aldrich UK, Fisher Scientific UK and Unilever China. All solvents were all 
stored over molecular sieves.  
 
Analytical methods: All NMR experiments were recorded using a JEOL JNM-
ECP400 FT NMR spectrometer (400MHz (1H), 99.5MHz (13C)) All data recorded 
are given a chemical shifts in δ (ppm). All 1H HMR multiplicity and integration 
were downfield from tetramethylsilane and 13C NMR from CDCl3. All NMR 
samples were unless stated otherwise run in deuterated chloroform solutions.  
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All MS experiments were performed using a Thermo-Finnigan LCQ Classic MS 
system with thermo separations LC including binary gradient pumping system 
and AS3000 autosampler. 
Melting point data were collected using an Olympus BH2 microscope and a 
Mettler FP52 heat platform and FP5 controller. The heating rate was 10°C/min 
up to a temperature of 140°C were the rate was lowered to 1°C/min. All 
elemental analysis was performed using a Fison EA 1108 CHN. 
 
2.3.1 Methods for testing the stability of EC 
2.3.1.1 Production of EC solution 
A simple stability test for epicatechin over time was carried out using 10 mM 
solutions of EC. To produce a 10 mM solution of EC, 0.0291 g was weighed out 
and dissolved in 1 mL of 100% methanol in a 15 mL tube. To this 9 mL of water 
was added and then vortexed to mix. The tube was wrapped in aluminium foil to 
protect against any possible photo degradation and stored in the fridge until it 
was required for analysis. New solutions were prepared at 20 day intervals, up 
to and including 100 days after the first solution had been prepared.  
 
2.3.1.2 Analysis of EC solutions 
The analysis of the EC solutions was performed using high performance liquid 
chromatography (HPLC). 10 µL samples of each solution were in turn injected 
into the HPLC machine. The elutant was a 20/80 mix of methanol and water, 
with a flow rate of 1000 mL/min. A Gemini 5 micron C18 (150 x 4.80mm) 
column was selected to gain the best retention time. The wavelength of the UV 
lamp was set to 280 as this was found to show catechins more effectively in this 
HPLC setup.  
 
2.3.2 Synthesis of deuterium labelled epicatechin – Method 1 
The initial methodology for this series of reactions was based on that reported 
by Kohri et al., 2001, adapted for the labelling of epicatechin and theaflavinin 
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batch by Peng and Yao (2009). The adapted reaction scheme can be seen in 
figure 13. 
 
2.3.2.1 Microfluidic reactor design and preparation 
The microreactor used in the labelling reactions was specifically designed and 
produced to allow the input of two separate solutions. The microreactor, which 
can be seen in figure 16 had channels etched using the technique shown in 
figure 10 to give a depth of 60 µm which would allow mixing to occur over its 
length. The channel width unless otherwise stated was 100 µm. 
 
Before use, the microfluidic reactor was washed with methanol to clean the 
channels and then flushed with acetic anhydride to prevent any residue 
methanol reacting with the reactants in the experiment. Methanol and water 
were used to flush the microreactor after the reaction had taken place, to avoid 
any crystal structures forming in the channels of the reactor, which might lead to 
future blockages. 
 
Figure 16. Microreactor design used in the multi step synthesis 
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2.3.2.2 Production and optimisation of 3,3’,4’,5,7-O-pentaacetyl-(-)-
epicatechin in a microreactor 
The synthesis of 3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin was performed in a T-
shaped microreactor as seen in figure 15. A reaction scheme for this shown in 
figure 17. 
 
A typical reaction involved flowing 3.5 mL of 20 mM epicatechin in pyridine 
alongside 0.5 mL of acetic anhydride in 3 mL of pyridine at 50 °C. The reaction 
was controlled by a syringe pump using a flow rate of either 20/15/10/5/2.5 
µL/min. Products were collected into a vial containing methanol, which acted as 
a quencher. This was to confirm that the reaction actually occurred in the 
microreactor and not in the vial.  
 
Figure 17. The reaction scheme for the production of 3,3’,4’,5,7-O-pentaacetyl-
(-)-epicatechin 
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Products collected were dissolved into diethyl ether and washed with 1M HCl 
several times before then being washed with brine. The organic layer was dried 
over MgSO4 filtered and concentrated under reduced pressure, which gave a 
yellow viscous oil. This was recrystilized in ethanol giving a white solid. The 
product was weighed before 1H’NMR, 13C NMR, CHN and melting point 
analysis was carried out. 
 
2.3.2.3 Bromination of 3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin in a 
microreactor 
In this reaction 3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin was brominated in a T-
shaped microreactor (see figure 16) using N-bromosuccinimide (NBS) in a 1:1 
reaction. The reaction scheme for this reaction can be seen in figure 18. 
 
Figure 18. The reaction scheme for the bromination of 3,3’,4’,5,7-O-pentaacetyl-
(-)-epicatechin with NBS 
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To 5 mL of carbon tetrachloride (CCl4) and 5 mL of acetic acid 0.025 g of NBS 
was added and dissolved in a round bottomed flask whilst warming in a water 
bath at 40 °C for five minutes. Once the NBS had dissolved 0.05 g of 3,3’,4’,5,7-
O-pentaacetyl-(-)-epicatechin was added and mixed. In this reaction a free 
radial initiator was used called 1,1’azobis(cyclohexanecarbonitrile). This was 
used as it was found to be a more efficient initiator (Sigma-Aldrich, 2009) than 
the 2,2’azobis(2-methylpropionitrile)  (AIBN) used by Kohri et al., (2001) and 
Peng and Yao (2009) in their bromination of EGCG and EC respectively. A 
1mM solution was used and prepared by dissolving 0.0024 g of 
1,1’azobis(cyclohexanecarbonitrile), in 10 mL of CCl4.  
 
A typical reaction involved flowing 10 mL the 1:1 NBS/3,3’,4’,5,7-O-pentaacetyl-
(-)-epicatechin in a CCl4/acetic acid solution alongside 10 mL of the 1mM 
1,1’azobis(cyclohexanecarbonitrile)/ CCl4 solution at 60 °C through a T-shaped 
microreactor. The reaction was controlled by a syringe pump using a flow rate 
of 5 µL/min. Products were collected into a vial containing water, which acted as 
a quencher. This was to confirm that the reaction actually occurred in the 
microreactor and not in the collecting vial.  
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Once the reaction was complete the product solution was washed with 
dichloromethane (DCM) and distilled water to remove the succinimide. The 
water was removed into a beaker and the products were washed again with 
DCM. The product solution was dried using magnesium sulphite, filtered and 
concentrated under reduced pressure leaving a dry red coloured powder. The 
product was weighed before 1H’NMR and LC/MS data were collected. 
 
2.3.2.4 Substitution of bromine with deuterium 
In this reaction NaBD4 was used in a 1:4 reaction with the brominated 
3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin to substitute the bromine with a 
deuterium. The reaction scheme for this can be seen in figure 19. 
 
Figure 19. The reaction scheme for the substitution of bromine using NaBD4 
 
 
 
For this reaction 0.06 g of crude bromination product was dissolved in 5 mL of 
dry methanol and flowed alongside 0.002 g NaBD4 in 5 mL of dry methanol in a 
T-shaped microreactor (Figure 16). Although the reaction is a 1:4 
(NaBH4:bromo-3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin) an excess was used 
due to the presence of succinimide from the previous step. The reactants were 
flowed alongside each other at 25 °C. The reaction was controlled by a syringe 
pump using a flow rate of 5 µL/min. Products were to be collected into a vial 
containing water, which acted as a quencher. 
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2.3.3 Microreactor synthesis of deuterium labelled epicatechin – Method 2 
2.3.3.1 Microreactor synthesis of 6-iodoepicatechin 
In this 1:1 reaction based on the batch method by Kiehlmann et al., (1988), N-
iodosuccinimide was reacted with epicatechin in a continuous flow microreactor. 
A reaction scheme of this can be seen in figure 20. 
 
Figure 20. The reaction scheme for the iodination of epicatechin 
 
 
 
In this reaction 0.058g of epicatechin was dissolved in 10 mL of dry acetone 
and flowed through a T-shaped microreactor (figure 16) alongside 0.045 g of N-
iodosuccinimide in 10 mL of acetone at 25 °C. The reaction was controlled by a 
syringe pump using a flow rate of 10 µL/min. Products were collected into a vial 
containing methanol, which acted as a quencher. This was to confirm that the 
reaction actually occurred in the microreactor and not in the collecting vial. 
Products were concentrated under reduced pressure leaving a brown/beige 
coloured powder. The product was weighed before 1H’NMR and LC/MS data 
were collected. Due to the insolubility of 6-iodoepicatechin in D-chloroform, 
1H’NMR analysis was performed in acetone-d6. 
 
2.3.3.2 Microreactor synthesis of deuterated epicatechin 
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In this 1:2 reaction the deuteration of 6-iodoepicatechin with trifluoroacetic acid-
d (deuterated TFA) was attempted in a T-shaped microreactor (see figure 16). A 
reaction scheme for this reaction can be seen in Figure 21. 
 
Figure 21. Showing the deuteration of 6-iodoepicatechin 
 
 
To prepare the reactants 0.10 g of crude 6-iodoepicatechin was dissolved in 5 
mL of acetone-d6. For the 1:2 reaction 0.046 g of deuterated TFA was needed. 
Therefore 31 µL of a 1.493 g/mL solution of deuterated TFA was added to 5 mL 
of acetone-d6. Both solutions were flowed through the T-shaped microreactor at 
25 °C. The reaction was controlled by a syringe pump with a flow rate of 10 
µL/min. Products were collected into a vial and then concentrated under 
reduced pressure leaving a purple/brown oil. The product was weighed before 
1H’NMR and MS analysis was performed in acetone-d6. The compound was 
stored in water for 24 h and analysed again to check its stability. 
 
 
 
2.3.4 Microreactor synthesis of double deuterium labelled epicatechin 
2.3.4.1 Microreactor synthesis of double iodinated epicatechin 
In this 2:1 reaction based on the batch method by Kiehlmann et al., (1988), N-
iodosuccinimide was reacted with epicatechin in a continuous flow microreactor. 
A reaction scheme of this can be seen in figure 22. 
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Figure 22. The reaction scheme for the double iodination of epicatechin 
 
In this reaction 0.058 g of epicatechin was dissolved in 10 mL of dry acetone 
and flowed through a T-shaped microreactor (figure 16) alongside 0.09 g of N-
iodosuccinimide in 10 mL of acetone at 25 °C. The reaction was controlled by a 
syringe pump using a flow rate of 10 µL/min. Products were collected into a vial 
containing methanol, which acted as a quencher. This was to confirm that the 
reaction actually occurred in the microreactor and not in the collecting vial. 
 
Products were concentrated under reduced pressure leaving a brown/beige 
coloured powder. The product was weighed before 1H’NMR and MS data were 
collected. As with 6-iodoepicatechin, the solubility of 6,8- iodoepicatechin 
produced was poor in D-chloroform. Therefore 1H’NMR analysis was performed 
in acetone-d6. 
 
2.3.4.2 Microreactor synthesis of double deuterated epicatechin 
In this 1:4 reaction the double deuteration of 6,8-iodoepicatechin with 
trifluoroacetic acid-d (deuterated TFA) was attempted in a T-shaped 
microreactor (see figure 16). A reaction scheme for this reaction can be seen in 
figure 23. 
To prepare the reactants 0.15 g of crude 6,8-iodoepicatechin was dissolved in 5 
mL of acetone-d6. For the 1:4 reaction 0.092 g of deuterated TFA was needed. 
Therefore 62 µL of a 1.493 g/mL solution of deuterated TFA was added to 5 mL 
of acetone-d6. Both solutions were flowed through the T-shaped microreactor at 
25 °C. 
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Figure 23. The reaction scheme for the double deuteration of 6,8-
iodoepicatechin 
 
 
The reaction was controlled by a syringe pump with a flow rate of 10 µL/min. 
Products were collected into a vial and then concentrated under reduced 
pressure leaving a purple oil. The product was weighed before 1H’NMR and MS 
analysis was performed in acetone-d6. The compound was stored in water for 
24 h and analysed again to check its stability. 
 
2.3.5 Microreactor synthesis of deuterium labelled epicatechin – Method 3 
This methodology is adapted from the batch method by Buffnoir, Rolando and 
Russell (1998). Unlike Buffnoir, Rolando and Russell (1998), tert 
butyldimethysilyl groups were added to protect the epicatechin OH groups 
instead of benzyl groups. It was felt that the removal tert-butyldimethylsilyl 
groups would be a more straight forward to carry out in a microreactor under 
acidic conditions. A reaction scheme of the deuteration in method 3 can be 
seen in figure 24. 
 
Figure 24. Method 3 for deuterating epicatechin 
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2.3.5.1 Microreactor synthesis of tert-butyldimethylsilyl protected 
epicatechin  
The method to protect epicatechin with tert-butyldimethylsilyl groups was based 
on that of Runarsson et al., (2008) in their preparation of (TBDMS)-chitosan. A 
reaction scheme for this reaction can be seen in figure 25. 
 
 
 
 
Figure 25. The reaction scheme for the addition of tert-butyldimethylsilyl  
protecting groups 
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In preparation of this reaction 0.058 g of epicatechin was dissolved in 10 mL of 
pre-warmed DMF. Also to 10 mL of prewarmed DMF 0.06 g of tert-butyldimethyl 
chlorosilane and 0.054 g of imidazole were added and dissolved. Both solutions 
were flowed through a T-shaped microreactor (Figure 16) at 5/10/15 µL/min. 
Products were collected into a vile containing water to quench the reaction. The 
products were extracted into DCM and washed 3 times with brine. The DCM 
layer was extracted onto MgSO4, filtered and dried under reduce pressure. 
Products were dissolved in chloroform-d and analysed using 1H’NMR. 
 
2.3.5.2 Microreactor synthesis of 3,3’,4’,7-O-tetraacetyl-(-)-epicatechin  
The synthesis of 3,3’,4’,7-O-tetraaacetyl-(-)-epicatechin was performed in a T-
shaped microreactor as seen in figure 16. A reaction scheme for this seen in 
figure 26. 
 
 
 
Figure 26. The reaction scheme for the production of 3,3’,4’,7-O-tetraacetyl-(-)-
epicatechin 
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In this reaction 3.5 mL of 20 mM (0.02 g) epicatechin in pyridine was flowed 
alongside 0.25 mL of acetic anhydride in 3.25 mL of pyridine at 50 °C. The 
reaction was controlled by a syringe pump using a flow rate of 5 µL/min. 
Products were collected into a vial containing methanol, which acted as a 
quencher. This was to confirm that the reaction actually occurred in the 
microreactor and not in the vial.  
 
Products collected were dissolved into diethyl ether and washed with 1M HCl 
several times before then being washed with brine. The organic layer was dried 
over MgSO4 filtered and concentrated under reduced pressure, which gave a 
yellow viscous oil. This was recrystilized in ethanol giving a white solid. Thin 
layer chromatography (TLC) was performed in ethanol:diethyl ether (1:3) giving 
3 spots. The spots were analysed via 1H’NMR showing the centre spot to be 
3,3’,4’,7-O-tetraacetyl-(-)-epicatechin. The product was weighed before 1H’NMR 
and MS analysis were performed. 
 
2.3.5.3 Microreactor synthesis of oxidised 3,3’,4’,7-O-tetraaacetyl-(-)-
epicatechin 
In this 1:1 Dess-Martin periodinane:3,3’,4’,7-O-tetraaacetyl-(-)-epicatechin 
oxidation reaction for which a reaction scheme can be seen in figure 27.  
 
 
Figure 27. Showing the reaction scheme for the Dess-Martin reaction 
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Dess-Martin periodinane was flowed alongside 3,3’,4’,7-O-tetraaacetyl-(-)-
epicatechin in a T-shaped microreactor which can be seen in figure 16.  A 10 
mM stock solution of Dess-Martin periodinane was made by adding 0.5 mL of 
0.3M Dess-Martin (from SigmaAldrich, UK) to 15 mL of DCM. 5 mL of this stock 
solution was flowed alongside a 5 mL of a 10 mM solution of 3,3’,4’,7-O-
tetraaacetyl-(-)-epicatechin in DCM at 10/15/20 µL/Min at room temperature. 
Products were collected into a vial containing water to quench the reaction. 
Products were washed with water several times and the DCM layer was 
concentrated under reduced pressure giving a yellow oil. Products were 
analysed via 1H’NMR. 
 
2.3.6 Synthesis of planar epicatechin in a microreactor 
2.3.6.1 Microreactor synthesis of planar epicatechin – Method 1 
Based on the batch methodology reported by Hakamata et al., (2006) 
trifluoromethanesulfonate and acetone was reacted with epicatechin in a 
continuous flow microreactor. The reaction scheme of this can be seen in figure 
28. 
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Figure 28. Showing the reaction scheme for method 1 of planar epicatechin 
production.  
 
 
 
For this reaction 0.05 g of epicatechin was dissolved in 5 mL of acetone and 
flowed through a T-shaped microreactor (figure 16) alongside 5 µL of 
trifluoromethanesulfonate in 5 mL of THF at flow rates of either 5 or 10 µL/min. 
To keep the reactants cool, the microreactor was placed on ice. Reactants were 
collected in a vial containing diethyl ether. Contents of the vial were washed 3 
times with brine and the diethyl ether layer was drained and then dried over 
Na2SO4. To purify the products column chromatography using toluene-acetone-
methanol (7:3:1) was undertaken Products were dried under reduced pressure 
giving a yellow oil. 1H’NMR was then used to analyse the product. 
 
2.3.6.2 Microreactor synthesis of planar epicatechin – Method 2 
This reaction is based on the batch methodology described by Fukuhara et al., 
(2002) in which borontrifluoride diethyletherate and acetone was reacted with 
epicatechin in a continuous flow microreactor. The reaction scheme of this can 
be seen in figure 29. 
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Figure 29. Showing the reaction scheme for method 2 of planar epicatechin 
production.  
 
 
For this reaction 0.05 g of epicatechin was dissolved in 5 mL of acetone and 
flowed through a T-shaped microreactor (figure 16) alongside 151 µL of 
borontrifluoride diethyletherate in 4.85 mL of acetone at  flow rates of either 5 or 
10 µL/min. To keep the reactants cool, the microreactor was placed on ice. 
Reactants were collected in a vial containing diethyl ether. Contents of the vial 
were washed 3 times with brine and the diethyl ether layer was drained and 
then dried over Na2SO4. To purify the products column chromatography using 
Dichloromethane:methanol (10:1) was undertaken. Products were dried under 
reduced pressure giving a yellow oil. 1H’NMR was then used to analyse the 
product. 
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2.4 Results and discussion 
2.4.1 Results for the stability of EC 
When observing the different EC solutions by eye, it was noticeable that a 
colour change occurred over time. This colour change, which can be seen in 
figure 30, increases in intensity with the age of the solution. At 0 days the 
sample solution of EC is transparent. However, as the age of the sample 
solution increases so does the yellow colour, with the 100 day old solution 
having the darkest colour. This indicates some oxidation/polymerization 
products were being produced.  
Figure 30. Colour change of epicatechin solutions over time 
 
 
When performing the HPLC on the stored samples the retention time of the EC 
peaks is between 1 minute and 34 seconds and 1 minute and 48 seconds. 
When analysing the HPLC data the peak area for EC is seen to reduce over 
time. In figure 31 the peak area can be seen to drop from 664648 to 465260 
over the period of 100 days. This equates to a drop in EC content of 30% over 
this duration and indicates some oxidation/polymerization had occurred. 
Although the peak for EC reduced over time, no new peaks from 
oxidation/polymerization products were observed. This would suggest that 
either the wavelength the detector was set at could not pick up any products or 
products were carried off the HPLC column in the elutant very quickly and 
therefore were not detected.  
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Figure 31. Graph to show the reduction in epicatechin concentration over time 
 
Peak area calculated from HPLC data (280 nm) using a Gemini 5 micron C18 
(150 x 4.80mm) column.  
 
Any further investigation would require experimenting with solvent ratios and/or 
flow rates to detect and analyse and oxidation/polymerisation products. 
 
2.4.2 Results for microreactor synthesis of labelled of epicatechin - 
Method 1 
The following results are from method 1 of the microreactor synthesis of 
deuterium labelled epicatechin. In figure 32 the adapted reaction scheme can 
be seen showing the steps involved for this synthetic route. 
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Figure 32. Reaction scheme adapted from Kohri et al., (2001) by Peng and Yao 
(2009) showing steps for 2 synthetic routes of producing a deuterium labelled 
epicatechin and theaflavin in batch reactions. 
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2.4.2.1 Optimization and production 3,3’,4’,5,7-O-pentaacetyl-(-)-
epicatechin in a microreactor 
The 3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin produced at 20 µL/min gave a 
melting point of 151-153.3 °C which compared to results from past literature 
results of  152-153 °C (Hergert and Kurth, 1953) was acceptable. The yield 
produced from this reaction was 57.14% (0.020 g). From the elemental analysis 
undertaken (See table 1), the results show the compound produced is that 
expected. 
 
Table 1. Showing elemental analysis from 3,3’,4’,5,7-O-pentaacetyl-(-)-
epicatechin produced from a reaction at 20 µL/min 
C25H24O11 (MW= 500.45 g/mol) 
Analysis % Expected Results % Found 
C 60.00 60.27 
H 4.83 5.03 
N 0.00 0.00 
 
From this reaction the following 1H’NMR and 13C-NMR data is reported where: d = 
doublets, dd = doublet of doubles, m = multiplet, s = singlet and bs = broad singlet. 
 
1H’NMR (CDCl3) 7.37 (1H, d, J=0.72 Hz, H-2’), 7.28 (1H, d, J=2.8Hz, H-6’), 7.21 
(1H, d, J=8.4Hz, H-5’), 6.67 (1H, d, J=2.36 Hz, H-6’), 6.57 (1H, d, J=2.2 Hz, H-
8’), 5.39 (1H, m, H-3’), 5.11 (1H, bs, H-2’), 2.98 (1H, dd, J=4.4, 22.36Hz, H-4’), 
2.89 (1H, dd, J=2.2, 9.0Hz, H-4), 2.31, 2.30, 2.30, 2.28 (4x3H,4xs, 4xCOCH3), 
1.92 (3H, xs, COCH3). 
 
13C-NMR (CDCl3) 170.5, 169.1, 168.5, 168.2, 168.1 (OCOCH3), 154.9 (C-8a), 
150.1 (C-7), 149.7 (C-5), 142.1, 141.9 (C-3’, 4’), 136.4 (C-1), 124.4 (C-6’), 123.4 
(C-5’), 121.9 (C-2’), 110.1 (C-4a). 108.8 (C-6), 108.1 (C-8), 77.9 (C-2), 66.6 (C-
3), 22.7 (C-4), 21.1, 20.8, 20.8, 20.7, 20.7 (OCOCH3). 
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The 3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin produced at 15 µL/min gave a 
melting point of 150.8-153.1 °C which compared to results from past literature 
results of  152-153 °C (Hergert and Kurth, 1953) was acceptable. The yield 
produced from this reaction was 65.7% (0.023 g). From the elemental analysis 
undertaken (See table 2), the results show the compound produced is as 
expected. 
 
Table 2. Showing elemental analysis from 3,3’,4’,5,7-O-pentaacetyl-(-)-
epicatechin produced from a reaction at 15 µL/min 
C25H24O11 (MW= 500.45 g/mol) 
Analysis % Expected Results % Found 
C 60.00 60.02 
H 4.83 4.76 
N 0.00 0.00 
 
From this reaction the following 1H’NMR and 13C-NMR data is reported where: d = 
doublets, dd = doublet of doubles, m = multiplet, s = singlet and bs = broad singlet. 
 
1H’NMR (CDCl3) 7.36 (1H, d, J=2.6 Hz, H-2’), 7.28 (1H, d, J=2 Hz, H-6’), 7.21 
(1H, d, J=8.4 Hz, H-5’), 6.67 (1H, d, J=2.2 Hz, H-6), 6.57 (1H, d, J=2.2 Hz, H-8), 
5.39 (1H, m, H-3), 5.11 (1H, bs, H-2), 2.98 (1H, dd, J=4.2, 22 Hz, H-4), 2.89 
(1H, dd, J=3.1, 12.8 Hz, H-4), 2.30, 2.30, 2.28, 2.27 (4x3H,4xs, 4xCOCH3), 1.92 
(3H, xs, COCH3). 
 
13C-NMR (CDCl3) 107.4, 169.0, 168.5, 168.2, 168.1 (OCOCH3), 154.9 (C-8a), 
150.1 (C-7), 149.7 (C-5), 142.2, 141.9 (C3’, 4’), 136.5 (C-1), 124.4 (C-6’), 123.4 
(C-5’), 121.9 (C-2’), 110.1 (C-4a), 108.8 (C-6), 108.0 (C-8), 77.9 (C-2), 66.6 (C-
3), 22.1, 20.8, 20.8, 20.6, 20.6 (OCOCH3). 
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The 3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin produced at 10 µL/min gave a 
melting point of 151.8-152.9 °C which compared to results from past literature 
results of  152-153 °C (Hergert and Kurth, 1953) was acceptable. The yield 
produced from this reaction was 82.9% (0.029 g). From the elemental analysis 
undertaken (See table 3), the results show the compound produced is as 
expected. 
 
Table 3. Showing elemental analysis from 3,3’,4’,5,7-O-pentaacetyl-(-)-
epicatechin produced from a reaction at 10 µL/min 
C25H24O11 (MW= 500.45 g/mol) 
Analysis % Expected Results % Found 
C 60.00 59.81 
H 4.83 4.82 
N 0.00 0.00 
 
From this reaction the following 1H’NMR and 13C-NMR data is reported where: d = 
doublets, dd = doublet of doubles, m = multiplet, s = singlet and bs = broad singlet. 
 
1H’NMR (CDCl3) 7.36 (1H, d, J=2.7 Hz, H-2’), 7.28 (1H, d, J=2.2 Hz, H-6’), 7.20 
(1H, d, J=8.2 Hz, H-5’), 6.67 (1H, d, J=2.4 Hz, H-6), 6.57 (1H, d, J=2.2 Hz, H-8), 
5.39 (1H, m, H-3), 5.11 (1H, bs, H-2), 2.98 (1H, dd, J=4.4, 22.2 Hz, H-4), 2.89 
(1H, dd, J=3.1, 12.6 Hz, H-4), 2.31, 2.30, 2.30, 2.28 (4x3H,4xs, 4xCOCH3), 
1.92(3H, xs, COCH3) 
 
13C-NMR (CDCl3) 169.6, 168.1, 167.5, 167.3, 167.2  (OCOCH3), 154.0 (C-8a), 
149.1 (C-7), 148.8 (C-5), 141.3, 140.9 (C3’, 4’), 135.5 (C-1), 123.5 (C-6’), 122.5 
(C-5’), 121.0 (C-2’), 109.2 (C-4a), 107.9 (C-6), 107.1 (C-8), 77.0 (C-2), 65.7 (C-
3), 21.8, 20.1, 19.9, 19.8, 19.7 (OCOCH3) 
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The 3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin produced at 5 µL/min gave a 
melting point of 151.9-153.2 °C which compared to results from past literature 
results of  152-153 °C (Hergert and Kurth, 1953) and was acceptable. The yield 
produced from this reaction was 90.9% (0.0318 g). From the elemental analysis 
undertaken (See table 4), the results show the compound produced is as 
expected. 
 
Table 4. Showing elemental analysis from 3,3’,4’,5,7-O-pentaacetyl-(-)-
epicatechin produced from a reaction at 5 µL/min 
C25H24O11 (MW= 500.45 g/mol) 
Analysis % Expected Results % Found 
C 60.00 60.05 
H 4.83 4.82 
N 0.00 0.00 
 
From this reaction the following 1H’NMR and 13C-NMR data is reported where: d = 
doublets, dd = doublet of doubles, m = multiplet, s = singlet and bs = broad singlet. 
 
1H’NMR (CDCl3) 7.36 (1H, d, J=1.8 Hz, H-2’), 7.28 (1H, d, J=2.0 Hz, H-6’), 7.21 
(1H, d, J=8.4 Hz, H-5’), 6.67 (1H, d, J=2.2 Hz, H-6), 6.57 (1H, d, J=2.2 Hz, H-8), 
5.38 (1H, m, H-3), 5.11 (1H, bs, H-2), 2.98 (1H, dd, J=4.6, 22.4 Hz, H-4), 2.88 
(1H, dd, J=1.8, 17.8 Hz, H-4), 2.33, 2.30, 2.30, 2.28 (4x3H,4xs, 4xCOCH3), 
1.92(3H, xs, COCH3) 
 
13C-NMR (CDCl3) 170.5, 169.0, 168.4, 168.1, 168.1  (OCOCH3), 154.9 (C-8a), 
149.7 (C-7), 149.7 (C-5), 142.0, 141.9 (C3’, 4’), 135.8 (C-1), 123.4 (C-6’), 123.2 
(C-5’), 122.0 (C-2’), 109.6 (C-4a), 108.8 (C-6), 108.1 (C-8), 77.0 (C-2), 66.6 (C-
3), 26.0, 21.1, 20.8, 20.7, 20.6 (OCOCH3) 
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The 3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin produced at 2.5 µL/min gave a 
melting point of 152.0-153.3 °C which compared to results from past literature 
results of  152-153 °C (Hergert and Kurth, 1953) was acceptable. The yield 
produced from this reaction was 94.3% (0.033 g). From the elemental analysis 
undertaken (See table 5), the results show the compound produced is as 
expected. This was a very high yield indicating that microreactors when 
optimized can equal or supersede traditional batch reactions 
 
Table 5. Showing elemental analysis from 3,3’,4’,5,7-O-pentaacetyl-(-)-
epicatechin produced from a reaction at 2.5 µL/min  
C25H24O11 (MW= 500.45 g/mol) 
Analysis % Expected Results % Found 
C 60.00 60.03 
H 4.83 4.82 
N 0.00 0.00 
 
From this reaction the following 1H’NMR and 13C-NMR data is reported where: d = 
doublets, dd = doublet of doubles, m = multiplet, s = singlet and bs = broad singlet. 
 
1H’NMR (CDCl3) 7.36 (1H, d, J=1.8 Hz, H-2’), 7.28 (1H, d, J=2.0 Hz, H-6’), 7.21 
(1H, d, J=8.2 Hz, H-5’), 6.67 (1H, d, J=2.2 Hz, H-6), 6.50 (1H, d, J=2.2 Hz, H-8), 
5.38 (1H, m, H-3), 5.11 (1H, bs, H-2), 2.99 (1H, dd, J=4.6, 58.1 Hz, H-4), 2.88 
(1H, dd, J=1.64, 58.1 Hz, H-4), 2.30, 2.30, 2.29, 2.28 (4x3H,4xs, 4xCOCH3), 
1.92 (3H, xs, COCH3) 
 
13C-NMR (CDCl3) 169.5, 168.0, 167.5, 167.4, 167.2  (OCOCH3), 153.9 (C-8a), 
149.2 (C-7), 148.8 (C-5), 141.3, 141.1 (C3’, 4’), 135.6 (C-1), 123.4 (C-6’), 122.5 
(C-5’), 121.1 (C-2’), 110.2 (C-4a), 108.8 (C-6), 108.5 (C-8), 77.1 (C-2), 65.8 (C-
3), 25.1, 21.2, 20.8, 20.7, 20.6 (OCOCH3) 
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From the optimization data a graph of % yield against flow rate was plotted to 
show visually how the yield is affected by flow rate in a microreactor (Figure 33). 
 
Figure 33. Graph showing the correlation between flow rate and yield obtained 
for the synthesis of 3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin 
 
 
From the data it can be clearly seen that the slower the flow rate the higher the 
yield. A flow rate of 2.5 µL/min produced the highest yield of 94.3%. All 
elemental, melting point, 13C-NMR and 1H’NMR data all confirm that in each 
reaction 3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin was produced. Flow rates less 
than 2.5 µL/min were not tested, as the benefits of a slightly higher yield would 
be negated by the reduction in the rate of the product synthesised. For 
example, it would take almost 7 hours to collect 1 mL of a 20mM solution of 
3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin for analysis at 2.5 µL/min, however, it 
would take over 16 hours to flow the same solution at 1 µL/min.  
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2.4.2.2 Bromination of 3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin in a 
microreactor 
In this reaction (see figure 32, step 2) 0.06 g of brominated 3,3’,4’,5,7-O-
pentaacetyl-(-)-epicatechin was produced. From this reaction the following 
H’NMR is reported where: d = doublets, dd = doublet of doubles, m = multiplet, 
s = singlet and bs = broad singlet. 
 
1H’NMR (CDCl3) 7.36 (1H, d, J=1.84 Hz, H-2’), 7.28 (1H, d, J=1.6 Hz, H-6’), 
7.21 (1H, d, J=8.28 Hz, H-5’), 6.67 (1H, d, J=2.36 Hz, H-6), 6.50 (1H, d, J=2.2 
Hz, H-8), 5.36 (1H, m, H-3), 5.12 (1H, bs, H-2), 2.98 (1H, dd, J=13.6, 25.2 Hz, 
H-4), 2.88 (1H, dd, J=19.6, 24.0 Hz, H-4), 2.37, 2.36, 2.30, 2.28 (4x3H,4xs, 
4xCOCH3), 1.91 (3H, xs, COCH3) 
 
The 1H’NMR data indicates that the bromination occurred as a mixture in the H-
8 and H-6 positions, shown in figure 34. These bromination positions were also 
found in batch reactions by Kiehlmann and Tracey (1986) and not on the centre 
tetrahydropyran ring as based on the research by Kohri et al., (2001) and Peng 
and Yao (2009). Variations in flow rates, initiators and temperatures where 
tested and none resulted in the 4-bromo 3,3’,4’,5,7-O-pentaacetyl-(-)-
epicatechin. 
 
Figure 34. 6-bromo and 8-bromo 3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin  
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In the acetylation reaction there were peaks in the H’NMR at regions 6.67 ppm 
and 6.50 ppm where as in the 1H’NMR for the bromination product the peaks at 
6.67 ppm and 6.50 ppm remained but the size of the peaks was significantly 
reduced. This indicates that bromination was not specific and occurred in either 
position 6 or 8. The reaction was confirmed with LC/MS where a single mass 
peak was seen at 580 m/z indicating that single bromination had occurred and a 
proton had been lost. Although these were not the positions needed for 
bromination it could still be used to label epicatechin. It also showed that the 
bromination of 3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin was possible in a 
microreactor, although like in batch reactions bromination occurs as a mixture in 
position 6 or 8.  
 
2.4.2.3 Substitution reaction 
In this reaction (see figure 32, step 3a) no result could be produced when using 
a microreactor. This was due to excessive gas production from the NaBD4 
resulting in high back pressure and causing the syringe to become 
disconnected from the microreactor. Unfortunately due to the nature of this 
reaction it could not be safely repeated again in a microreactor. In the reaction 
scheme in figure 8 the alternative would be to choose step 3b. Unfortunately 
this was not an option due to the reactants use in this method contain tin 
compounds, which are difficult to remove and can cause cell death (Nguyen, 
Foller and Lang, 2008). Due to the future usage of the labelled compounds with 
microbial and possibly mammalian cells, this was too high a risk factor and 
therefore other methods needed to be considered. 
 
2.4.3 Results for microreactor synthesis of deuterium labelled epicatechin 
– Method 2 
The following results are from the second synthetic route used to deuterium 
label epicatechin in a microreactor. In figure 35 a reaction scheme can again be 
seen for this 2-step synthesis. 
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Figure 35. Reaction scheme for method 2 of the microreactor synthesis of 
deuterium labelled epicatechin. 
 
 
2.4.3.1 Iodination of epicatechin in a microreactor 
The reaction produced a crude product with a weight of 0.1 g with LC/MS 
showing a very small mass peak at 290 m/z and much larger mass peak at 
416.8 m/z. Although some starting material was still present, H’NMR data from 
the crude product showed that the reaction was almost 100% complete. From 
this reaction the following 1H’NMR is reported where: d = doublets, dd = doublet 
of doubles, m = multiplet, s = singlet and bs = broad singlet. 
 
1H’NMR (400 MHz, CD3COCD3) 6.95 (1H, d, J=1.36 Hz, H-2’), 6.81 (1H, d, 
J=2.2 Hz, H-6’), , 6.14 (1H, d, J=2.76 Hz, H-8), 5.45 (1H, m, H-3), 4.87 (1H, bs, 
H-2), 2.90 (1H, dd, J=19.2, 4.67 Hz, H-4), 2.70 (1H, dd, J=16.6, 2.2 Hz, H-4) 
 
 78 
13C’NMR (400 MHz, CD3COCD3) 157.4 (C-8a), 156.3 (C-7), 156.2 (C-5), 145.2, 
141.1 (C-3’, C-4’), 131.8 (C-1’), 119.2 (C-6’), 115.7 (C-2’), 115.0 (C-5’), 100.5 
(C-4a), 96.2 (C-8), 79.8 (C-6), 67.2 (C-2), 66.4 (C-3), 29.6 (C-4) 
 
A peak was also seen at 2.61 ppm indicating succinimide. As in the research by 
Kiehlmann et al., (1988) we noticed the disappearance of a peak at 6.25 ppm 
indicating that the proton in that region had been lost and 6-iodoepicatechin had 
been produced. However a direct comparison with the work of Kiehlmann et al., 
(1988) could not be made, due to the variation in peaks produced by catechin 
and epicatechin. The 1H’NMR and the LC/MS data confirmed that the iodination 
had been successful and proved for the first time that a polyphenol could be 
iodinated in a microreactor. Although this reaction in effect produces a similar 
result as the bromination reaction, it is position specific and protecting the OH 
groups was not necessary. This increases speed of production and therefore 
costs can be reduced. 
 
2.4.3.2 Deuteration of 6-iodoepicatechin in a microreactor 
In this reaction, a purple/brown oil was produced indicating that there free iodine 
in the mixture. The product oil weighed 0.105 g. LC/MS spectra of the product 
showed a main mass peaks at 292 m/z and a smaller peak at 293 m/z 
indicating the mass of single and double D-labelled epicatechin with the 
additional deuterium most likely being from hydrogen transfer with one of the 
phenol groups. From this reaction the following 1H’NMR is reported where: d = 
doublets, dd = doublet of doubles, m = multiplet, s = singlet and bs = broad 
singlet. 
 
1H’NMR (400 MHz, CD3COCD3) 6.95 (1H, d, J=1.36 Hz, H-2’), 6.81 (1H, d, 
J=2.2 Hz, H-6’), , 6.14 (1H, d, J=2.76 Hz, H-8), 5.45 (1H, m, H-3), 4.87 (1H, bs, 
H-2), 2.90 (1H, dd, J=18.1, 4.76 Hz, H-4), 2.70 (1H, dd, J=16.2, 2.2 Hz, H-4) 
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13C’NMR (400 MHz, CD3COCD3) 157.5 (C-8a), 157.0 (C-7), 156.6 (C-5), 145.2, 
145.1 (C-3’, C-4’), 132.4 (C-1’), 119.4 (C-6’), 115.7 (C-2’), 115.2 (C-5’), 100.1 
(C-4a), 99.8 (C-8), 95.6 (C-6), 79.9 (C-2), 66.6 (C-3), 29.6 (C-4) 
 
The 1H’NMR spectra showed that only one peak remained at 6.14 ppm and the 
peak at 6.25 ppm had not returned. Although it appeared from the colour of the 
product that there was some free iodine present, LC/MS and 1H’NMR spectra 
indicated that the conversion was very high. This represented the first occasion 
epicatechin had been deuterium labelled in a microreactor 
 
The immediate stability results of deuterium labelled epicatechin showed that in 
water it was stable for up to 2 hours. LC/MS performed at 0, 1 and 2 hours after 
storage showed the main mass peak remained at 292 m/z. The mass peak at 
293 m/z had been reduced indicating hydrogen transfer had again occurred and 
the extra deuterium being lost. However this does not represent the stability in 
serum and this would need to be investigated further if it were to be used in 
toxicological studies. 
 
2.4.4 Results for Double deuteration of epicatechin 
The following results are from the second synthetic route used to deuterium 
label epicatechin in a microreactor. In figure 36 a reaction scheme can again be 
seen for this 2-step synthesis. 
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Figure 36. Reaction scheme for the microreactor synthesis of double deuterium 
labelled epicatechin. 
 
 
 
 
2.4.4.1 Double iodination of epicatechin 
The reaction produced a crude product with a weight of 0.15 g with LC/MS 
showing very small mass peaks at 290 m/z and 416.8 m/z and a much larger 
mass peak at 543.6 m/z. This LC/MS and H’NMR data indicated that the 
reaction produced both single and double iodinated products, with the greater 
amount being double deuterated. From this reaction the following 1H’NMR is 
reported where: d = doublets, dd = doublet of doubles, m = multiplet, s = singlet 
and bs = broad singlet. 
 
1H’NMR (400 MHz, CD3COCD3) 6.95 (1H, d, J=1.36 Hz, H-2’), 6.81 (1H, d, 
J=2.2 Hz, H-6’), 6.14 (1H, d, J=2.76 Hz, H-8), 5.45 (1H, m, H-3), 4.87 (1H, bs, 
H-2), 2.90 (1H, dd, J=19.2, 4.67 Hz, H-4), 2.70 (1H, dd, J=16.6, 2.2 Hz, H-4) 
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13C’NMR (400 MHz, CD3COCD3) 157.4 (C-8a), 156.3 (C-7), 156.2 (C-5), 145.2, 
141.1 (C-3’, C-4’), 131.8 (C-1’), 119.2 (C-6’), 115.7 (C-2’), 115.0 (C-5’), 100.5 
(C-4a), 94.1 (C-8), 76.8 (C-6), 67.2 (C-2), 66.4 (C-3), 29.6 (C-4) 
 
A large peak in the 1H’NMR spectra was also seen at 2.61 ppm indicating 
succinimide. As in the single iodination the disappearance of the peak at 6.25 
ppm was noticed. The 1H’NMR spectra revealed that the peak at 6.14 ppm had 
also been reduced, signifying a second proton had been replaced in some of 
the epicatechin. The 1H’NMR and the LC/MS data did confirm that the double 
iodination had been achieved but the reaction had not been as successful as 
with the single iodination. However it did prove for the first time that a 
polyphenol could not only be iodinated, but double iodinated in a continuous 
flow microreactor.  
 
2.4.4.2 Deuteration of 6,8 –iodoepicatechin 
In this reaction, a purple oil was produced. This would indicate, that as in the 
single deuteration some free iodine was present. The product oil weighed 0.111 
g. LC/MS spectra of the product showed a main mass peaks at 293 m/z and a 
smaller peaks at 292 m/z 294 m/z indicating the mass of single and double D-
labelled epicatechin with the majority being double deuterated. The mass peak 
at 294 m/z would have been most likely from proton exchange From this 
reaction the following 1H’NMR is reported where: d = doublets, dd = doublet of 
doubles, m = multiplet, s = singlet and bs = broad singlet. 
 
1H’NMR (400 MHz, CD3COCD3) 6.95 (1H, d, J=1.36 Hz, H-2’), 6.81 (1H, d, 
J=2.2 Hz, H-6’), 6.14 (1H, d, J=2.76 Hz, H-8), 5.45 (1H, m, H-3), 4.87 (1H, bs, 
H-2), 2.90 (1H, dd, J=18.1, 4.76 Hz, H-4), 2.70 (1H, dd, J=16.2, 2.2 Hz, H-4) 
 
13C’NMR (400 MHz, CD3COCD3) 157.5 (C-8a), 157.0 (C-7), 156.6 (C-5), 145.2, 
145.1 (C-3’, C-4’), 132.4 (C-1’), 119.4 (C-6’), 115.7 (C-2’), 115.2 (C-5’), 100.1 
(C-4a), 99.9 (C-8), 96.6 (C-6), 79.9 (C-2), 66.6 (C-3), 29.6 (C-4) 
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The 1H’NMR spectra showed that a small peak had remained at 6.14 ppm and 
the peak at 6.25 ppm had not returned. From the 1H’NMR and LC/MS spectra it 
can be concluded that double and single deuteration had occurred. It can also 
be concluded that the double iodination is not as successful as single 
deuteration. This could be due to the iodination in the first reaction being less 
effective in position 8. However, this represents the first occasion epicatechin 
had been double deuterated labelled in a microreactor. 
 
The immediate stability results of deuterium labelled epicatechin showed that in 
water it was not stable. LC/MS performed at 0 hours showed a main mass peak 
at 293. However after 1 and 2 hours of storage in water the main mass peak 
was 292 m/z. The mass peaks at 293 m/z and 294 m/z had disappeared 
indicating hydrogen transfer had again occurred and the deuterium in position 8 
had also been lost. This shows that’s although double iodination of epicatechin 
is possible in a microreactor only deuteration in position 6 is stable for > 2 
hours. However this does not represent the stability in serum and this would 
need to be investigated further if it were to be used in toxicological studies. 
 
2.4.5 Results for the synthesis of deuterium labelled epicatechin – 
Methodology 3 
The following results are from the third synthetic route used to try and deuterium 
label epicatechin in a microreactor. In figure 37 the scheme can again be seen 
for this series of reactions. 
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Figure 37. Method 3 for the microreactor synthesis of deuterated epicatechin 
 
 
2.4.5.1 Results for tert-butyldimethylsilyl protection 
The 1H’NMR spectra obtained from the protection products showed multiple 
peaks masking any product peaks that would be visible. Even after further 
purification was undertaken the products could not be seen in the 1H’NMR 
spectra. From this it was determined that the reaction was either unsuccessful, 
or of such low yield that it would not be valuable enough to replicate. It was 
decided that even though they have reduced stability, acetyl groups would be 
used for protection.  
 
2.4.5.2 Results for the production of 3,3’,4’,7-O-tetraacetyl-(-)-epicatechin 
From LC/MS f the purified product one main mass peak was seen at 458.3 m/z 
indicating acetylation had occurred in four positions. Spectra from 1H’NMR also 
confirmed this showing only four acetyl groups. When comparing the 1H’NMR 
with that of pentaacetly-(-)-epicatechin it was clear that the acetyl group in 
position 5 was missing. This confirmed that 3,3’,4’,7-O-tetraacetyl-(-)-
 84 
epicatechin had been produced. In this reaction the purified product weighed 
0.025 g giving a yield of 78.1%.  
 
From this reaction the following 1H’NMR is reported where: d = doublets, dd = 
doublet of doubles, m = multiplet, s = singlet and bs = broad singlet. 
 
1H’NMR (CDCl3) 7.36 (1H, d, J=1.8 Hz, H-2’), 7.28 (1H, d, J=2.0 Hz, H-6’), 7.21 
(1H, d, J=8.2 Hz, H-5’), 6.67 (1H, d, J=2.2 Hz, H-6), 6.50 (1H, d, J=2.2 Hz, H-8), 
5.38 (1H, m, H-3), 5.11 (1H, bs, H-2), 2.99 (1H, dd, J=4.6, 58.1 Hz, H-4), 2.88 
(1H, dd, J=1.64, 58.1 Hz, H-4), 2.30, 2.30, 2.29, 2.28 (4x3H,4xs, 4xCOCH3) 
 
2.4.5.3 Results for Dess-Martin reaction 
When reading the 1H’NMR spectra for this reaction it was clear that it was 
unsuccessful. Multiple peaks in all regions were observed and therefore 
masking any product peaks that could possibly have been present. This could 
have been due to the protecting groups not being sufficient for the reaction, 
resulting in oxidation at multiple regions on the compound. When analysing 
products from all flow rates tested the results were the same. A possible 
solution to this would be to use benzyl groups to protect epicatechin. 
Unfortunately when consulting the literature, protecting epicatechin with benzyl 
gives very poor yields in batch (20%, Tckmantel, Kozikowski and Ramanczyk, 
1999) making the procedure more costly.  Transferring this reaction to 
microreactor production would be unlikely to increase the yield. A possible 
alternative would be to follow the work of Hiipakka et al., (2002) and produce 
tert-butldimethulsilyl (TBDMS) protected epicatechin in a 4-step methodology, 
not a one step process. In this case epicatechin would be protected with acetyl 
groups prior to the TBDMS reaction. This would give the more stabile TBDMS 
protecting groups and possibly lead to a more successful Dess-Martin reaction. 
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2.4.6.1 Results for microreactor synthesis of planar epicatechin - Method 1 
The following results are from the first synthetic route used to try and synthesize 
planar epicatechin in a microreactor. In figure 38 a scheme can again be seen 
for this reaction. 
 
After examining the 1H’NMR spectra of the products from this reaction it was 
clear the reaction had not been successful. Even after purification multiple 
peaks were seen and when comparing to the research of Van der Western, 
Steenkamp and Ferreira (1990) no product resembling planar epicatechin or 
catechin could be seen. 
 
Figure 38. The reaction scheme for method 1 of the microreactor synthesis of 
planar epicatechin. 
 
 
 
With the exception of Van der Western, Steenkamp and Ferreira (1990) no 
other group has attempted to produce planar epicatechin and instead have 
opted for the production of planar catechin. This could be due to the fact that 
the either the yield was so poor in their reaction or the stereochemistry for 
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epicatechin i.e. both the B ring and the OH group attached to the C ring are 
projecting into the same plane, makes it unlikely for a planar compound to form. 
However, with catechin the B ring and OH group on the C ring are in different 
planes and when the reaction to form planar catechin takes places the two are 
moved into line, straightening/creating the planar molecule. 
 
2.4.6.2 Results for the microreactor synthesis of planar epicatechin - 
Method 2 
The following results are from the first synthetic route used to try and synthesize 
planar epicatechin in a microreactor. In figure 39 a scheme can again be seen 
for this reaction. 
 
Figure 39. Showing the reaction scheme for method 2 of planar epicatechin 
production.  
 
 
As with the methodology 1 the 1H’NMR spectra did not show the expected 
product and multiple peaks were shown making interpretation difficult. This did 
not change even when the flow rate of the reaction was altered.  
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2.5 Conclusions 
In conclusion, it has been shown for the first time that the synthesis of 
3,3’,4’,5,7-O-pentaacetyl-(-)-epicatechin is possible in a microfluidic reactor and 
that very high yields can be achieved, equal to or better than those performed in 
previous batch methods. It has also been shown that in this reaction, flow rate 
does have a significant impact on both the yields and product purity. In addition, 
the methodology described can also be applied to various other types of 
protecting group chemistry, to aid in not only optimisation but also to increase 
product yields.  
 
It was discovered that the bromination of 3,3’,4’,5,7-O-pentaacetyl-(-)-
epicatechin could not occur in the position originally thought and in practice the 
bromine prefers the electron rich position 6 or 8. It was found that in step 3 
shown in figure 13 was not possible in a microreactor due to increased pressure 
in the resulting in backflow.  
 
A faster two-step method was shown to be effective in producing D-labelling 
epicatechin. This was the first time 6-iodoepicatecin and 6-deuterium labelled 
epicatechin had been produced in a continuous flow microreactor. The 
compound was shown to be stable in water for 2 hours. Future investigations 
could investigate the stability of deuterated epicatechin over 24 hours in various 
solvents. If it were to be used in toxicological studies the stability in serum 
should also be investigated.  
 
It was also shown that double iodination and deuteration of epicatechin could 
also be performed in a microreactor, although not as successful as single 
iodination/deuteration. Stabiliy testing also confirmed that the second deuterium 
was not stable in position 8 most likely due to easier proton transfer in water.  
 
A third methodology for labelling epicatechin was proven to be unsuccessful 
due to problems with protecting epicatechin. Future investigations should look 
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into protecting epicatechin using a 4-step methodology with TBDMS. With 
increased stability the Dess-Martin step in the synthesis should be more 
successful.  
 
It was also shown that using two different methods, planar epicatechin could not 
be produced in a microreactor at this time. It was predicted that the procedures 
appear to be successful only with catechin due to its altered stereochemistry. 
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Chapter 3  
Antimicrobial and synergistic effects of tea 
polyphenols against problematic hospital pathogens 
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3.1 Introduction 
3.1.1 Hospital pathogens, antibiotics and resistance 
3.1.1.1 Antibiotic groups 
There are many different types of antibiotics, which are used to treat bacterial 
infections. Antibiotics are put in groups that relate to there modes of action 
(Table 6). Many groups of antibiotics have experienced resistance and 
manufacturers have modified their structures in order for their use to be 
continued. 
 
Table 6. Important antibiotics and their modes of action and bacterial targets 
(Madigan et al., 2009) 
Antibiotic Group Examples of 
Antibiotic group 
Mode of action Bacterial 
targets 
Penicillins     (β-
lactam) 
Ampicillin, penicillin Disrupts peptidoglycan 
synthesis used in bacterial 
cell walls 
Gram-positive and 
some gram 
negative 
Aminoglycosides Gentamycin Binding to bacterial 30S 
ribosome leading to loss of 
protein production vital to 
cell growth 
Mostly gram-
negative, some 
gram positive e.g. 
Staphylococcus 
spp. 
Carbapenems  Imipenem Inhibition of cell wall 
synthesis 
Gram-positive and 
gram-negative 
Cephalosporins (β-
lactam) 
Cefoxitin, 
cefotaxime 
Disruption of cell wall 
synthesis 
5 generations of 
antibiotic some 
more effect against 
gram-positive or 
gram-negative 
Glycopeptides Vancomycin Disruption of cell wall 
synthesis 
Gram-positive 
Macrolides Clarithromycin Inhibition of bacterial 
protein synthesis due to 
binding to ribosome 50S 
Gran-positive 
Quinolones Ciprofloxacin Inhibits DNA replication Gram-positive and 
gram-negative 
Sulfonamides Sulfadiazine Folate synthesis inhibition, 
leading to blocking of 
nucleic acid synthesis 
Gram-positive and 
gram-negative 
Tetracyclines Tetracycline Binds to 30S ribosome 
subunit preventing mRNA 
translation 
Gram-positive and 
gram-negative 
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There have been 5 previous generations of cephalosporins antibiotics, where 
modifications have been made to combat continuing resistance (Lynch and 
Zhanel, 2009). Several bacterial species including MRSA are resistant to many 
types of antibiotics, especially beta-lactams.  
 
There are 5 mechanisms of acquired bacterial resistance (Greenwood et al., 
2008). These include: 
• Prevention of antibiotic entry to the cell  
• Antibiotic removal  
• Antibiotic destruction  
• Target site modification 
• Metabolic by-pass  
 
Prevention of entry to a bacterial cell is often due to the modification of proteins 
in the cell wall, which are able to form channels or pores called porins (Vila, 
Marti and Sanchez-Cespedes, 2007). Antibiotics such as Beta-lactams pass 
through these porins and are therefore dependant on their size (Greenwood et 
al., 2008). By reducing the size of the porins the bacterium can prevent the 
antibiotic from passing through the cell wall and into the cell.  
 
Antibiotic removal is a mechanism of resistance in which a bacterium actively 
removes an antibiotic from itself. This occurs via the synthesis of a membrane 
protein, which actively facilitates the efflux of the antibiotic preventing 
accumulation and reaching the concentration required for inhibition (Kumar and 
Schweizer, 2005). This can occur with many groups of antibiotics including 
Beta-lactam, quinolone and aminoglycoside antibiotics and has been shown in 
bacteria such as Escherichia coli and Heliocobacter pylori (Falsafi, Ehsani and 
Niknam, 2009). 
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Antibiotic destruction is a method of resistance where the bacteria activity 
destroys or modifies the antibiotic thereby inhibiting it from reaching its target 
(Davies, 1994). This mechanism was described in 1973 (Benveniste and 
Davies) against aminoglycoside antibiotics, where enzymes produced by 
Actinomycetes spp. acetylated the 6’-amino group of gentamycin. This 
modification inactivated the antibiotic. Enzymes called Beta-lactamases are 
produced by many resistant bacteria such as MRSA and modify/inactivate Beta-
lactam antibiotics for example penicillin and ampicillin.  
 
Target site modifications confer resistance and are often from pre-existent 
mutant strains (Greenwood et al., 2008). These mutations give rise to 
resistance in a single step and like other mechanisms of resistance, become 
prevalent due to the failure of an individual to complete a course of antibiotics. 
Types of modifications include those caused by modified nucleosides in 
ribosomal RNA (Vester and Long, 2009), which results in the antibiotic being 
unable to bind to the area of importance. If effective the antibiotic would hinder 
any ribosomal activity. Use of duel/combination treatments can be effective in 
treating resistance infections (Rahal, 2006).  
 
Metabolic by-pass is another mechanism that can convey I high level of 
resistance to antibiotic in bacteria. This mechanism has been shown to give 
resistance to trimethoprim (Tait and Amyes, 1994), an antibiotic that inhibits 
dihydrofolate reductase, an enzyme required for the metabolism of folic acid. In 
this mutation described by Tait and Amyes (1994) plasmid encoded 
dihydrofolate reductases arise that are not sensitive to trimethroprim.  
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3.1.1.2 Hospital pathogens and resistance 
There are many pathogens, which can cause a variety of infections in many 
different situations. In the US alone there are almost 1.7 million healthcare-
associated infections every year with mortality due to these infections affecting 
99,000 patients (Guilbeau, 2010). In the UK there in evidence to suggest that 
the number of hospital-acquired infections are continuing to increase and are 
responsible for up to 5000 deaths every year (Scott, 2004). Many of these 
infections are caused by organisms, which are resistant to many clinical 
antibiotics often causing significant increase in patient stay and the cost of their 
treatment (Rowland et al., 1999). The distribution of these costs can be seen in 
figure 40. In Canada, infections caused by MRSA alone, result in an estimated 
cost of $42-49 million a year (Kim, Oh and Simor, 2001). Four pathogens that 
are of particular importance in the area of hospital infections are Acinetobacter 
baumannii, Stenotrophomonas maltophilia, methicillin-resistant Staphylococcus 
aureus (MRSA) and Enterococcus faecalis know as vancomycin resistant 
enterococci (VRE) (Madigan et al., 2009). 
 
Figure 40. Distribution of Costs incurred from resistant infections (Rowland et 
al., 1999) 
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A. baumannii is a common gram-negative bacterium, which is an opportunistic 
nosocomial pathogen (Bergogne-Berezin and Towner, 1996). In figure 41 an 
electron micrograph of A. baumannii can be seen showing its coccobacilli 
structure.  
 
Figure 41. A scanning electron micrograph of Acinetobacter baumannii 
magnified 13331x (CDC, 2004) 
 
 
A. baumannii is of increasing medical importance due to its ability to colonise 
quickly and give resistance to many antibiotics (Dijkshoorn, Nemec and Seifert, 
2007). The infections it causes can seriously affect immuno-
suppressed/compromised individuals such as, the critically ill, burns patients 
and the elderly (Van Looveren et al., 2004). With the increase in the number of 
individuals with HIV this could be of particular concern (CDC, 2002). Due to the 
increasing resistance of Acinetobacter spp. infections have become increasingly 
difficult to treat (Turton et al., 2004). There have also been many reports of 
resistance of infections in military personnel (Jones et al., 2006), and have 
shown a wide variety in types of infection caused by Acinetobacter (Davis et al., 
2005). Over the last 30 years the types of infection that Acinetobacter 
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baumannii cause has increased not only in hospitals but also in community-
acquired infections (Joly-Guillou, 2005). 
 
Staphylococcus aureus is a cocci shaped gram-positive bacteria (Prescott, 
Harley and Klein, 2007). S. aureus is part of the natural flora of the human body 
and is found in the nose of up to 40% of the population (Enright, 2006). Unlike 
MRSA, S. aureus causes infections that are often easily treated. MRSA, which 
can be seen in figure 42 is, like A. baumannii an opportunistic pathogen in 
hospitals and in the community (Bloomfield, 2006). MRSA emerged shortly after 
the introduction of the antibiotic methicillin in the early 1960’s (Maltezou and 
Giamarella, 2006) and is now a problematic organism around the world. Like 
many opportunistic pathogens, MRSA infections can affect people who are 
immuno-compromised, elderly and those whom have undergone recent surgery 
(Kanerva et al., 2007) and can be very costly to treat.  
 
Figure 42. A scanning electron micrograph of MRSA magnified 9560x (CDC, 
2005) 
 
 
Vancomycin resistant enterococci are resistant strains of Enterococcus that are 
resistant to the antibiotic vancomycin and were identified as hospital-associated 
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pathogens in the middle of the 1980’s (Tacconelli and Cataldo, 2008). VRE are 
cocci shaped (see figure 43), gram-positive opportunistic hospital pathogens 
(Madigan et al., 2009). Like MRSA and A. baumannii, infections caused by VRE 
often affect individuals who are immuno-compromised, elderly or those whom 
have undergone recent surgery (Masterton, 2005). VRE are able to exchange 
genes with other gram-positive bacteria and therefore can transfer resistance 
(Albrich et al., 1999). The number individuals with nosocomial infections caused 
by VRE increased by 55% between 1993 and 1997 in ICU departments in 
Taiwan (Hsueh et al., 2002) and became increasingly difficult to treat. The 
resistance to vancomycin is not just a problem linked to VRE as resistance has 
occurred in many different organisms, often due to over prescribing of 
antibiotics and requires education to prevent further resistance (Weber et al., 
1999). 
 
Figure 43. A Scanning electron micrograph of VRE magnified 12000x (CDC, 
2005) 
 
 
Stenotrophomonas maltophilia is a gram-negative bacilli and an opportunistic 
pathogen (figure 44), which can readily colonise epithelial cells in the human 
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respiratory tract and can cause problems when using medical devices such as 
respirators (Looney, Narita and Muhlemann, 2009). This can be especially 
dangerous in immunocompromised patients. Although rare, S. maltophilia has 
been shown to cause meningitis (Yemisen et al., 2008), a condition, which can 
lead to the death of a patient. S. maltophilia has been shown to be highly 
resistant to many clinical antibiotics (Alonso and Martinez, 1997). There are 
various mechanisms attributed for antibiotic resistance in S. maltophilia 
including active efflux of the antibiotic. S. maltophilia can form biofilms, which is 
another key factor in drug resistance (Liaw, Lee and Hsueh, 2010).  
 
Figure 44. A Scanning electron micrograph of S. maltophilia (Nangia et al., 
2009) 
 
 
3.1.2 The use of natural compounds in antimicrobial drug discovery 
In recent years there has been increasing research into the antimicrobial 
properties of natural compounds, especially into extracts from honey, herbs and 
tea (Al-Waili, 2004; Lai and Roy, 2004 and Taguri et al., 2004). Many of the 
positive effects from these extracts are due to their content of phenolic and 
polyphenolic compounds (Estevinho et al., 2008 and Hamilton-Miller, 1995). 
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Meyer et al., (2008) found that catechins and epicatechin from grape seed 
extracts showed antibacterial activity against 10 different pathogens. An 
advantage of using natural compounds such as honey, herbs and tea is that 
there are often less side affects than antibiotics, which can kill off your natural 
flora and can lead to serious gastrointestinal infections caused by Clostridium 
difficile (Marciniak et al., 2006). 
 
Past research has shown that green tea extracts have significant antibacterial 
effects against antibiotic resistant isolates of Acinetobacter spp. (Jazani et al., 
2007) and MRSA (Cho, Schiller and Oh, 2008). It was also shown by Osterburg 
et al., (2009) that epigallocatechin gallate has a significant antibacterial effect 
against A. baumannii. Unfortunately there has been no research undertaken to 
show if other specific extracts from green tea or black tea have antibacterial 
properties against Acinetobacter spp. It is essential to undertake more 
susceptibility testing to discover if other catechins in green tea or theaflavins 
from black tea could potentially have even greater antibacterial effect against 
this organism. epigallocatechin gallate has been shown to have antifolate 
activity against Stenotrophomonas maltophilia (Navarro-Martinez et al., 2005). 
Green tea polyphenols have shown to be effective against spore forming 
bacteria such as Clostridium thermoaceticum  (Sakanaka, Juneja and 
Taniguchi, 2000) with the highest activity being form epigallocatechin gallate. 
Tea extracts have been shown to be effective as antibacterial agents against 
other organisms including Listeria spp (Mbata, Debiao and Saikia, 2006) and 
strains of Escherichia coli, Shigella spp and Salmonella spp (Bandyopadhyay et 
al., 2005). 
 
3.1.3 Susceptibility testing and determining minimum inhibitionary 
concentrations (MICs) 
A. baumannii can be cultured in the laboratory using a variety of different media 
including susceptibility agar (ISO) and Columbia blood agar (CBA) (Oxoid, 
2009). Susceptibility testing is performed to determine the effect of an 
antibacterial agent on a particular organism (Scorzoni et al., 2007). This can 
lead to the minimum inhibitory concentration (MIC) of the compound against the 
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organism being discovered (Andrews, 2001). This can be determined by various 
methods including growth methods, whereby the growth performance of an 
organism is monitored with the addition of a compound. Another method is the 
diffusion method, where the investigated compound in impregnated onto a 
paper disc and gradually diffuses into agar, showing a circular zone around the 
disc, if an antibacterial effect occurs (Rios, Recio and Villar, 1988). 
 
3.2 Aims 
One aim of this study is to conduct a preliminary investigation into the 
susceptibility of important opportunistic pathogens to tea polyphenols and 
various antibiotics. The main aim of this study is to discover the potential 
antibacterial effect of theaflavin against hospital isolates of MRSA, A. baumannii 
and S. maltophilia and if any synergy exists with the green tea polyphenol 
epicatechin and to discover their minimum inhibitory concentrations against S. 
maltophilia. Another aim of this project is to identify if any synergy exists 
between either theaflavin, epicatechin or a combination of theaflavin and 
epicatechin with clinical antibiotics against these hospital isolates. 
 
3.3 Preliminary antimicrobial testing against MRSA, VRE and A. baumannii 
3.3.1 Microbiology methodologies 
All methods were performed using aseptic procedures to reduce the risk of any 
contamination. 
 
3.3.1.1 Preparing stock cultures 
Freeze dried cell cultures for A. baumannii, MRSA PLD46 and Enterococcus 
faecalis (VRE) were obtained from BSAC laboratories, UK. To each freeze dried 
culture 500µL of peptone broth was added and dissolved. Each dissolved 
culture was then used to inoculate an individual CBA (blood agar) plate and 
incubated at 37 °C for 24 hours. After this time the stock cultures were stored at 
4 °C until further use.  
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3.3.1.2 Method of inoculating ISO plates from stock cultures 
The method used for inoculating agar plates, from stock cultures, was based on 
the method by Moosdeen et al., (1988). Using this method two A. baumannii 
colonies from a blood agar culture were added to 5 mL of a peptide broth and 
was mixed using a vortex machine. A blank tube containing only peptide broth 
was used to zero the spectrophotometer before a reading from the inoculated 
tube was taken. A reading of 0.155 nm was recorded and using the dilution 
chart 40 µL of the broth was added to 5 mL of sterile distilled water. Swabs 
were used to inoculate two ISO agar plates from the distilled water. 
 
Two VRE colonies from the blood agar culture were added to 5 mL of a peptide 
broth and mixed. A blank tube containing only peptide broth was used to zero 
the spectrophotometer before a reading from the inoculated tube was taken. A 
reading of 0.232 nm was recorded and using the dilution chart 40 µL of the 
broth was added to 5 mL of sterile distilled water. Swabs were used to inoculate 
two ISO agar plates from the distilled water. This was repeated for S. aureus 
where a spectrophotometer reading of 0.814 nm was produced and as a result 
20 µL of the peptide broth was added to 5 mL of sterile distilled water. 
 
3.3.1.3 Preparation of polyphenol stock solutions  
A 60 mM epicatechin solution was prepared by adding 0.174 g of epicatechin to 
10 mL of ethanol and mixing for 5-10 min. A 100 mM epigallocatechin gallate 
was prepared by adding 0.458 g of epigallocatechin gallate to 10 mL of ethanol 
and mixing for 2 min. A 80 mM theaflavin solution was prepared by adding 
0.415 g of theaflavin to 1 mL of ethanol and mixing for 5 min until the compound 
had dissolved. A 0.05 g/mL solution of mixed theaflavins containing theaflavin, 
theaflavin 3,3’-digallate and theaflavin monogallate (supplied by Unilever, 
China) was prepared by adding 0.5 g of the theaflavins powder to 10 mL of 
ethanol and mixing for 5 min. 
 
All solutions were stored at 4 °C and were replaced every week to avoid any 
problems with compound stability/degradation. 
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3.3.1.4 Production of impregnated susceptibility discs 
All discs were prepared by injecting 10 µL of compound solution at a time onto a 
blank susceptibility disc using a pipette. The discs were allowed to dry for 30 
min before any further solution was added. This method was repeated until the 
required amount of compound was injected onto each disc. Ethanol control 
discs were prepared by injecting the same volume of ethanol as the maximum 
loaded polyphenol disc before allowing to dry. For example, if discs were 
prepared with a total of 60µL and 80µL of a polyphenol solution, the ethanol 
disc would be injected with 80 µL of ethanol. All susceptibility discs were dried 
prior to their addition to a culture plate to eliminate any effects from the ethanol 
solvent. 
 
3.3.1.5 Antibiotic susceptibility testing 
To test the organisms used for antibiotic resistance, various commonly used 
antibiotics were used. For MRSA and VRE susceptibility discs containing 
Rifampicin (2µg), Penicillin (1 unit – standard purchased concentration), 
Nitrofurantoin (200µg), Cefotaxime (30µg), Ciprofloxacin (1µg), Tetracycline 
(10µg), Gentamycin (10µg), Vancomycin (5µg) and Amoxicillin/clavulanic acid 
(30µg) 2:1 were added to inoculated ISO agar plates and incubated for 24hrs at 
37°C. For A. baumannii susceptibility discs containing Rifampicin (2µg), 
Penicillin (1 unit), Nitrofurantoin (200µg), Ampicillin (25µg), Cefotaxime (30µg), 
Ciprofloxacin (1µg), Tetracycline (10µg), Gentamycin (10µg), 
Amoxicillin/clavulanic acid (30µg) 2:1 and Vancomycin (5µg) were added to 
inoculated ISO agar plates and incubated for 24hrs at 37°C. 
 
After 24hrs the area surrounding each disc with no growth (zone of inhibition) 
was examined. The diameter across the zone was measured and noted. All 
antibiotic susceptibility tests were repeated to eliminate any abnormalities. 
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3.3.1.6 Susceptibility testing with tea compounds 
To test the antibacterial activity of epicatechin against A. baumannii 
susceptibility discs containing 40 µL (0.7 mg of epicatechin), 60 µL (1.0 mg of 
epicatechin) and 80 µL (1.4 mg of epicatechin) of epicatechin, a 10 mg 
gentamycin disc and an ethanol control disc were added onto inoculated ISO 
agar. To test the antibacterial activity of epicatechin against MRSA and VRE 
susceptibility discs containing 10 µL (0.17 mg of epicatechin), 20 µL (0.35 mg of 
epicatechin), 40 µL (0.7 mg of epicatechin), 60 µL (1.0 mg of epicatechin) and 
80 µL (1.4 mg of epicatechin) of epicatechin and an ethanol control disc were 
added onto inoculated ISO agar for each organism. All plates were incubated 
for 24hrs at 37°C.  
 
After 24hrs the area surrounding each disc with no growth (zone of inhibition) 
was examined. The diameter across the zone was measured and noted. All 
antibiotic susceptibility tests were repeated to eliminate any abnormalities. 
 
To test the antibacterial activity of epigallocatechin gallate against A. baumannii, 
MRSA and VRE, susceptibility discs containing 10 µL (0.46 mg of 
epigallocatechin gallate), 20 µL (0.92 mg of epigallocatechin gallate), 40 µL (1.8 
mg of epigallocatechin gallate), 60 µL (2.7 mg of epigallocatechin gallate) and 
80 µL (3.7 mg of epigallocatechin gallate) of epigallocatechin gallate and an 
ethanol control disc were added onto inoculated ISO agar for each organism. All 
plates were incubated for 24 h at 37 °C.  
 
After 24 h the area surrounding each disc with no growth (zone of inhibition) 
was examined. The diameter across the zone was measured and noted. All 
antibiotic susceptibility tests were repeated to eliminate any abnormalities. 
 
To test the antibacterial activity of theaflavin against A. baumannii and VRE 
susceptibility discs containing 25 µL (1.1 mg of theaflavin), 30 µL (1.4 mg of 
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theaflavin), 35 µL (1.6 mg of theaflavin) and 40 µL (1.8 mg of theaflavin) of 
theaflavin, gentamycin (10 mg) and an ethanol control disc were added onto 
inoculated ISO agar for each organism. All plates were incubated for 24 h at 37 
°C. After 24 h the area surrounding each disc with no growth (zone of inhibition) 
was examined. The diameter across the zone was measured and noted. All 
antibiotic susceptibility tests were repeated to eliminate any abnormalities. 
 
To test the antibacterial activity of mixed theaflavins against A. baumannii, 
MRSA and VRE, susceptibility discs containing 10 µL (0.5 mg of mixed 
theaflavins), 20 µL (1.0 mg of mixed theaflavins), 40 µL (2.0 mg of mixed 
theaflavins), 60 µL (3.0 mg of mixed theaflavins) and 80 µL (4.0 mg of mixed 
theaflavins) of mixed theaflavins and an ethanol control disc were added onto 
inoculated ISO agar for each organism. All plates were incubated for 24 h at 37 
°C. After 24 h the area surrounding each disc with no growth (zone of inhibition) 
was examined. The diameter across the zone was measured and noted. All 
antibiotic susceptibility tests were repeated to eliminate any abnormalities. 
 
3.4 Results and discussion for preliminary antibacterial testing  
During this study any chemical that created a zone of inhibition ≥7.5 mm was 
considered to have antibacterial activity. 
 
3.4.1 Antibiotic susceptibility testing 
This results in figures 45 and table 7 show that the A. baumannii used was 
resistant to penicillin, nitrofurantoin, ampicillin, vancomycin and 
amoxicillin/clavulanic acid. It can be seen in figure 45 that their zones including 
the disc were not above 6.5 mm. All of these antibiotics are commonly used in 
treating a variety of infections. However, in the case of an infection caused by 
A. baumannii they would be very unsuccessful. In this study the antibiotic with 
the greatest effect against A. baumannii was gentamycin. 
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Figure 45.  Antibiotic disc susceptibility testing for A. baumannii on ISO-agar. 
 
Discs on the left petri dish from the top moving anti-clockwise are 2µg 
rifampicin, 1 unit penicillin, 200 µg nitrofurantoin, 25 µg ampicillin and 30 µg 
cefotaxime. Discs on the right petri dish from the top moving anti-clockwise are 
1 µg ciprofloxacin, 10 µg Tetracycline, 10 µg gentamycin, 5 µg vancomycin and 
30 µg amoxicillin/clavulanic acid 2:1. Zone outlines are highlighted. 
 
 
Table 7. Showing the zones of inhibition for a variety of antibiotics against the 
bacterium A. baumannii 
Antibiotic Zone of inhibition (mm)* 
Rifampicin (2 µg) 14.5 
Penicillin (1 unit) 6.5 
Nitrofurantoin (200 µg)  8.5 
Ampicillin (25 µg) 6.5 
Cefotaxime (30 µg) 12.5 
Ciprofloxacin (1 µg) 14.5 
Tetracycline (10 µg) 16.5 
Gentamycin (10 µg) 18.5 
Vancomycin (5 µg) 6.5 
Amoxicillin/clavulanic acid (30 µg) 2:1 6.5 
* note: the zone of inhibition includes the disc diameter of 6.5mm 
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Figure 46 and table 8 clearly show that MRSA in this case was resistant to 
penicillin, tetracycline and cefotaxime with zones not greater than 6.5 mm. The 
antibiotic with the greatest effect against MRSA in this study was nitrofurantoin 
an antibiotic commonly used to treat urinary tract infections (Lee et al., 2008).  
 
Figure 46. Antibiotic disc susceptibility testing for MRSA on ISO-agar.  
 
Discs on the left petri dish from the top moving anti-clockwise are 30 µg 
amoxicillin/clavulanic acid 2:1, 1 unit penicillin, 2 µg rifampicin, 1 µg 
ciprofloxacin and 10 µg Tetracycline. Discs on the right petri dish from the top 
moving anti-clockwise are 30 µg cefotaxime, 10 µg gentamycin, 200 µg 
nitrofurantoin and 5 µg vancomycin. Zone outlines are highlighted. 
 
From Table 8 gentamycin and ciprofloxacin would be useful oral antibiotics to 
treat an infection from this strain of MRSA, where often intravenous vancomycin 
would normally be given (Zvethkova, Laffeach and Goldstein, 2004).  
 
In this study VRE showed resistance to less antibiotics than MRSA and A. 
baumannii with the results in figure 47 and table 9 showing only resistance to 
penicillin and lower effectiveness for the antibiotics gentamycin and tetracycline. 
Surprisingly this strain of VRE showed no resistance against vancomycin (5 µg). 
However previous research found MIC values of vancomycin for VRE are 
greater than 128 µg/mL (CDC, 1999).  
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Table 8. Zones of inhibition for a variety of antibiotics against MRSA 
Antibiotic Zone of inhibition (mm)* 
Rifampicin (2 µg) 40.5 
Penicillin (1 unit) 6.5 
Nitrofurantoin (200 µg)  27.5 
Cefotaxime (30 µg) 22.5 
Ciprofloxacin (1 µg) 21.5 
Tetracycline (10 µg) 6.5 
Gentamycin (10 µg) 26.5 
Vancomycin (5 µg) 19.5 
Amoxicillin/clavulanic acid (30 µg) 2:1 20.5 
* note: the zone of inhibition includes the disc diameter of 6.5mm 
 
Figure 47. Antibiotic disc susceptibility testing for VRE on ISO-agar 
 
Discs on the left petri dish from the top moving anti-clockwise are 30 µg 
amoxicillin/clavulanic acid 2:1, 1 unit penicillin, 2 µg rifampicin, 1 µg 
ciprofloxacin and 10 µg Tetracycline. Discs on the right petri dish from the top 
moving anti-clockwise are 30 µg cefotaxime, 10 µg gentamycin, 200 µg 
nitrofurantoin and 5 µg vancomycin. Zone outlines are highlighted. 
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Table 9. Zones of inhibition for a variety of antibiotics against VRE 
Antibiotic Zone of inhibition (mm)* 
Rifampicin (2 µg) 20.5 
Penicillin (1 unit) 6.5 
Nitrofurantoin (200 µg)  28.5 
Cefotaxime (30 µg) 30.5 
Ciprofloxacin (1 µg) 18.5 
Tetracycline (10 µg) 10.5 
Gentamycin (10 µg) 11.5 
Vancomycin (5 µg) 14.5 
Amoxicillin/clavulanic acid (30 µg) 2:1 32.5 
* note: the zone of inhibition includes the disc diameter of 6.5mm 
 
3.4.2 Theaflavin, epicatechin and epigallocatechin gallate susceptibility 
testing 
Interesting results were observed from the polyphenol testing. Colour diffusion 
into the agar that often was greater that the zone of inhibition. Other variations 
in colour are due to unintentional differences in photo exposure. Results from 
the EC susceptibility testing for A. baumannii, which can be seen in figure 48 
and table 10 showed very little antibacterial activity. On the disc containing 0.7 
µg no antibacterial action was seen.  
 
In figure 48 a significant colour change can be seen where epicatechin has 
diffused into the ISO agar. This could be due to the compound being 
metabolised by the organism or that some decomposition is taking place. In the 
susceptibility discs containing 1.0 mg and 1.4 mg of epicatechin, little 
antibacterial action was seen against A. baumannii. However results shown in 
table 10 are encouraging and indicate that if the concentration was increased it 
could result in a much improved antibacterial activity. In this preliminary study 
the MIC of Epicatechin against A. baumannii was found to be 1.0 mg. 
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Figure 48. A. baumannii susceptibility testing with epicatechin (EC).  
 
Discs on the petri disc are from the top moving anti-clockwise 0.7 mg EC, 1.0 
mg EC, 1.4 mg EC, ethanol control disc and 10 µg gentamycin. Zone outlines 
are highlighted. 
 
Table 10. Mean zones of inhibition for epicatechin (EC) at various 
concentrations against A. baumannii 
Disc content Mean Zone of inhibition (mm)* 
0.7 mg EC 6.5 
1.0 mg EC 8.5 
1.4 mg EC 9.5 
Ethanol control 6.5 
10µg gentamycin 20.5 
* note: the zone of inhibition includes the disc diameter of 6.5mm 
 
In the epicatechin susceptibility testing against MRSA no antibacterial activity 
was seen with any of the compound amounts on the discs. Like with A. 
baumannii it is possible this could be improved by further increasing the 
concentration of epicatechin on the discs in a future investigation. In past 
investigations no antibacterial activity was seen with catechin (epicatechin's 
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stereo isomer) against S. aureus (Stapleton et al., 2004). In figure 49 increasing 
decolouration of the agar can be seen which corresponds to an increase in the 
amount of epicatechin on the susceptibility discs. In table 11 the lack of 
antibacterial activity of the compound is shown as the zone of inhibition does 
not increase above 6.5 mm, which is the diameter of the disc. At these 
concentrations it is suspected that epicatechin would not be a viable agent to 
treat a MRSA infection either in Vivo or topically. 
 
Figure 49. MRSA susceptibility testing with epicatechin (EC).  
 
The discs from the top moving anti-clockwise on the petri dish are 0.17 mg EC, 
0.35 mg EC, 0.7 mg EC, 1.0 mg EC, 1.4 mg EC and an ethanol control disc 
 
Like in the case of MRSA it can be seen from figure 50 and table 12 that 
epicatechin had no antibacterial activity against VRE. The results from table 11 
show that the compound on all the discs failed to achieve a zone of inhibition 
greater than 6.5 mm (the disc diameter). Like in the tests for A. baumannii and 
MRSA a small increasing colour change can be seen as the compound 
concentration increases, indicating its decomposition or that it has been 
metabolised giving a coloured by-product. 
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Table 11. Mean zones of inhibition for epicatechin (EC) at various 
concentrations against MRSA 
Disc content Mean Zone of inhibition (mm)* 
0.17 mg EC 6.5 
0.35 mg EC 6.5 
0.7 mg EC 6.5 
1.0 mg EC 6.5 
1.4 mg EC 6.5 
Ethanol control 6.5 
* note: the zone of inhibition includes the disc diameter of 6.5 mm 
 
Figure 50. VRE susceptibility testing with epicatechin (EC).  
 
The discs from the top moving anti-clockwise on the petri dish are 0.17 mg EC, 
0.35 mg EC, 0.7 mg EC, 1.0 mg EC, 1.4 mg EC and an ethanol control disc. 
 
Due to this result it can be concluded that it is highly unlikely epicatechin will 
have a antibacterial effect even if the concentration is doubled. This is also 
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confirmed from previous research by Cushnie et al., (2008), who found no 
antibacterial activity of epicatechin against VRE at similar concentrations. 
 
Table 12. Mean zones of inhibition for epicatechin (EC) at various 
concentrations against VRE 
Disc content Mean Zone of inhibition (mm)* 
0.17 mg EC 6.5 
0.35 mg EC 6.5 
0.7 mg EC 6.5 
1.0 mg EC 6.5 
1.4 mg EC 6.5 
Ethanol control 6.5 
* note: the zone of inhibition includes the disc diameter of 6.5mm 
 
 
Epigallocatechin gallate showed a high antibacterial activity against A. 
baumannii and in figure 51 and table 13 zones of inhibition of up to 19 mm can 
be seen. These results exceed that of all the antibiotics in table 7 that were 
tested. The antibiotic with the highest antibacterial activity shown in table 7 was 
gentamycin with a zone of 18.5 mm. This shows that epigallocatechin gallate is 
a very strong antimicrobial agent as the 19 mm zone was created by only 3.7 
mg of epigallocatechin gallate whereas 10 µg of gentamycin produced the 18.5 
mm zone. The MIC of epigallocatechin gallate was found to be 0.92 mg in this 
preliminary study. 
 
In figure 51 an increasing large coloured zone can be seen which corresponds 
to the increase in epigallocatechin gallate on the susceptibility discs. 
 
 
 
 113 
 
Figure 51. A. baumannii susceptibility testing with epigallocatechin gallate 
(EGCG) 
 
The discs from the top moving anti-clockwise on the petri dish are 0.46 mg 
EGCG, 0.92 mg EGCG, 1.8 mg EGCG, 2.7 mg EGCG, 3.7 mg EGCG and an 
ethanol control disc. Zone outlines are highlighted. 
 
Table 13. Mean zones of inhibition for epigallocatechin gallate (EGCG) at 
various concentrations A. baumannii 
Disc content Mean Zone of inhibition (mm)* 
0.46 mg EGCG 6.5 
0.92 mg EGCG 8.0 
1.8 mg EGCG 14.5 
2.7 mg EGCG 17.0 
3.7 mg EGCG 19.0 
Ethanol control 6.5 
* note: the zone of inhibition includes the disc diameter of 6.5 mm 
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From figure 52 and table 14 the high antibacterial effect of epigallocatechin 
gallate is observed against MRSA. From these results a maximum zone of 29 
mm from 3.7 mg of epigallocatechin gallate can be seen which exceeds all the 
zones from antibiotics shown in table 8 with the exception of rifampicin. This 
confirms again that epigallocatechin gallate is a powerful antibacterial agent 
with an MIC in this study of 0.46 mg. The high antibacterial effect of 
epigallocatechin gallate against MRSA confirms the research of many groups 
including that of Cho, Schiller and Oh (2008). However, in that particular study 
the MIC ranged from 50-180 mg/mL which is higher than that found in this 
investigation. 
 
Figure 52. MRSA susceptibility testing with epigallocatechin gallate (EGCG).  
 
The discs from the top moving anti-clockwise on the petri dish are 0.46 mg 
EGCG, 0.92 mg EGCG, 1.8 mg EGCG, 2.7 mg EGCG, 3.7 mg EGCG and an 
ethanol control disc. Zone outlines are highlighted. 
 
As with the A. baumannii test in figure 48 an increasing large coloured zone can 
be seen which corresponds to the increase in epigallocatechin gallate on the 
susceptibility discs 
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epigallocatechin gallate showed to be an effective antibacterial agent against 
VRE and in figure 53 and table 15 significant zones of inhibition can be seen. 
This suggests that in this study epigallocatechin gallate is a greater antibacterial 
agent that over 50% of the antibiotics tested in table 9. 
 
Table 14. Mean zones of inhibition for epigallocatechin gallate (EGCG) at 
various concentrations against MRSA 
Disc content Mean Zone of inhibition (mm)* 
0.46 mg EGCG 9 
0.92 mg EGCG 17 
1.8 mg EGCG 22 
2.7 mg EGCG 25 
3.7 mg EGCG 29 
Ethanol control 7 
* note: the zone of inhibition includes the disc diameter of 6.5mm 
 
Figure 53 Showing VRE susceptibility testing with epigallocatechin gallate 
(EGCG).  
 
The discs from the top moving anti-clockwise on the petri dish are 0.46 mg 
EGCG, 0.92 mg EGCG, 1.8 mg EGCG, 2.7 mg EGCG, 3.7 mg EGCG and an 
ethanol control disc. Zone outlines are highlighted. 
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The largest zone of inhibition was 19.5 mm from a disc containing 3.7 mg of 
epigallocatechin gallate, which is greater than that by ciprofloxacin, which 
created a zone of 18.5 mm, although this was from only 1 µg. This still proves 
that epigallocatechin gallate could be a very effective agent in treating infections 
caused by VRE. 
 
Figure 15. Mean zones of inhibition for epigallocatechin gallate (EGCG) at 
various concentrations against VRE 
Disc content Mean Zone of inhibition (mm)* 
0.46 mg EGCG 9 
0.92 mg EGCG 11 
1.8 mg EGCG 15 
2.7 mg EGCG 18 
3.7 mg EGCG 19.5 
Ethanol control 6.5 
* note: the zone of inhibition includes the disc diameter of 6.5 mm 
 
Epigallocatechin gallate has shown to be a much greater antibacterial agent 
than epicatechin. This is possibly be due to the gallate group and also could be 
related to the increase in the number of phenol groups, which have been found 
to have antibacterial properties.  
 
Theaflavin also showed antibacterial effects against A. baumannii, which can be 
seen in figure 53 and table 16. Although the zones of inhibition produce by 
theaflavin are not as large as those by epigallocatechin gallate it still shows a 
significant antibacterial effect. In this study 1.8 mg of theaflavin produces a zone 
of 11.5 mm which is almost equal to that produced by 30 µg of Cefotaxime (see 
table 7). In figure 53 zone around the discs containing theaflavin can clearly be 
seen. This is the first time the antibacterial effects of pure theaflavin have been 
seen against A. baumannii and are encouraging that it could be used as a 
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future treatment against infections caused by the organism. The MIC of 
theaflavin against A. baumannii was shown in table 16 to be ≤1.1 mg. 
 
Figure 53. A. baumannii susceptibility testing with theaflavin.  
 
The discs from the top moving anti-clockwise on the petri dish are 1.1 mg 
theaflavin, 1.4 mg theaflavin, 1.6 mg theaflavin, 1.8 mg theaflavin, an ethanol 
control disc and 10 µg gentamycin. Zone outlines are highlighted. 
 
Table 16. Mean zones of inhibition for theaflavin at various concentrations 
against A. baumannii 
Disc content Mean Zone of inhibition (mm)* 
1.1 mg theaflavin 8.5 
1.4 mg theaflavin 9.5 
1.6 mg theaflavin 10.5 
1.8 mg theaflavin 11.5 
Ethanol control  6.5 
10µg gentamycin 19.5 
* note: the zone of inhibition includes the disc diameter of 6.5 mm 
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Theaflavin showed some antibacterial effects against VRE at higher 
concentrations. From figure 54 and table 17 it can be seen that theaflavin only 
had an antibacterial effect with the disc containing 1.8 mg of the compound 
where it produced a zone of inhibition of 8.5 mm. Although this was still less 
than the effect of tetracycline (10.5 mm), it was still more effective than penicillin 
as can be seen from table 9. Diffusion of theaflavin into the ISO agar can be 
seen in figure 54. The MIC of theaflavin for VRE in this study was 1.8 mg. It is 
possible that if the concentration of theaflavin on the discs was increased a 
greater antibacterial effect would be seen against VRE.  
 
Figure 54. VRE susceptibility testing with theaflavin.  
 
The discs from the top moving anti-clockwise on the petri dish are 1.1 mg 
theaflavin, 1.4 mg theaflavin, 1.6 mg theaflavin, 1.8 mg theaflavin, an ethanol 
control disc and 10µg gentamycin. Zone outlines are highlighted. 
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Table 17. Mean zones of inhibition for theaflavin at various concentrations 
against VRE 
Disc content Mean Zone of inhibition (mm)* 
1.1 mg theaflavin 6.5 
1.4 mg theaflavin 6.5 
1.6 mg theaflavin 6.5 
1.8 mg theaflavin 8.5 
Ethanol control  6.5 
10µg gentamycin 6.5 
* note: the zone of inhibition includes the disc diameter of 6.5 mm 
 
 
Mixed theaflavins showed a significant antibacterial effect against A. baumannii 
producing a maximum zone of inhibition in this study of 14 mm with 4.0 mg. 
This can be seen in figure 55 and table 18 where a MIC of 1.0 mg was 
discovered. Overall, mixed theaflavins showed to be a less effective 
antimicrobial agent against A. baumannii than EGCG. It was also less effect 
against A. baumannii than pure theaflavin where 2.0 mg of mixed theaflavins 
produced a zone of 10 mm (table 18) where as pure theaflavin produced a zone 
of 11.5 mm for 1.8 mg. This could be due to the mixed theaflavins containing 3 
different theaflavins and therefore each one at a lower concentration that the 
pure theaflavin alone. This could suggest that there is little synergy between the 
different theaflavins against A. baumannii. In this case it is shown that mixed 
theaflavins have almost the same antibacterial effect as rifampicin and 
ciprofloxacin (Table 7). 
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Figure 55. A. baumannii susceptibility testing with mixed theaflavins.  
 
The discs from the top moving anti-clockwise on the petri dish are 0.5 mg mixed 
theaflavins, 1.0 mg mixed theaflavins, 2.0 mg mixed theaflavins, 3.0 mg mixed 
theaflavins, 4.0 mg mixed theaflavins and an ethanol control disc. Zone outlines 
are highlighted. 
 
Figure 18. Mean zones of inhibition for mixed theaflavins at various 
concentrations against A. baumannii 
Disc content Mean Zone of inhibition (mm)* 
0.5 mg mixed theaflavins 6.5 
1.0 mg mixed theaflavins 7.5 
2.0 mg mixed theaflavins 10 
3.0 mg mixed theaflavins 12 
4.0 mg mixed theaflavins 14 
Ethanol control  6.5 
* note: the zone of inhibition includes the disc diameter of 6.5 mm 
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Figure 56. MRSA susceptibility testing with mixed theaflavins.  
 
The discs from the top moving anti-clockwise on the petri dish are 0.5 mg mixed 
theaflavins, 1.0 mg mixed theaflavins, 2.0 mg mixed theaflavins, 3.0 mg mixed 
theaflavins, 4.0 mg mixed theaflavins and an ethanol control disc. Zone outlines 
are highlighted. 
 
Table 19. Showing the mean zones of inhibition for mixed theaflavins at various 
concentrations against MRSA 
Disc content Mean Zone of inhibition (mm)* 
0.5 mg mixed theaflavins 6.5 
1.0 mg mixed theaflavins 12.0 
2.0 mg mixed theaflavins 16.0 
3.0 mg mixed theaflavins 18.0 
4.0 mg mixed theaflavins 19.0 
Ethanol control  6.5 
* note: the zone of inhibition includes the disc diameter of 6.5 mm 
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The results in figure 56 and table 19 indicated that mixed theaflavins have a 
significant effect against MRSA with a maximum zone of inhibition in this case 
of 19 mm for 4.0 mg of the compounds. This was comparable with 5µg of 
vancomycin as shown in figure 27. The MIC for mixed theaflavins was found to 
be 1.0 mg. Although mixed theaflavins showed significant antibacterial effects 
there were not as great as those from epigallocatechin gallate against MRSA. 
 
From the information in figure 57 and table 20 it can be clearly seen that mixed 
theaflavins had a significant antibacterial effect against VRE. With a maximum 
zone of inhibition of 12 mm it was as effective against VRE as the antibiotic 
gentamycin (table 8). Mixed theaflavins were more also more effective against 
VRE than pure theaflavin with a zone of 9 mm with 1.0 mg of the compounds 
rather than the 8.5 mm for 1.8 mg of pure theaflavin (almost twice the amount).  
 
Figure 57. VRE susceptibility testing with mixed theaflavins.  
 
The discs from the top moving anti-clockwise on the petri dish are 0.5 mg mixed 
theaflavins, 1.0 mg mixed theaflavins, 2.0 mg mixed theaflavins, 3.0 mg mixed 
theaflavins, 4.0 mg mixed theaflavins and an ethanol control disc. Zone outlines 
are highlighted. 
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A possible reason for the greater antibacterial effect of mixed rather than pure 
theaflavin is due to the increase in OH groups on the gallate forms. This should 
be investigated in future studies.  
 
An MIC of 1.0 mg was discovered for the mixed theaflavins against VRE in this 
study. This is over twice the quantity than the amount of epigallocatechin gallate 
required to produce the same zone for its MIC. 
 
Table 20. Mean zones of inhibition for mixed theaflavins at various 
concentrations against VRE 
Disc content Mean Zone of inhibition (mm)* 
0.5 mg mixed theaflavins 6.5 
1.0 mg mixed theaflavins 9.0 
2.0 mg mixed theaflavins 10.0 
3.0 mg mixed theaflavins 11.0 
4.0 mg mixed theaflavins 12.0 
Ethanol control  6.5 
* note: the zone of inhibition includes the disc diameter of 6.5 mm 
 
Although epigallocatechin gallate, theaflavin and mixed theaflavins show 
antibacterial effects against all three organisms in this study the effect in Vivo is 
not entirely known and the concentrations needed to be effective in treating an 
infection could also be toxic to the patient. However, even if this were so the 
compounds could be used topically to treat for example infections of the skin or 
abscesses.  
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3.5 Antimicrobial and synergistic testing against hospital isolates of 
MRSA, Acinetobacter baumannii and Stenotrophomonas maltophilia 
 
3.5.1 Clinical isolates 
A. baumannii strains were isolated from sputum samples of respiratory patients 
at Northern General Hospital, Sheffield, UK. S. maltophilia isolates were 
obtained from sputum samples of respiratory patients at Hull Royal Infirmary, 
UK. All strains of A. baumannii and S. maltophilia were isolated on blood agar 
and identified via antibiotic susceptibility tests and biochemical profiling using 
API 20E testing kits (bioMérieux, France). Hospital isolates of MRSA were 
obtained from routine screening swabs at Northern General Hospital, Sheffield, 
UK. All isolates were identified using Chromogenic media, Staph latex kits, 
DNase and antibiotic susceptibility tests. Gram stains were performed on all 
received isolates to check for correct morphology and gram type. Control strains 
of A. baumannii (NCTC 13485) and S. maltophilia (NCTC 13014) were 
purchased from the Health Protection Agency Culture Collections, Porton 
Down, UK. 
 
3.5.2 Tea polyphenols 
Epicatechin (EC) with purity ≥ 90% was purchased from Sigma-Aldrich, UK. 
Theaflavin (TF) and epigallocatechin (EGC) samples each with a purity ≥ 95% 
were donated by Unilever, Shanghai, China. 
 
3.5.3 Culture media, antibiotics and other materials 
Antibiotic discs including ampicillin (AMP) 25 µg, gentamycin (CN) 10 µg, 
imipenem (IPM) 10 µg, tetracycline (TE) 10 µg, cefoxitin (FOX) 10 µg and 
ciprofloxacin (CIP) 1 µg were purchased from Oxoid, UK. Blank susceptibility 
discs were purchased from Mastdiscs, UK. Iso-sensitive agar and Iso-sensitive 
broth powders were purchased from Oxoid, UK. All media and materials were 
autoclaved before their use to ensure sterility.  
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3.5.4 Methodologies for hospital isolate testing 
3.5.4.1 Microbiology methodologies 
All methods were performed using aseptic procedures to reduce the risk of any 
contamination. 
 
3.5.4.2 Gram stains 
Gram stains were performed on all clinical isolates. For each isolate a colony 
was taken from a previously incubated culture on blood agar. The colony was 
emulsified onto a glass slide with 1 drop of sterile water and left to dry for 5 
minutes. When dried the slide was passed through the blue flame of a Bunsen 
burner to fix the cells. The slide was then flooded with crystal violet to stain the 
bacteria and left for 1 minute before being briefly washed with water. The slide 
was then flooded with iodine and left for 1 minute and after which was washed 
with water and drained. Ethanol (95%) was then used as a decolourizer for 10 
seconds before being washed off with water. Finally the slide was flooded with a 
counterstain (Safranin) for 30 seconds and then washed off with water. The 
slide was drained and blotted with blotting paper and observed under a 
microscope using a x100 oil immersion lens. 
 
When observing the slide any cells stained purple were considered gram-
positive due to the crystal violent stain adhering the cells thick peptidoglycan 
cell wall. Any cells stained pink were considered gram-negative due to their thin 
cell wall, which is stained pink by the counter stain. 
 
3.5.4.3 Stock culture preparation 
All clinical isolates were inoculated into an individual CBA (blood agar) plates 
and incubated at 37 °C for 24 hours. After this time the stock cultures were 
stored at 4 °C until further use. 
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3.5.4.4 Method inoculating ISO plates from stock cultures 
The method used for inoculating agar plates from stock cultures, was based on 
the method by Moosdeen et al., (1988) and is the same as that described in the 
methodologies for the preliminary antimicrobial testing. 
 
3.5.4.5 Preparation of polyphenol stock solutions  
Two epicatechin stock solutions were prepared. One stock solution was a 25 
mg/mL and the other which was a 50 mg/mL. The 25 mg/mL was prepared by 
adding 0.25 g of epicatechin to 10 mL of ethanol and mixed for 15-20 min. The 
50 mg/mL was prepared by adding 0.5 g of epicatechin to 10 mL of ethanol and 
mixed for 25 min. A 50 mg/mL theaflavin stock solution was prepared by adding 
0.5 g of theaflavin to 10 mL of ethanol and mixed for 5 min until the compound 
had dissolved. A stock solution of theaflavin and epicatechin was prepared by 
adding 0.5 g of the theaflavin and 0.25 g of epicatechin to 10 mL of ethanol and 
mixed for 5 min. This produced a combination solution of 50 mg/mL 
theaflavin:25 mg/mL epicatechin. All stock solutions were stored at 4 °C and 
were replaced every week to avoid any problems with compound 
stability/degradation. 
 
3.5.4.6 Production of impregnated susceptibility discs 
As in the preliminary testing, discs were prepared by injecting 10 µL of 
compound solution at a time onto a blank susceptibility disc using a pipette. The 
discs were allowed to dry for 30 min before any further solution was added. This 
method was repeated until the required amount of compound was injected onto 
each disc. Ethanol control discs were prepared by injecting the same volume of 
ethanol as the maximum loaded polyphenol disc before allowing to dry. For 
example, if discs were prepared with a total of 60 µL and 80 µL of a polyphenol 
solution, the ethanol disc would be injected with 80 µL of ethanol. The 
experimental organisation can be seen in table 21.  
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Table 21. Experimental organisation of inoculated discs on plates 1-6 for 
MRSA, A. baumannii and S. maltophilia, where EC = Epicatechin, TF = 
Theaflavin and TF:EC = Theaflavin:epicatechin combination (2:1) 
 
All susceptibility discs were dried prior to their addition to a culture plate to 
eliminate any effects from the ethanol solvent. All isolates were incubated at 
37°C for 24 hours. At the end of the incubation period, zones of inhibition 
around each disc were measured (mm) and recorded. Results are presented as 
the Mean Value +/- Standard Error on the Mean. 
 
3.5.5 Determination of minimum inhibitory concentrations (MICs) 
To determine the MIC of epicatechin, theaflavin and a combination of theaflavin 
and epicatechin against each isolate of S. maltophilia, a microtiter assay was 
performed. For this assay 9 clinical isolates and 1 control strain (NCTC 13014) 
of S. maltophilia were used. Stock solutions of each compound were first 
prepared in sterile dimethyl sulfoxide (DMSO). A 80 mg/ml stock solution of TF 
was produced by adding 160 mg of theaflavin to 2 mL of DMSO and mixed to 
dissolve for 5 minutes. To make a 80 mg:40 mg/mL of TF:EC 160 mg of 
theaflavin and 80 mg of epicatechin were added to 2 mL of DMSO and mixed to 
dissolved for 5-10 minutes. A 100 mg/mL stock solution of EC was produced by 
dissolving 200 mg of EC into 2 mL of DMSO and mixed for 5-10 minutes. 
 Disc 1 Disc 2 Disc 3 Disc 5 
Plate 1 EC (4 mg) EC (3 mg) EC (2 mg) Ethanol 
Plate 2 EC (1 mg) EC (0.75 mg) EC (0.5 mg) Ethanol 
Plate 3 TF (4 mg) TF (3 mg) TF (2 mg) Ethanol 
Plate 4 TF (1 mg) TF (0.75 mg) TF (0.5 mg) Ethanol 
Plate 5 TF:EC (4 mg:2 
mg) 
TF:EC (3 mg:1.5 
mg) 
TF:EC (2 mg:1 mg) Ethanol 
Plate 6 TF:EC (1 mg:0.5 
mg) 
TF:EC (0.75 
mg:0.375 mg) 
TF:EC (0.5 
mg:0.25 mg) 
Ethanol 
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A serial dilution of each stock solution was then performed into sterile ISO-
sensitive broth. For this 40 µL of stock solution was added to a sterile tube 
containing 2 mL of ISO-sensitive broth. From this solution a double dilution was 
performed 4 times, giving 5 different concentrations of the polyphenol in ISO-
sensitive broth and a tube containing just ISO-sensitive broth, used as a control.  
 
For each concentration of theaflavin in broth, 75 µL was pipetted into 10 
horizontal wells of a 96 well cell culture plate (1 well per concentration per 
isolate). To each well 75 µL of a 0.5 MacFarland solution of an isolate of 
S. maltophilia was pipetted. The organisation of the 96 well plate can be seen in 
Figure 58. The procedure was repeated for each compound giving final well 
concentrations, which can be seen in table 22. Each plate was incubated in a 
rocking incubator at 30°C for 24 hours. 
 
Figure 58. Organisation of a 96 well cell culture plate for MIC testing where C = 
Control strain and B = Blank (no isolate). 
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Table 22. Final compound concentrations in the 96 well plate 
 
Final compound concentration 
TF TF:EC combi (2:1) EC 
800 µg/mL 800:400 µg/mL 1000 µg/mL 
400 µg/mL 400:200 µg/mL 500 µg/mL 
200 µg/mL 200:100 µg/mL 250 µg/mL 
100 µg/mL 100:50 µg/mL 125 µg/mL 
50 µg/mL 50:25 µg/mL 62.5 µg/mL 
0 µg/mL control 0 µg/mL control 0 µg/mL control 
 
After incubation wells were observed for turbidity and 2 µL from each well was 
spotted onto ISO-sensitive agar and incubated for a further 18 hours. After this 
period, if any growth was observed from any of the spots it was deemed that the 
concentration of compound was ineffective. The lowest concentration to show 
no growth was considered the minimum inhibitory concentration for that isolate. 
 
3.5.6 Production of polyphenol impregnated antibiotic susceptibility discs 
For each of the 6 clinical isolates and control strain of A. baumannii and for the 
6 clinical isolates and control strain of S. maltophilia used in this test, 7 ISO-
sensitive agar plates were made up. Plate 1 was inoculated Discs 1-4 
containing 0.25 mg epicatechin, 0.5 mg TF, 0.25 mg epigallocatechin and an 
ethanol control, respectively. Plate 2 was inoculated with Discs 1-5 containing 
ampicillin (AMP) (25 µg), AMP + epicatechin (0.25 mg), AMP + theaflavin (0.5 
mg), AMP + epigallocatechin (0.25 mg) and an ethanol control, respectively. 
Plates 3-7 were similar to Plate 2 but AMP was substituted with either 
gentamycin (CN) (10 µg), imipenem (IPM) (10 µg), tetracycline (TE) (20 µg), 
cefoxitin (FOX) (10 µg) or ciprofloxacin (CIP) (1 µg). The experimental 
organization is summarized in Table 23.  All isolates were incubated at 37°C for 
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24 hours. At the end of the incubation period, zones of inhibition around each 
disc were measured (mm) and recorded. Each experimental plate was 
replicated 6 times. Results are presented as the Mean Value +/- Standard Error 
on the Mean. Different types of antibiotic were chosen to determine if synergy or 
antagonism is antibiotic type specific. Ampicillin is a type of Beta-lactam, 
gentamycin is a type of aminoglycoside, Imipenem is a type of carbapenem, 
tetracycline in a type of polyketide, cefoxitin is a type of cephalosporin and 
ciprofloxacin is a type of fluoroquinolone. With the exception of a sulphonamide, 
all relevant antibiotic types were used. 
 
Table 23. Experimental organisation of inoculated discs and antibiotic disc on 
plates 1-7 for A. baumannii and S. maltophilia. Where AMP = ampicillin, CN = 
gentamycin, IPM = imipenem, TE = tetracycline, FOX = cefoxitin, CIP = 
ciprofloxacin, EC = epicatechin, TF = theaflavin and EGC = epigallocatechin 
 Disc 1 Disc 2 Disc 3 Disc 4 Disc 5 
Plate 1 - EC TF TF:EGC Ethanol 
Plate 2 AMP AMP+EC AMP+TF AMP+EGC Ethanol 
Plate 3 CN GEN+EC GEN+TF GEN+EGC Ethanol 
Plate 4 IPM IPM+EC IPM+TF IPM+EGC Ethanol 
Plate 5 TE TE+EC TE+TF TE+EGC Ethanol 
Plate 6 FOX FOX+EC FOX+TF FOX+EGC Ethanol 
Plate 7 CIP CIP+EC CIP+TF CIP+EGC Ethanol 
 
For each of the 4 clinical isolates MRSA a different selection of antibiotics was 
used. Penicillin (a beta lactam) and clarithromycin (a macrolide) replaced 
cefoxitin, tetracycline and ciprofloxacin. 
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3.5.7 Statistical analysis 
A student T-test (paired, 2 tailed) was performed to ascertain the significance of 
the results collected with, the null hypothesis for the statistical analysis being 
that there will be no significant difference between the antibacterial effect of 
polyphenols and combinations of polyphenols and that there will be no 
significant difference between the antibacterial effect of antibiotics and 
antibiotics with the addition of polyphenols. The test was performed using 
Graphpad InStat 3.00 for PC. Results with a P value > 0.05 were considered to 
prove the null hypothesis and results with a P value of ≤ 0.05 were considered 
to disprove the null hypothesis. 
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3.6 Results and discussion for hospital isolates 
3.6.1 Gram staining results 
The result from the gram stains confirmed the correct morphology and gram 
types for each clinical isolate. The MRSA clinical isolates were stained purple 
and confirmed to be gram-positive cocci (Figure 59). The A. baumannii clinical 
isolates were stained light pink and confirmed to be gram-negative coccobacilli 
(Figure 60) and the S. maltophilia clinical isolates were stained pink and 
confirmed to be gram-negative bacilli (Figure 61). 
 
Figure 59. An example of a gram stain undertaken for a MRSA clinical isolate 
 
 
 
Control strains of A. baumannii and S. maltophilia were also confirmed to have 
the correct morphology and gram type. 
 
 
 
 133 
Figure 60. An example of a gram stain undertaken for a clinical isolate of 
A. baumannii  
 
Figure 61. An example of a gram stain undertaken for a clinical isolate of 
S. maltophilia  
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3.6.2 Results for antimicrobial and polyphenol synergy testing 
It is clear from figures 62-73 that epicatechin shows no antibacterial activity 
against all isolates of MRSA, A. baumannii and S. maltophilia.  
 
In figures 62-73 theaflavin shows antibacterial activity against all isolates of 
MRSA, A. baumannii and S. maltophilia. This was significantly higher (P ≥ 0.05) 
than that of epicatechin (Tables 24, 25 and 26). However, against A. baumannii 
and S. maltophilia there is a significant reduction in antibacterial activity when 
disc concentrations are less than 3 mg as mean zones of inhibitions reduce in 
size. Against MRSA this reduction in activity occurs with disc concentrations of 
less than 2 mg. 
 
The theaflavin:epicatechin combination shows a significant increase in 
antibacterial activity (P ≤ 0.05) compared with theaflavin alone against all but 
one isolate of A. baumannii and S. maltophilia above disc concentrations of 1 
mg. The exception was isolate 2 of A. baumannii where the increase was above 
disc concentrations of 2 mg. In figures 63-65 and figure 70 the antibacterial 
activity of the theaflavin:epicatechin combination dramatically reduced when the 
disc concentrations was lower than 3 mg, whereas in figures 66 and 68-69 the 
large reduction in antibacterial effect is observed when the combination disc 
concentration was lower than 2 mg. In figures 62-65 significant antibacterial 
activity of the theaflavin:epicatechin combination can be seen against all MRSA 
isolates. Unlike with A. baumannii and S. maltophilia the theaflavin:epicatechin 
combination shows significantly more antibacterial activity than theaflavin (P ≤ 
0.05) at all disc concentrations above 0.5 mg.   
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Figure 62. Mean zones of inhibition of theaflavin, theaflavin:epicatechin 
combination and epicatechin against the MRSA isolate 1. Zones include the 6 
mm disc diameter. 
 
 
 
 
In figure 62 the mean zones of inhibition for theaflavin and the 
theaflavin:epicatechin combination can be seen to reduce as there disc 
concentration is also reduced. However, for all concentrations of epicatechin on 
disc the zone of inhibition does not increase above the actual 6mm disc 
diameter. This confirms epicatechin has no antibacterial activity against this 
isolate of MRSA.  
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Figure 63. Mean zones of inhibition for the MRSA isolate 2. Zones include the 6 
mm disc diameter. 
 
 
 
In figure 63 the mean zones of inhibition for theaflavin and the 
theaflavin:epicatechin combination can be seen to reduce as the disc 
concentration is also reduced. However, for all concentrations of epicatechin on 
disc the zone of inhibition does not increase above the actual 6mm disc 
diameter. This confirms epicatechin has no antibacterial activity against this 
isolate of MRSA.  
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Figure 64. Mean zones of inhibition for the MRSA isolate 3. Zones include the 6 
mm disc diameter. 
 
 
 
In figure 64 the mean zones of inhibition for theaflavin and the 
theaflavin:epicatechin combination can be seen to reduce after the disc 
concentration is also reduced below 2 mg. However, for all concentrations of 
epicatechin on disc the zone of inhibition does not increase above the actual 
6mm disc diameter. This confirms epicatechin has no antibacterial activity 
against this isolate of MRSA.  
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Figure 65. Mean zones of inhibition for the MRSA isolate 4. Zones include the 6 
mm disc diameter. 
 
 
 
From the results seen in figure 65 the mean zones of inhibition for theaflavin 
and the theaflavin:epicatechin combination reduces as the disc concentration is 
also reduced. However, for all concentrations of epicatechin on disc the zone of 
inhibition does not increase above the actual 6mm disc diameter. This confirms 
epicatechin has no antibacterial activity against this isolate of MRSA.  
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Figure 66. Mean zones of inhibition for the A. baumannii isolate 1. Zones 
include the 6 mm disc diameter. 
 
 
 
From the results seen in figure 66 the mean zones of inhibition for theaflavin 
and the theaflavin:epicatechin combination reduces as the disc concentration is 
also reduced. However, for all concentrations of epicatechin on disc the zone of 
inhibition does not increase above the actual 6mm disc diameter. This confirms 
epicatechin has no antibacterial activity against this isolate of A. baumannii.  
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Figure 67. Mean zones of inhibition for the A. baumannii isolate 2. Zones 
include the 6 mm disc diameter. 
 
 
 
 
From figure 67 the mean zones of inhibition for theaflavin and the 
theaflavin:epicatechin combination can be seen to reduce as the disc 
concentration is also reduced. However, for all concentrations of epicatechin on 
disc the zone of inhibition does not increase above the actual 6mm disc 
diameter. This confirms epicatechin has no antibacterial activity for this isolate 
of A. baumannii.  
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Figure 68. Mean zones of inhibition for the A. baumannii isolate 3. Zones 
include the 6 mm disc diameter. 
 
 
 
The mean zones of inhibition for theaflavin and the theaflavin:epicatechin 
combination can be seen to reduce in figure 68 as the disc concentration is also 
reduced. However, for all concentrations of epicatechin on disc the zone of 
inhibition does not increase above the actual 6mm disc diameter. This again 
confirms epicatechin has no antibacterial activity against this isolate of 
A. baumannii.  
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Figure 69. Mean zones of inhibition for the A. baumannii isolate 4. Zones 
include the 6 mm disc diameter. 
  
 
 
From the results seen in figure 69 the mean zones of inhibition for theaflavin 
and the theaflavin:epicatechin combination reduces as the disc concentration is 
also reduced. No zone of inhibition beyond the 6 mm disc diameter was seen 
for theaflavin below a disc concentration of 1 mg for this isolate. However, for all 
concentrations of epicatechin on the disc the zone of inhibition did not increase 
above the actual 6mm disc diameter. This confirms epicatechin has no 
antibacterial activity against this isolate of A. baumannii. 
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Figure 70. Mean zones of inhibition for the S. maltophilia isolate 1. Zones 
include the 6 mm disc diameter. 
 
 
 
From the results seen in figure 70 the mean zones of inhibition for theaflavin 
and the theaflavin:epicatechin combination reduces as the disc concentration is 
also reduced up until 0.5 mg where no antibacterial activity it seen. However, for 
all concentrations of epicatechin on disc the zone of inhibition does not increase 
above the actual 6mm disc diameter. This confirms epicatechin has no 
antibacterial activity against this isolate of S. maltophilia. 
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Figure 71. Mean zones of inhibition for the S. maltophilia isolate 2. Zones 
include the 6 mm disc diameter. 
 
 
 
In figure 71 the mean zones of inhibition for theaflavin and the 
theaflavin:epicatechin combination reduces as the disc concentration is also 
reduced. However, for all concentrations of epicatechin on disc the zone of 
inhibition does not increase above the actual 6mm disc diameter. This confirms 
epicatechin has no antibacterial activity against this isolate of S. maltophilia. 
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Figure 72. Mean zones of inhibition for the S. maltophilia isolate 3. Zones 
include the 6 mm disc diameter. 
 
 
 
In figure 72 the mean zones of inhibition for theaflavin and the 
theaflavin:epicatechin combination reduces as the disc concentration is also 
reduced where at 0.5 mg almost no antibacterial activity is seen. However, for 
all concentrations of epicatechin on disc the zone of inhibition does not increase 
above the actual 6mm disc diameter. This confirms epicatechin has no 
antibacterial activity against this isolate of S. maltophilia. 
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Figure 73. Mean zones of inhibition for the S. maltophilia isolate 4. Zones 
include the 6 mm disc diameter. 
 
 
 
In figure 73 the mean zones of inhibition for theaflavin and the 
theaflavin:epicatechin combination reduces as the disc concentration is also 
reduced where at 0.5 mg almost no antibacterial activity is seen. However, for 
all concentrations of epicatechin on disc the zone of inhibition does not increase 
above the actual 6mm disc diameter. This confirms epicatechin has no 
antibacterial activity against this isolate of S. maltophilia. 
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Table 24. Results of a student T-test (paired, 2 tailed) to show significant difference between antibacterial effects of polyphenols and 
polyphenol combinations against isolates of MRSA. 
 Organism 
MRSA 
[EC] vs. [TF] [EC] vs. [TF:EC] [TF:EC] vs. [TF] 
Isolate no. 1 2 3 4 1 2 3 4 1 2 3 4 
4 mg P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
3 mg P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
2 mg P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
1 mg P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0144 
S 
P = 0.0004 
S 
P = 0.0001 
S 
P = 0.0001 
S 
0.5 mg P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0021 
S 
P = 0.0001 
S 
P = 0.1019 
S 
P = 0.0010 
S 
0.75 mg P = 0.3632 
N 
P = 0.0250 
S 
P = 0.0001 
S 
P = 0.0761 
N 
P = 0.0756 
N 
P = 0.0912 
N 
P = 0.0041 
S 
P = 0.0001 
S 
P = 0.3632 
N 
P = 0.6109 
N 
P = 0.0001 
N 
P = 0.0103 
S 
Where epicatechin = EC, theaflavin = TF and epigallocatechin gallate = EGC. S = significant difference (Null hypothesis rejected) and N= no significant difference 
(Null hypothesis accepted). P = 2 tailed P value. 
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Table 24. Results of a student T-test (paired, 2 tailed) to show significant difference between antibacterial effects of polyphenols and 
polyphenol combinations against isolates of MRSA. 
 Organism 
A, baumannii 
[EC] vs. [TF] [EC] vs. [TF:EC] [TF:EC] vs. [TF] 
Isolate no. 1 2 3 4 1 2 3 4 1 2 3 4 
4 mg P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
3 mg P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0005 
S 
P = 0.0001 
S 
2 mg P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0409 
S 
P = 0.0010 
S 
P = 0.0025 
S 
1 mg P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0005 
S 
P = 0.3632 
N 
P = 0.0006 
S 
P = 0.0001 
S 
P = 0.0012 
S 
P = 0.0010 
S 
P = 0.9999 
N 
P = 0.0305 
S 
P = 0.9999 
N 
P = 0.0010 
S 
0.5 mg P = 0.3632 
N 
P = 0.0912 
N 
P = 0.0001 
S 
P = 0.3632 
N 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0006 
S 
P = 0.0001 
S 
P = 0.3632 
N 
P = 0.0004 
S 
P = 0.0117 
S 
P = 0.0001 
S 
0.75 mg P = 0.3632 
N 
P = 0.0068 
S 
P = 0.3632 
N 
P = 0.3632 
N 
P = 0.3632 
N 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.3632 
N 
P = 0.3632 
N 
P = 0.0583 
N 
P = 0.0001 
S 
P = 0.3632 
N 
Where epicatechin = EC, theaflavin = TF and epigallocatechin gallate = EGC. S = significant difference (Null hypothesis rejected) and N= no significant difference 
(Null hypothesis accepted). P = 2 tailed P value. 
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Table 24. Results of a student T-test (paired, 2 tailed) to show significant difference between antibacterial effects of polyphenols and 
polyphenol combinations against isolates of MRSA. 
 Organism 
S. maltophilia 
[EC] vs. [TF] [EC] vs. [TF:EC] [TF:EC] vs. [TF] 
Isolate no. 1 2 3 4 1 2 3 4 1 2 3 4 
4 mg P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
3 mg P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0005 
S 
P = 0.0001 
S 
P = 0.0009 
S 
P = 0.0001 
S 
2 mg P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
1 mg P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.3632 
N 
P = 0.0015 
S 
P = 0.0001 
S 
P = 0.0001 
S 
0.5 mg P = 0.3632 
N 
P = 0.0156 
S 
P = 0.0004 
S 
P = 0.0001 
S 
P = 0.0138 
S 
P = 0.0001 
S 
P = 0.0018 
S 
P = 0.0001 
S 
P = 0.0138 
S 
P = 0.0034 
S 
P = 0.1357 
N 
P = 0.0409 
S 
0.75 mg P = 0.3632 
N 
P = 0.0912 
N 
P = 0.4838 
N 
P = 0.3632 
N 
P = 0.3632 
N 
P = 0.0006 
S 
P = 0.0001 
S 
P = 0.0138 
S 
P = 0.3632 
N 
P = 0.1106 
N 
P = 0.0041 
S 
P = 0.0001 
S 
Where epicatechin = EC, theaflavin = TF and epigallocatechin gallate = EGC. S = significant difference (Null hypothesis rejected) and N= no significant difference 
(Null hypothesis accepted). P = 2 tailed P value. 
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In the present study epicatechin shows no antibacterial activity against any 
clinical isolate tested, whereas previous research (Hirao et al., 2010 and Toda et 
al., 1992) did find activity against periodontal bacteria and Vibrio cholera. 
However, the work here parallels another (Cushnie et al., 2008) were 
epicatechin was found to be an ineffective antibacterial agent, in their case 
against Staphylococcus aureus. This variation in antibacterial activity is often 
observed when testing antimicrobial agents against various bacterial species. 
 
When examining the results for theaflavin, it shows strong antibacterial effects 
that could potentially be of clinical relevance when dealing with microorganism’s 
resistance to conventional antibiotics. In this study MRSA and S. maltophilia 
isolates are most susceptible to the antibacterial action of theaflavin. When 
examining previous research is thought that the potential mechanism is related 
to membrane interaction (Sirk, Friedman and Brown, 2011). Further research is 
required to determine whether this is a bactericidal or bacteriostatic effect and 
what other mechanisms are involved. 
 
It is apparent from the results reported here that significant synergism exists 
between theaflavin and epicatechin against all isolates of MRSA. A. baumannii 
and S. maltophilia. It is suggested that the mechanism behind the synergy is 
similar to that shown for ascorbic acid and epigallocatechin gallate (Hatano et 
al., 2008). In this study it is believed that epicatechin inhibits the oxidation of 
theaflavin and prolongs its antibacterial effect. Although synergy is observed 
when low concentrations of the compounds are used, the greatest levels of 
synergy are observed when the compounds are used in concentrations in 
excess of 2 mg per susceptibility disc. This could be due to either diffusion rate 
limitations of the compounds into the media, the impact of polyphenol 
concentration on bacterial osmolality or a saturation point of any polyphenol 
expulsion by the bacteria. 
 
It is believed this is the first occasion where the antibacterial effects of theaflavin 
against clinical isolates of A. baumannii and S. maltophilia are reported. It is 
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also believed to be the first report of antibacterial synergy between theaflavin 
and epicatechin against hospital isolates of MRSA, A. baumannii and S. 
maltophilia.  
 
3.6.3 Results for the minimum inhibitory concentration testing against 
clinical isolates of S. maltophilia 
The results from the MIC testing confirm that epicatechin has no antibacterial 
effect against the strains of S. maltophilia used in this study. Concentrations of 
up to 1 mg/mL of epicatechin did not inhibit the growth of S. maltophilia and 
therefore no MIC was achieved. 
 
The MIC results for theaflavin confirmed that the polyphenol produced 
antibacterial effects even when used in a broth culture. The MIC of theaflavin 
ranged between 400 µg/mL and 800 µg/mL. This can be seen in figure 74. The 
S. maltophilia had a MIC for theaflavin of 400 µg/mL. 
 
For the theaflavin:epicatechin combination the MIC value ranged between 
200 µg/mL and 400 µg/mL (see figure 74). This was significantly lower than 
when using just theaflavin. The S. maltophilia control strain (NCTC 13014) had 
a MIC of 200 µg/mL for the theaflavin:epicatechin combination.  
  
Figure 74. Graphs representing the percentage of isolate MICs for theaflavin 
(TF) and theaflavin:epicatechin combination (TF:EC) 
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The result confirms that a significant synergistic relationship exists between 
theaflavin and epicatechin. This would also present a large reduction in cost if 
the combination treatment was used. The reason for this is that half of the more 
expensive theaflavin would be required to treat an isolate of S. maltophilia in 
comparison with theaflavin alone. 
 
Although the mechanisms underlying the antibacterial activity and synergy are 
not yet clear, the findings indicate that there might be important clinical potential 
for these polyphenols, especially when used in combination. Further studies are 
recommended to determine the mechanisms involved and the potential synergy 
of theaflavin or epicatechin with other polyphenols from natural sources. 
 
3.6.4 Results and discussion for antibiotic synergy testing 
In this study all isolates of MRSA, A. baumannii and S. maltophilia showed 
resistance to ampicillin (Figures 75-92). Epicatechin showed significant P ≤ 0.05 
synergistic effects with ampicillin against every isolate and control strain of 
MRSA, A. baumannii and S. maltophilia as did theaflavin Table (27–29). 
Epigallocatechin showed synergy with ampicillin against most isolates with the 
exception to those in figures 77, 79, 81, 83-86 and 89. 
 
As expected, all clinical isolates of MRSA showed resistance to penicillin G. 
Epicatechin gave no additional antibacterial effect against any isolate of MRSA, 
indicating no synergy occurred. However, theaflavin showed significant synergy 
with penicillin G against all isolates of MRSA (Figures 75-78) and 
epigallocatechin showed synergy with isolates 1 and 4 of MRSA. 
 
No bacterial isolates in this investigation were resistant to gentamycin. 
Gentamycin appeared to have strong antibacterial activity against MRSA, A. 
baumannii and S. maltophilia. However, when gentamycin was used in 
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combination with theaflavin or epigallocatechin a significant reduction in 
antibacterial effect was recorded at P ≤ 0.05 (Table 27-29, figures 75-80, 82-83 
and 85-91). With the exception of isolate 3 of A. baumannii where no effect was 
seen (Table 28, figure 81) with TF and isolate 6 of A. baumannii and the 
S. maltophilia control when used with epigallocatechin. In most cases 
epicatechin showed no effect when used with gentamycin, with the exception of 
MRSA isolates 1 and 2 where antagonism and synergy was seen respectively 
(Figures 77-78, table 27), isolate 3 of A. baumannii where synergy was seen 
(Figure 81, table 28) and isolate 1 of S. maltophilia (Figure 86, table 29) where 
antagonism was seen. 
 
In this study imipenem was an effective antibacterial agent against all clinical 
isolates of MRSA, clinical isolates of A. baumannii and its control NCTC 13485 
(Tables 27 and 28, figures 75-85). However all isolates of S. maltophilia and its 
control NCTC 13014 were resistant to imipenem (Table 29, figures 86-93) with 
the exception of isolate 6 which showed sensitivity (Figure 91). When used in 
conjunction with epicatechin synergy (P ≤ 0.05) was seen for isolate 1 of MRSA, 
6 of A. baumannii and 5 and 6 of S. maltophilia (Figures 75, 84, 90 and 91). 
However with isolates 1 and 3 of A. baumannii significant antagonism was 
observed (Figures 79 and 81). When imipenem was used with theaflavin 
significant synergy was produced with isolates 1 and 2 of MRSA (Figures 75 
and 76) and isolates 5 and 6 of S. maltophilia (Figures 90 and 91). However, 
significant antagonism was produced when the combination was used against 
isolate 6 of A. baumannii (Figure 84). When Imipenem was used with 
epigallocatechin mixed results were also produced. Against MRSA synergy was 
seen against isolates 1 and 2 and no effects against isolates 3 and 4 (Figures 
75-78). However, against A. baumannii mixed results were produced as 
antagonism was seen against isolates 1 and 3 (Figures 79 and 81) and 
significant synergy (P ≤ 0.05) against isolates 4-6 (Figures 82-84, table 28). 
Against S. maltophilia the combination of imipenem and epigallocatechin 
showed no difference with the exception of isolate 4 were significant synergy 
was produced (Figure 89, table 29). 
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Clarithromycin was seen to be effective against clinical isolates 3 and 4 of 
MRSA with no effect seen against isolates 1 and 2. When epicatechin was used 
with clarithromycin no effect was seen indicating it produces no synergy or 
antagonism when used with this antibiotic. Mixed results were seen when 
clarithromycin was used with epigallocatechin. With isolates 1 and 2 of MRSA 
significant synergy was produced (P ≤ 0.05), with isolate 3 antagonism was 
seen and with isolate 4, no significant difference was observed (Figures 75-78, 
table 27). However, against all isolates of MRSA used, significant synergy (P ≤ 
0.05) was produced between theaflavin and clarithromycin (Figures 75-78, table 
27). 
 
Tetracycline was shown to be an effective antibacterial agent against all clinical 
isolates and the control of A. baumannii and also effective for clinical isolates 
1,4 and 6 of S. maltophilia (Figures 79-86, 89 and 91). Clinical isolates 2, 3 and 
5 and the control strain (NCTC 13014) of S. maltophilia were resistant to 
tetracycline (Figures 87, 88, 90 and 92). With the exception of A. baumannii 
isolates 3 and 5 where synergy was seen and isolate 1 of S. maltophilia where 
antagonism was shown, epicatechin produced no other synergy or antagonism 
when combined with tetracycline. Theaflavin shown only significant antagonism 
(P ≤ 0.05) or no effect against all isolates (Figures 79-92, table 28 and 29). 
When tetracycline was used in combination with epigallocatechin mixed results 
were seen. With A. baumannii isolate 1 and the control strain, antagonism was 
produced, but with isolate 6, synergy was observed (Figures 79-85). With 
S. maltophilia isolate 1 gave antagonism, whereas isolates 2 and 6 produced 
significant synergy (P ≤ 0.05). 
 
Cefoxitin only showed an antibacterial effect against isolates 1, 4 and 5 of 
A. baumannii and with the control strain of S. maltophilia. With all other isolates, 
cefoxitin showed no action. A synergistic effect was observed when epicatechin 
was used with cefoxitin against isolates 2 and 5 of A. baumannii, antagonism 
with isolate 4 and no effect with all other isolates of A. baumannii (including 
control) and also no effect with all isolates and control of S. maltophilia. 
However, when cefoxitin was used with theaflavin significant synergy was 
 155 
produced against all isolates of S. maltophilia and all but isolate 1 of 
A. baumannii (Figures 79-92, tables 28 and 29). The combination of 
epigallocatechin and cefoxitin gave similar results with significant synergy 
observed with all isolates with the exception of isolate 1 and the control strain of 
A. baumannii and control strain of S. maltophilia.  
 
Ciprofloxacin showed strong antibacterial activity against all isolates of 
A. baumannii (Figures 79-85) and the control strain (NCTC 13485). Against 
clinical isolates of S. maltophilia the effect was mixed, with isolates 1, 2, 5 and 
the control strain showing resistance (Figures 86, 87, 90 and 92). When used 
with epicatechin mixed results were produced with significant synergy (P ≤ 0.05) 
shown for isolates 2, 3, 5 and 6 of A. baumannii and isolates 6 0f S. maltophilia 
(Figures 80, 81, 83, 84, and 91, table 28 and 29), antagonism for isolate 4 of 
A. baumannii and isolates 2 and 4 of S. maltophilia (Figures 82, 88 and 89, 
tables 28 and 29) and no difference with all other isolates. When ciprofloxacin 
was used in combination with theaflavin significant antagonism (P ≤ 0.05) was 
seen with all isolates of A. baumannii (Figures 79-85, table 28) and isolates 4 
and 6 of S. maltophilia (Figures 89 and 91, table 29). However, significant 
synergy was produced against isolates 1-3 and 5 of S. maltophilia (Figures 86-
88 and 90, table 29). The combination of epigallocatechin and ciprofloxacin 
produced a antagonistic effect with the majority of A. baumannii isolates and 
control strain (Figures 81-85) and mixed results against S. maltophilia. Against 
isolates 2, 3 and 5 of S. maltophilia an significantly increased antibacterial effect 
with the combination of epigallocatechin and ciprofloxacin was seen (Figures 
87, 88 and 90), whereas against isolate 6 the antibacterial effect was reduced 
meaning antagonism between the 2 compounds took place. 
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Figure 75. Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against isolate 1 of MRSA.   
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin 
= AMP, penicillin G = P, gentamycin = CN, imipenem = IPM and 
clarithromycin = CLM. Zones include the 6 mm disc diameter. 
 
In figure 75, isolate 1 of MRSA is seen to be resistant to ampicillin, penicillin G 
and clarithromycin although very susceptible to gentamycin and susceptible to 
Imipenem. With the exception of ampicillin and imipenem epicatechin shows no 
significant synergy or antagonism with any other antibiotic. Both TF and the 
epigallocatechin show significant antagonism with gentamycin but significant 
synergy with all other antibiotics used (P≤ 0.05). As expected the control 
concentrations used for epicatechin, theaflavin, epigallocatechin controls and 
the ethanol control show no significant antibacterial effect. 
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Figure 76. Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against isolate 2 of MRSA.  
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin 
= AMP, penicillin G = P, gentamycin = CN, imipenem = IPM and 
clarithromycin = CLM. Zones include the 6 mm disc diameter. 
 
In figure 76, isolate 2 of MRSA is seen to be resistant to ampicillin, penicillin G 
and clarithromycin although very susceptible to gentamycin and susceptible to 
Imipenem. epicatechin shows no significant synergy or antagonism with any 
antibiotic with the exception of ampicillin where significant synergy is seen for 
this isolate. Both theaflavin and epicatechin show significant antagonism with 
gentamycin but significant synergy with all other antibiotics used (P≤ 0.05) with 
the exception of epigallocatechin with penicillin G where no difference is seen. 
As expected the concentrations used for epicatechin, theaflavin, 
epigallocatechin controls and the ethanol control show no significant 
antibacterial effect. 
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Figure 77. Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against isolate 3 of MRSA.   
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin 
= AMP, penicillin G = P, gentamycin = CN, imipenem = IPM and 
clarithromycin = CLM. Zones include the 6 mm disc diameter. 
 
In figure 77, isolate 3 of MRSA is seen to be resistant to penicillin G and 
ampicillin, although it is highly susceptible to gentamycin, imipenem and 
clarithromycin. With this isolate of MRSA epicatechin only shows significant 
synergy with ampicillin but no antagonism with any antibiotic. Both theaflavin 
and the epigallocatechin show significant antagonism with gentamycin and 
clarithromycin (P≤ 0.05) but significant synergy with ampicillin (P≤ 0.05) and no 
significant effect with imipenem. Theaflavin also shows significant synergy with 
penicillin G. As expected the concentrations used for epicatechin, theaflavin, 
epigallocatechin controls and the ethanol control show no significant 
antibacterial effect. 
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Figure 78. Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against isolate 4 of MRSA.   
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin 
= AMP, penicillin G = P, gentamycin = CN, imipenem = IPM and 
clarithromycin = CLM. Zones include the 6 mm disc diameter. 
 
In figure 78, isolate 4 of MRSA is seen to be resistant to ampicillin and penicillin 
G although it is highly susceptible to gentamycin, imipenem and clarithromycin. 
With this isolate of MRSA epicatechin only shows significant synergy with 
ampicillin. With all other antibiotics no significant synergy or antagonism is 
seen. Both theaflavin and the epigallocatechin show significant antagonism with 
gentamycin. Significant synergy between theaflavin and clarithromycin was 
observed and antagonism with imipenem (P≤ 0.05). Both theaflavin and 
epigallocatechin showed significant synergy with penicillin G (P≤ 0.05). As 
expected the concentrations used for epicatechin, theaflavin, epigallocatechin 
controls and the ethanol control show no significant antibacterial effect. 
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Figure 79. Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against isolate 1 of A. baumannii. 
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin = 
AMP, gentamycin = CN, imipenem = IPM, tetracycline = TE, cefoxitin = FOX 
and ciprofloxacin = CIP. Zones include the 6 mm disc diameter. 
 
In figure 79, isolate 1 of A. baumannii is seen to be resistant to ampicillin 
although it is highly susceptible to all other antibiotics tested. With this isolate of 
A. baumannii epicatechin only shows significant synergy with ampicillin and 
gentamycin. Both theaflavin and the epigallocatechin show significant 
antagonism with gentamycin (P≤ 0.05) but theaflavin show significant synergy 
with ampicillin (P≤ 0.05). Theaflavin produces significant antagonism with 
ciprofloxacin and tetracycline. No significant synergy or antagonism is observed 
between theaflavin and imipenem or cefoxitin. No significant synergy or 
antagonism was observed between epigallocatechin and tetracycline, cefoxitin 
or ciprofloxacin and As expected the concentrations used for the epicatechin, 
theaflavin, epigallocatechin controls and the ethanol control show no significant 
antibacterial effect. 
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Figure 80. Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against isolate 2 of A. baumannii.  
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin = 
AMP, gentamycin = CN, imipenem = IPM, tetracycline = TE, cefoxitin = FOX 
and ciprofloxacin = CIP. Zones include the 6 mm disc diameter. 
 
In figure 80, isolate 2 of A. baumannii is seen to be resistant to ampicillin and 
cefoxitin. However, it is highly susceptible to all other antibiotics used. With this 
isolate of A. baumannii epicatechin shows significant synergy with ampicillin, 
cefoxitin and ciprofloxacin and no significant difference with any other antibiotic. 
When used with gentamycin and tetracycline, epigallocatechin and theaflavin 
show significant antagonism (P≤ 0.05) but both show significant synergy with 
ampicillin and cefoxitin (P≤ 0.05). No significant synergy or antagonism is 
observed between imipenem and theaflavin or epigallocatechin. However 
significant antagonism is seen between theaflavin and ciprofloxacin. As 
expected the concentrations used for epicatechin, theaflavin, epigallocatechin 
controls and the ethanol control show no significant antibacterial effect. 
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Figure 81. Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against isolate 3 of A. baumannii.  
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin = 
AMP, gentamycin = CN, imipenem = IPM, tetracycline = TE, cefoxitin = FOX 
and ciprofloxacin = CIP. Zones include the 6 mm disc diameter. 
 
In figure 81, isolate 3 of A. baumannii is seen to be resistant to ampicillin and 
cefoxitin. However, it is highly susceptible to all other antibiotics used. With this 
isolate of A. baumannii epicatechin shows significant synergy with ampicillin, 
gentamycin, tetracycline and ciprofloxacin, no significant difference with 
cefoxitin and significant antagonism with imipenem. When used with 
ciprofloxacin, epigallocatechin and theaflavin show significant antagonism (P≤ 
0.05) but both show significant synergy with ampicillin and cefoxitin (P≤ 0.05). 
No significant synergy or antagonism is observed between imipenem and 
theaflavin. However significant antagonism is seen with epigallocatechin and 
theaflavin against ciprofloxacin. epigallocatechin also shows antagonism when 
used with imipenem. As expected the concentrations used for epicatechin, 
theaflavin, epigallocatechin controls and the ethanol control show no significant 
antibacterial effect. 
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Figure 82. Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against isolate 4 of A. baumannii.  
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin = 
AMP, gentamycin = CN, imipenem = IPM, tetracycline = TE, cefoxitin = FOX 
and ciprofloxacin = CIP. Zones include the 6 mm disc diameter. 
 
In figure 82, isolate 4 of A. baumannii is seen to be resistant to ampicillin and is 
highly susceptible to all other antibiotics used. With this isolate of A. baumannii 
epicatechin shows significant synergy with ampicillin, no significant difference 
with imipenem, tetracycline and gentamycin and significant antagonism with 
cefoxitin and ciprofloxacin. When used with ciprofloxacin and gentamycin, 
epigallocatechin and theaflavin show significant antagonism (P≤ 0.05) but both 
show significant synergy with ampicillin and cefoxitin (P≤ 0.05). No significant 
synergy or antagonism is observed between imipenem and theaflavin. 
Epigallocatechin also shows synergy when used with imipenem. As expected 
the concentrations used for epicatechin, theaflavin, epigallocatechin controls 
and the ethanol control show no significant antibacterial effect. 
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Figure 83. Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against isolate 5 of A. baumannii.  
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin = 
AMP, gentamycin = CN, imipenem = IPM, tetracycline = TE, cefoxitin = FOX 
and ciprofloxacin = CIP. Zones include the 6 mm disc diameter. 
 
In figure 83, isolate 5 of A. baumannii is seen to be resistant to ampicillin and is 
highly susceptible to all other antibiotics used. With this isolate of A. baumannii 
epicatechin shows significant synergy with ampicillin, tetracycline, cefoxitin and 
ciprofloxacin and no significant difference with imipenem and gentamycin. 
When used with ciprofloxacin, epigallocatechin and theaflavin show significant 
antagonism (P≤ 0.05) but both show significant synergy with ampicillin and 
cefoxitin (P≤ 0.05). No significant synergy or antagonism is observed between 
imipenem or tetracycline and theaflavin or epigallocatechin. When gentamycin 
when used with epigallocatechin synergy seen but when used with theaflavin 
antagonism is shown. As expected the concentrations used for epicatechin, 
theaflavin, epigallocatechin controls and the ethanol control show no significant 
antibacterial effect. 
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Figure 84. Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against isolate 6 of A. baumannii.  
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin = 
AMP, gentamycin = CN, imipenem = IPM, tetracycline = TE, cefoxitin = FOX 
and ciprofloxacin = CIP. Zones include the 6 mm disc diameter. 
 
In figure 84, isolate 6 of A. baumannii is seen to be resistant to ampicillin and 
cefoxitin, but is highly susceptible to all other antibiotics used. With this isolate 
of A. baumannii epicatechin shows significant synergy with ampicillin, imipenem 
and ciprofloxacin and no significant difference with gentamycin and cefoxitin. 
When used with ciprofloxacin, Eepigallocatechin and theaflavin show significant 
antagonism (P≤ 0.05) but both show significant synergy with ampicillin and 
cefoxitin (P≤ 0.05). Antagonism is observed between theaflavin and 
gentamycin, imipenem and tetracycline. No significant synergy or antagonism is 
observed between gentamycin epigallocatechin. Combinations of tetracycline or 
imipenem with epicatechin show synergy. As expected the concentrations used 
for epicatechin, theaflavin, epigallocatechin controls and the ethanol control 
show no significant antibacterial effect. 
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Figure 85. Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against the control strain (NCTC 13485) of 
A. baumannii. Zones include the 6 mm disc diameter. 
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin = 
AMP, gentamycin = CN, imipenem = IPM, tetracycline = TE, cefoxitin = FOX 
and ciprofloxacin = CIP. Zones include the 6 mm disc diameter. 
 
In figure 85, control NCTC 13485 of A. baumannii is seen to be resistant to 
ampicillin and cefoxitin and is highly susceptible to all other antibiotics used. 
With this isolate of A. baumannii epicatechin shows significant synergy with 
ampicillin and no significant difference with any other antibiotic. When used with 
gentamycin and ciprofloxacin, epigallocatechin and theaflavin show significant 
antagonism (P≤ 0.05) but theaflavin shows significant synergy with ampicillin 
(P≤ 0.05). No significant synergy or antagonism is observed between imipenem 
and theaflavin or epigallocatechin. When used with theaflavin antagonism is 
shown for tetracycline but synergy is observed with cefoxitin. As expected the 
concentrations used for epicatechin, theaflavin, epigallocatechin controls and 
the ethanol control show no significant antibacterial effect. 
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Figure 86. Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against isolate 1 of S. maltophilia.  
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin = 
AMP, gentamycin = CN, imipenem = IPM, tetracycline = TE, cefoxitin = FOX 
and ciprofloxacin = CIP. Zones include the 6 mm disc diameter. 
 
In figure 86, isolate 1 of S. maltophilia is seen to be resistant to ampicillin, 
Imipenem, cefoxitin and ciprofloxacin. However, it is highly susceptible to 
gentamycin and tetracycline. With this isolate of S. maltophilia epicatechin 
shows significant synergy with ampicillin, antagonism with gentamycin and 
tetracycline and no effect with all other antibiotics used. Both theaflavin and the 
epigallocatechin show significant antagonism with gentamycin (P≤ 0.05) and 
tetracycline but significant synergy with cefoxitin (P≤ 0.05) and no effect with 
imipenem. theaflavin also showed significant synergy with ampicillin and 
ciprofloxacin. As expected the concentrations used for the epicatechin, 
theaflavin, epigallocatechin controls and the ethanol control show no significant 
antibacterial effect. 
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Figure 87. Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against isolate 2 of S. maltophilia.  
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin = 
AMP, gentamycin = CN, imipenem = IPM, tetracycline = TE, cefoxitin = FOX 
and ciprofloxacin = CIP. Zones include the 6 mm disc diameter. 
 
In figure 87, isolate 2 of S. maltophilia is seen to be resistant to all antibiotics 
used in this study with the exception of gentamycin. With this isolate of S. 
maltophilia epicatechin shows significant synergy with ampicillin and no effect 
with any other antibiotic used. Both theaflavin and the epigallocatechin show 
significant antagonism with gentamycin (P≤ 0.05), significant synergy with 
ampicillin and ciprofloxacin (P≤ 0.05) and no effect with imipenem and 
tetracycline. theaflavin also showed significant synergy with cefoxitin. As 
expected the concentrations used for the epicatechin, theaflavin, 
epigallocatechin controls and the ethanol control show no significant 
antibacterial effect. 
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Figure 88. Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against isolate 3 of S. maltophilia.  
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin = 
AMP, gentamycin = CN, imipenem = IPM, tetracycline = TE, cefoxitin = FOX 
and ciprofloxacin = CIP. Zones include the 6 mm disc diameter. 
 
In figure 88, isolate 3 of S. maltophilia is seen to be resistant to all antibiotics 
used in this study with the exception of gentamycin and ciprofloxacin. With this 
isolate of S. maltophilia epicatechin shows significant synergy (P≤ 0.05) with 
ampicillin and no effects with any other antibiotic used. Both theaflavin and 
epigallocatechin show significant synergy (P≤ 0.05) with ampicillin, cefoxitin 
and ciprofloxacin, however theaflavin shows significant antagonism with 
gentamycin (P≤ 0.05). As expected the concentrations used for the 
epicatechin, theaflavin, epigallocatechin controls and the ethanol control show 
no significant antibacterial effect. 
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Figure 89. S Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against isolate 4 of S. maltophilia.  
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin = 
AMP, gentamycin = CN, imipenem = IPM, tetracycline = TE, cefoxitin = FOX 
and ciprofloxacin = CIP. Zones include the 6 mm disc diameter. 
 
In figure 89, isolate 4 of S. maltophilia is seen to be resistant to ampicillin, 
imipenem and cefoxitin. However, it is highly susceptible to gentamycin, 
tetracycline and ciprofloxacin. With this isolate of S. maltophilia epicatechin 
shows significant synergy (P≤ 0.05) with ampicillin, antagonism with 
ciprofloxacin and no effect with any other antibiotic used. Both theaflavin and 
epigallocatechin show significant synergy (P≤ 0.05) with ampicillin and cefoxitin 
and antagonism with gentamycin (P≤ 0.05). Theaflavin shows antagonism with 
ciprofloxacin and tetracycline and epigallocatechin shows significant synergy 
with imipenem and no effect with ciprofloxacin or tetracycline. As expected the 
concentrations used for epicatechin, theaflavin, epigallocatechin controls and 
the ethanol control show no significant antibacterial effect. 
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Figure 90. Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against isolate 5 of S. maltophilia.  
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin = 
AMP, gentamycin = CN, imipenem = IPM, tetracycline = TE, cefoxitin = FOX 
and ciprofloxacin = CIP. Zones include the 6 mm disc diameter. 
 
In figure 90, isolate 5 of S. maltophilia is seen to be resistant to all antibiotics 
used in this study with the exception of gentamycin. With this isolate of 
S. maltophilia epicatechin shows significant synergy (P≤ 0.05) with ampicillin 
and imipenem, antagonism with gentamycin and no effect with any other 
antibiotic used. Both theaflavin and epigallocatechin show significant synergy 
(P≤ 0.05) with ampicillin, cefoxitin and ciprofloxacin, antagonism with 
gentamycin (P≤ 0.05) and no effect with tetracycline. Theaflavin shows 
significant synergy with imipenem (P≤ 0.05) whereas epigallocatechin shows no 
effect. As expected the concentrations used for epicatechin, theaflavin, 
epigallocatechin controls and the ethanol control show no significant 
antibacterial effect. 
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Figure 91. Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against isolate 6 of S. maltophilia.  
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin = 
AMP, gentamycin = CN, imipenem = IPM, tetracycline = TE, cefoxitin = FOX 
and ciprofloxacin = CIP. Zones include the 6 mm disc diameter. 
 
In figure 91, isolate 6 of S. maltophilia is seen to be resistant to ampicillin and 
cefoxitin and susceptible to all antibiotics used in this study. With this isolate of 
S. maltophilia epicatechin shows significant synergy (P≤ 0.05) with ampicillin, 
imipenem and ciprofloxacin and no effect with any other antibiotic used. Both 
theaflavin and epigallocatechin show significant synergy (P≤ 0.05) with 
ampicillin and cefoxitin, but antagonism with gentamycin, and ciprofloxacin (P≤ 
0.05). Theaflavin shows significant synergy with imipenem (P≤ 0.05) whereas 
epigallocatechin shows no effect. Significant antagonism exists between 
theaflavin and tetracycline whereas with epigallocatechin synergism occurs. As 
expected the concentrations used for epicatechin, theaflavin, epigallocatechin 
controls and the ethanol control show no significant antibacterial effect. 
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Figure 92. Graph showing the synergistic and antagonistic effects of 
polyphenols with antibiotics against the control strain (NCTC 13014) of 
S. maltophilia.  
 
Where theaflavin = TF, epicatechin = EC, epigallocatechin = EGC, ampicillin = 
AMP, gentamycin = CN, imipenem = IPM, tetracycline = TE, cefoxitin = FOX 
and ciprofloxacin = CIP. Zones include the 6 mm disc diameter. 
 
In figure 92, control strain NCTC 13014 of S. maltophilia is seen to be resistant 
to all antibiotics used in this study with the exception of gentamycin and 
cefoxitin. With this strain of S. maltophilia epicatechin shows significant synergy 
(P≤ 0.05) with ampicillin and no effect with any other antibiotic used. Both 
theaflavin and epigallocatechin show significant synergy (P≤ 0.05) with 
ampicillin and no effect with ciprofloxacin, tetracycline or imipenem. Theaflavin 
shows significant antagonism with gentamycin (P≤ 0.05) and significant synergy 
with cefoxitin (P≤ 0.05). As expected the concentrations used for epicatechin, 
theaflavin, epigallocatechin controls and the ethanol control show no significant 
antibacterial effect. 
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Table 27. Results of a student T-test (paired, 2 tailed) to show significant difference between antibacterial effects of antibiotics and 
antibiotic-polyphenol combinations against MRSA isolates. 
 Organism 
MRSA 
[Antibiotic] vs. [Antibiotic + EC] [Antibiotic] vs. [Antibiotic + TF] [Antibiotic] vs. [Antibiotic + EGC] 
Isolate no. 1 2 3 4 1 2 3 4 1 2 3 4 
AMP 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
PEN 
P = 0.3632 
N 
P = 0.3632 
N  
P = 0.3632 
N 
P = 0.3632 
N  
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
CN 
P = 0.3632 
N  
P = 0.3632 
N  
P = 0.4838 
N 
P = 0.1019 
N 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
IPM 
P = 0.0001 
S 
P = 0.3632 
N 
P = 0.3632 
N 
P = 0.3632 
N 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.3632 
N  
P = 0.0429 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.1747 
N 
P = 0.1747 
N  
CLM 
P = 0.3632 
N 
P = 0.3632 
N 
P = 0.3632 
N 
P = 0.4838 
N 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.0001 
S 
P = 0.3632 
N  
Where ampicillin = AMP, penicillin G = PEN, gentamycin = CN, imipenem = IPM and clarithromycin = CLM, epicatechin = EC, theaflavin = TF and epigallocatechin 
gallate = EGC. S = significant difference (Null hypothesis rejected) and N= no significant difference (Null hypothesis accepted). P = 2 tailed P value. 
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Table 28. Results of a student T-test (paired, 2 tailed) to show significant difference between antibacterial effects of antibiotics and 
antibiotic-polyphenol combinations against A. baumannii isolates. 
 Organism 
A. baumannii 
[Antibiotic] vs. [Antibiotic + EC] [Antibiotic] vs. [Antibiotic + TF] [Antibiotic] vs. [Antibiotic + EGC] 
Isolate 
no. 
1 2 3 4 5 6 C 1 2 3 4 5 6 C 1 2 3 4 5 6 C 
AMP P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0011 
S 
P = 
0.3632 
N 
CN P = 
0.025 
S 
P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.999 
N 
P = 
0.3632 
N 
P = 
0.4838 
N 
P = 
0.0756 
N 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.3632 
N 
P = 
0.0002 
S 
P = 
0.0041 
S 
P = 
0.0301 
S 
P = 
0.0001 
S 
P = 
0.0409 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.3632 
N 
P = 
0.0001 
S 
IPM P = 
0.0004 
S 
P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.3632 
N 
P = 
0.1747 
N 
P = 
0.0001 
S 
P = 
0.1747 
N 
P = 
0.1747 
N 
P = 
0.4650 
N 
P = 
0.2374 
N 
P = 
0.6952 
N 
P = 
0.3632 
N 
P = 
0.0005 
S 
P = 
0.1019 
N 
P = 
0.0001 
S 
P = 
0.0756 
N 
P = 
0.0001 
S 
P = 
0.0009 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.3632 
N 
TE P = 
0.3148 
N 
P = 
0.999 
N 
P = 
0.0002 
S 
P = 
0.1886 
N 
P = 
0.0001 
S 
P = 
0.1747 
N 
P = 
0.2031 
N 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0756 
N 
P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.6109 
N 
P = 
0.0001 
S 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.1019 
N 
P = 
0.0001 
S 
P = 
0.0001 
S 
FOX P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0005 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0756 
N 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.3632 
N 
CIP P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0015 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.999 
N 
P = 
0.1747 
N 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0005 
S 
Where ampicillin = AMP, gentamycin = CN, imipenem = IPM, tetracycline = TE, cefoxitin = FOX and ciprofloxacin = CIP, epicatechin = EC, theaflavin = TF and 
epigallocatechin gallate = EGC. S = significant difference (Null hypothesis rejected) and N= no significant difference (Null hypothesis accepted). P = 2 tailed P value. 
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Table 29. Results of a student T-test (paired, 2 tailed) to show significant difference between antibacterial effects of antibiotics and 
antibiotic-polyphenol combinations against S. maltophilia isolates. 
 Organism 
S. maltophilia 
[Antibiotic] vs. [Antibiotic + EC] [Antibiotic] vs. [Antibiotic + TF] [Antibiotic] vs. [Antibiotic + EGC] 
Isolate 
no. 
1 2 3 4 5 6 C 1 2 3 4 5 6 C 1 2 3 4 5 6 C 
AMP P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.3632 
N 
P = 
0.0005 
S 
P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.0009 
S 
P = 
0.0001 
S 
P = 
0.0019 
S 
CN P = 
0.011 
S 
P = 
0.79 
N 
P = 
0.3632 
N 
P = 
0.0756 
N 
P = 
0.0429 
S 
P = 
0.3632 
N 
P = 
0.999 
N 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0041 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.1747 
N 
P = 
0.42 
N 
P = 
0.0305 
N 
P = 
0.0001 
S 
P = 
0.999 
N 
IPM P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.0015 
S 
P = 
0.0009 
S 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.1747 
N 
P = 
0.42 
N 
P = 
0.3632 
N 
TE P = 
0.019 
S 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.0628 
N 
P = 
0.3632 
N 
P = 
0.6109 
N 
P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.3632 
N 
P = 
0.0041 
S 
P = 
0.3632 
N 
P = 
0.0429 
S 
P = 
0.0001 
S 
P = 
0.3632 
N 
P = 
0.1852 
N 
P = 
0.3632 
N 
P = 
0.0015 
S 
P = 
0.3632 
N 
FOX P = 
0.3632 
S 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0429 
S 
P = 
0.0071 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0011 
S 
P = 
0.0011 
S 
P = 
0.3632 
N 
CIP P = 
0.3632 
N 
P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.0009 
S 
P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.3632 
N 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.3632 
N 
P = 
0.0756 
S 
P = 
0.0001 
S 
P = 
0.0002 
S 
P = 
0.999 
N 
P = 
0.0001 
S 
P = 
0.0001 
S 
P = 
0.3632 
N 
Where ampicillin = AMP, gentamycin = CN, imipenem = IPM, tetracycline = TE, cefoxitin = FOX and ciprofloxacin = CIP, epicatechin = EC, theaflavin = TF and 
epigallocatechin gallate = EGC. S = significant difference (Null hypothesis rejected) and N= no significant difference (Null hypothesis accepted). P = 2 tailed P value. 
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The results in this study have demonstrated that the tea polyphenols 
epicatechin and theaflavin had significant synergy with ampicillin against every 
isolate tested with epicatechin giving the highest increase of antibacterial 
activity. Epigallocatechin also showed significant synergy with ampicillin against 
all but 5 isolates.  The proposed mechanism for this synergy is the modification 
or destruction of the Beta-lactamases produced by the organisms 
Hemaiswarya, Kruthiventi and Doble, 2008). This work clearly shows the 
potential for polyphenol-ampicillin combination drugs to treat infections caused 
by ampicillin resistant bacteria. 
 
From the results with penicillin G it was clear that theaflavin showed significant 
synergy against MRSA with epigallocatechin giving either synergy or 
indifference. As in the study by Zhao et al. (2001), who used epigallocatechin 
gallate against Staphylococcus aureus, it is clear that the addition of 
polyphenols can enable penicillin to be once again an effective antibiotic. 
However, further investigations should take place as previous studies have 
found that some polyphenols can also produce antagonistic effects with 
penicillin (Denny, West and Mathew, 2008). 
 
In the case of gentamycin in combination with theaflavin or epigallocatechin, 
significant antagonism was produced when used against almost all the isolates. 
It is unclear of the mechanism of the antagonism. However, it is possible that 
the polyphenols either blocked the site of action for gentamycin or interacted 
with the structure of the antibiotic to reduce its effectiveness. Another proposal 
to explain the antagonism is that theaflavin somehow reduced the ability of the 
antibiotic to diffuse into the agar, therefore reducing its apparent antimicrobial 
effect. However, from a previous study it was discovered that pomegranate 
extracts, comprised of high levels of polyphenols, produced significant synergy 
with gentamycin against MRSA (Braga et al., 2005). In their research they 
demonstrated the extracts inhibit the bacteria’s efflux pump NorA or enhanced 
the efflux of the drug. The variation in the chemical structures of the 
polyphenols in the extract could account for the differences in the results 
achieved in the previous study to this study. From this research it is clear that 
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using epicatechin, theaflavin and epigallocatechin with gentamycin would be of 
little clinical use against isolates of MRSA, A. baumannii and S. maltophilia. 
 
When using imipenem with the addition of epicatechin mixed results were seen. 
Further research should be undertaken to confirm whether overall epicatechin 
could be a useful addition to increase the antibacterial action of imipenem. 
However, when imipenem is used in conjunction with theaflavin or the 
epigallocatechin synergy was produced against MRSA ≥ 50% indicating that a 
future duel treatment could be possible. Future research should investigate this 
further with a larger number of MRSA isolates. This was also found by Hu et al., 
(2002), when epigallocatechin gallate was used in combination with imipenem 
against MRSA. In combination with theaflavin imipenem showed antagonism or 
no difference against A. baumannii and although further work into the 
mechanisms behind the relationship should take place, the preliminary results 
suggest a combination treatment would not be beneficial. However, against S. 
maltophilia there is potential due to the synergy observed although the reason 
for this is unclear and further investigation is required for confirmation. This 
variation between isolates might also indicate that the change is related to the 
site of antimicrobial attachment and that in certain strains the theaflavin reduces 
the ability of imipenem to inhibit cell wall synthesis. When imipenem is used in 
combination with epigallocatechin mixed results suggest that synergy or 
antagonism varies between isolates. Further investigations should investigate if 
any interactions between polyphenols and imipenem occur.  
 
The results for clarithromycin indicated that there is no synergy with epicatechin 
but there is overall synergy with theaflavin. Previous research supports 
polyphenol synergy with clarithromycin (Yanagawa et al., 2003) and it was 
concluded that the polyphenol epigallocatechin gallate had a synergistic effect 
with the antibiotic. Although the previous work investigated synergy between 
polyphenols and clarithromycin against gram-negative bacteria, this study 
confirms that the synergy also exists against gram-positive bacteria. As with 
their work it is suggested here that the clinical application of theaflavin and 
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clarithromycin should be investigated further as a method of treating resistant 
infections. 
The A. baumannii isolates used in this investigation were all susceptible to 
tetracycline unlike the isolates of S. maltophilia where only ≤ 50% were affected 
by the antibiotic. Previous research has shown polyphenols interact well with 
this antibiotic whereby the polyphenol epigallocatechin to produces synergy 
with tetracycline against S. aureus by inhibiting the efflux of the antibiotic 
(Roccaro et al., 2004). Unlike the previous investigation this research found no 
overall synergy between epicatechin, theaflavin or epigallocatechin and 
tetracycline. However, unlike the previous research this investigation 
investigated the effects against gram-negative bacteria. The different outer 
structure of the gram-negative bacteria used could be a possible reason for the 
antagonism or the polyphenol either preventing uptake of the antibiotic due to 
interacting with the cells mechanism of active transport. Further in vitro studies 
should investigate this mechanism to highlight the cause of the antagonism. 
 
In this investigation it has be shown that synergies exist between polyphenols 
and cefoxitin with theaflavin and epigallocatechin showing synergy against 
almost all isolates used. This indicates a huge potential for polyphenols to be 
used in combination with this antibiotic to treat bacterial infections caused by 
gram-negative bacteria. Further research should look into the interaction of 
theaflavin and cefoxitin with gram-positive bacteria. With epicatechin, synergy 
was shown against 2 of 14 isolates and antagonism in 1 isolate. It could be 
concluded that the benefits of using epicatechin with this antibiotic are unclear 
and further research has been conducted. Present indications are that it would 
be unsuitable for combination therapy with cefoxitin. In a previous investigation, 
when using polyphenols with cefoxitin, no antagonism was observed (Denny, 
West and Mathew, 2008) showing that overall polyphenols do not lower the 
antibacterial activity of this antibiotic. Further research should be conducted to 
discover the mechanism behind the synergy of polyphenols and cefoxitin. 
 
The A. baumannii isolates used in this investigation were all susceptible to 
Ciprofloxacin unlike the isolates of S. maltophilia where only ≤ 50% were 
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affected by the antibiotic. Against all A. baumannii isolates theaflavin and 
ciprofloxacin combinations showed significant antagonism and with 
epigallocatechin this was shown against 5 of the 7 isolates. It can be concluded 
that these 2 polyphenols would not be good candidates for a duel treatment of 
infections caused by A. baumannii. A more positive result was seen when these 
combination were used against S. maltophilia with ≥ 50% synergy produced. A 
previous investigation showed that when leaf extracts, containing polyphenols 
were used with ciprofloxacin against various gram-positive and gram-negative 
bacteria, a synergy rate of ≥ 60% was found (Aiyegoro, Afolayan and Okoh, 
2009). With epicatechin a potential for a duel treatment exists as against 4 of 
the 7 isolates of A. baumannii synergy was shown. Further investigations to 
check the synergy should be undertaken.  
 
Epicatechin had mixed synergy, antagonism and indifference with all other 
antibiotics against A. baumannii and S. maltophilia. Although results by Martins 
et al., (2011) saw synergy of epicatechin and Ciprofloxacin against Salmonella 
strains, against A. baumannii and S. maltophilia mixed results were seen, with 
synergy and indifference occurring more times than antagonism. Overall this 
research cannot totally confirm or disagree with data previously presented by 
Stapleton et al., (2004) where it was found that due to the lack of a gallate 
group epicatechin lacks synergy with antibiotics. 
 
The mechanisms of the synergy between polyphenols, particularly theaflavin 
and clinical antibiotics are not yet fully understood. However, previous studies 
have proposed that synergy when using polyphenols and flavanols could be 
due to inhibition of β-lactamases (Zhao et al., 2002) and destabilisation of the 
bacterial cytoplasmic membrane (Wang et al., 2010). 
 
From the antibiotic testing it was clear that the isolates with the highest level of 
antibiotic resistance were S. maltophilia. In future cases, the effectiveness of 
antibiotic therapies to treat infections caused by this bacterium will continually 
decline. To combat its high level of resistance, combination therapies could be 
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used to slow the rate of resistance and also increase the effectiveness of the 
treatment. Antibiotics often have problematic side effects, using lower dosages 
in combination with other natural compounds such as polyphenols could be the 
answer.  
 
It is clear from the results in this study that synergy and antagonism between 
polyphenols and clinical antibiotics varies between bacterial genera and isolates 
of species. If clinical antibiotic/polyphenol combinations were to be considered 
as treatments for bacterial infections, there is an obvious requirement for 
preliminary susceptibility testing beforehand, in order to check the efficacy as is 
done with all infections in hospitals. 
 
3.7 Conclusions 
In the preliminary testing the antibacterial effects of epigallcatechin gallate, 
theaflavin and mixed theaflavins against A. baumannii, MRSA and VRE are 
very encouraging and hopefully in the future these compounds will be used as 
an alterative to antibiotics for treating infections. This investigation found 
epigallocatechin gallate to be the most effect antimicrobial agent against all 
three organisms. However, the results from theaflavin show it is an antimicrobial 
agent that is as effective against A. baumannii organisms as many antibiotics. 
Mixed theaflavins showed a higher antibacterial effects against VRE but less of 
an effect against A. baumannii than pure theaflavin. This, like in the case of 
epicatechin and epigallocatechin gallate could be due to the extra gallate group 
possessed by theaflavin 3,3’-digallate and theaflavin monogallate in the 
theaflavins mixture. Mixed theaflavins also showed a significant antibacterial 
effect against MRSA. Further tests will need to be performed to identify other 
organisms that theaflavin and mixed theaflavins can be used as antimicrobial 
agents against. 
 
Due to the large difference between the antibacterial effects of epicatechin and 
epigallocatechin gallate a further investigation using labelled epicatechin and 
epigallocatechin gallate could be performed to identify how the compounds 
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interact within bacteria. This would lead to increased knowledge and potential 
modifications to the compounds to further increase their beneficial properties.  
 
When testing the antibacterial effects of flavonoids against hospital isolates it 
was found that not only did theaflavin show significant antibacterial activity, but 
also this activity was significantly increased with the addition of epicatechin. As 
epicatechin had no obvious antibacterial action by itself, the results showed that 
a synergistic effect had occurred. It is the first time that the synergy between 
theaflavin and epicatechin has been reported against hospital isolates of 
A. baumannii, MRSA and S. maltophilia. These research findings are significant 
in that the results could be used to develop new antimicrobial combination 
therapies to treat infections caused by resistant microorganisms. This study 
also reported for the first time the MICs of theaflavin and a 
theaflavin:epicatechin combination against hospital isolates of S. maltophilia. 
Future work should look into the mechanisms behind the synergy and 
undertake time-kill studies against not only S. maltophilia but also against other 
important hospital pathogens. 
 
This is also believed to be the one of the first reports providing evidence of 
synergistic or antagonistic properties of theaflavin, epicatechin and EGC when 
used with antibiotics against clinical isolates of MRSA, A. baumannii and 
S. maltophilia. From the results in this study it is clear that there is huge 
potential for polyphenols to be used in combination with traditional antibiotics to 
treat infections caused by resistant organisms. Further work is recommended to 
investigate the mechanisms underlying the interactions of these antimicrobial 
agents and their effectiveness in the wider bacterial spectrum. Further work 
should also be conduction in vivo to understand if the poor bioavailability of 
polyphenols affects the synergistic benefits seen in vitro, if this can be 
overcome and if this limits their medial uses to topical treatments.  
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Chapter 4 
Production of theaflavin in a microreactor and the 
road to integrated antimicrobial testing 
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4.1 Introduction 
4.1.1 Synthesis of theaflavin 
Theaflavin is a flavanoid found in black tea where it is produced during a 
fermentation process (Tu et al., 2005) and was first identified in 1954 
(Cartwright and Roberts). The synthesis of theaflavin does however occur 
naturally in the leaves of Camellia sinensis in the presence of oxygen and is 
often due to leaf damage (Jhoo et al., 2004). The reaction involves the coupling 
of the polyphenols epicatechin and epigallocatechin (Wang et al., 2008). 
Epicatechin and epigallocatechin are found abundantly in green tea where no 
oxidation has taken place. The reaction by which the enzyme polyphenol 
oxidase (PPO), catalyses the coupling of the two polyphenols is shown in figure 
93.  
 
Figure 93. Enzyme coupling of epicatechin and epigallocatechin to form 
theaflavin 
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Polyphenol oxidase is found in the cell vacuoles of the leaf cells and is released 
when disruptions in the intracellular compartments occur (Subramanian et al., 
1999). In the food industry this occurs due to the maceration of the tea leaves 
leading to fermentation (UK tea council, 2011). Polyphenol oxidases, 
sometimes known as catechol oxidases are members of the type-3 copper 
proteins (Klabunde et al., 1998), which contain a dinuclear copper centre. An 
example of the structure of a catechol oxidase can be see in figure 94.  
 
Figure 94. Example of the structure of catechol oxidase (Klabunde et al., 1998)  
 
 
The mechanism is similar to that of a wound response, where it is proposed that 
via one of its oxygen atoms, the polyphenol substrate binds to the second 
catalytic copper of the enzyme. In the co-oxidation reaction the benzotropolone 
skeleton in theaflavin is formed from the selected pair of catechins when 
polyphenol oxidase is present. In this reaction one catechin must have a ortho-
dihydroxyphenyl structure and the other a vic-trihydroxyphenyl moiety (Sang et 
al., 2004). The same polyphenol oxidase enzyme will also catalyse reactions 
between different polyphenols to form compounds other than theaflavin. 
Another example of this is when epigallocatechin gallate and epicatechin form 
theaflavin-3’-gallate in the presence of oxygen and polyphenol oxidase (Jhoo et 
al., 2004). The enzyme has been found to be relatively unstable and is 
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susceptible to conditions of extreme pH and high temperatures that can lead to 
its inactivation (Sharma, Bari and Singh, 2008).  
 
The production of theaflavin has been previously undertaken in batch reactions 
(Peng and Yao, 2009; Sang et al., 2004; Jhoo et al., 2004), in which epicatechin 
and epigallocatechin where reacted with polyphenol oxidase in the presence of 
oxygen. In the work by Peng and Yao (2009) a crude polyphenol oxidase 
extract from tea leaves was used producing a theaflavin yield of 43 %. In the 
study by Jhoo et al., (2004) polyphenol oxidase was extracted from banana 
flesh and produced a poor theaflavin yield of 15.2 %. However, in the reaction 
described by Sang et al., (2004) horseradish peroxidase was used to form the 
same theaflavin product producing a yield of 25 %.  
 
In previous research, polyphenol oxidase has been immobilized to try and 
increase the yield of theaflavin produced and to prolong the use of the enzyme 
(Sharma, Bari and Singh, 2008; Tu et al., 2005). In the work by Sharma, Bari 
and Singh (2008) a cellulose matrix is used to immobilize the PPO. By doing 
this the group claims that the enzyme still had 94 % activity after being used on 
15 occasions and that an 85 % conversion of catechins to theaflavins was 
achieved. In the method by Tu et al., (2005) the PPO was immobilized on a 
microporous metal plate to form a membrane that was cross-linked using 
glutaraldehyde. In this study the enzyme still had 73 % activity after 75 days of 
storage at 4 °C. Another method of PPO immobilization is to use a cross-linked 
chitosan-SiO2 gel. This has previously been undertaken to remove aqueous 
phenol (Shao, Ge and Yang, 2007). In this study it was shown that unlike free 
PPO, the immobilized PPO could be easily removed from the reaction solution 
and be reused for a subsequent reaction.  
 
Due to the increased surface area to volume ratio in a microreactor, transferring 
this reaction to a continuous flow system could potentially increase the low 
yields often obtained in this biosynthesis.  
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4.1.2 Synthesis of deuterium labelled theaflavin 
The synthesis of deuterated compounds is very important as their application in 
toxicological, metabolite and mechanistic studies is vital for the understanding 
of how compounds interact with living organisms. Whilst the synthesis of 
theaflavin and deuterated theaflavin has been demonstrated in batch (Peng and 
Yao, 2009), yields are often poor and reactants can be expensive. By 
transferring the reaction to a microreactor, the synthesis could be made more 
efficient and linked to bioreactors for direct use. As in the study by Peng and 
Yao (2009) the methodology to produce deuterated theaflavin would be the 
same as that to produce theaflavin with the substitution of one of the substrates 
one has been previously labelled (Figures 20 and 21). A schematic of the 
proposed reaction can be seen in figures 95.  
 
Figure 95. Enzyme coupling of deuterated epicatechin and epigallocatechin to 
form deuterated theaflavin 
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4.1.3 Enzymatic synthesis in a microreactor 
There have been many reports of the use of enzymes in microreactors for 
biosynthesis with the enzymes usually requiring immobilization in a support 
layer or monolith (Kataoka et al., 2009), although this is not always the case 
(Shaw et al., 2010). 
 
In the literature there are 3 mains methods for immobilizing enzymes in 
microreactors (Asanomi et al., 2011) these are: 
• Enzyme immobilization within microchannels 
• Immobilization of enzymes on the microchannel surface 
• Enzyme immobilization onto a membrane within the microchannel 
 
The method of immobilizing enzymes within channels has proven to be very 
successful producing high enzyme reactivities (Matsuura et al., 2011). One 
example of this is the use of a silica monolith to immobilize enzymes. In this 
method, enzymes such as proteases have been successfully immobilized and 
proven to give significantly higher conversion rates than corresponding 
reactions in batch (Kawakami et al., 2005). Another example of this type of 
immobilization was shown in research by Kataoka et al., (2009), where a lipase 
was immobilized onto a mesoporous silica support layer. This study found that 
the immobilized enzyme was stable and showed good activity over a 24 hour 
period whilst catalysing continuous ester hydrolysis reactions.  Although using a 
monolith has advantages, many other groups use an agarose complex to which 
the enzyme is bound. Previous research, hydroxylase enzymes were 
immobilized onto Ni-NTA agarose beads and loaded into a microreactor 
(Srinivasan et al., 2004). In this study it was found that reaction times were not 
only short but the volumes and enzyme amounts required for the reaction were 
far smaller than in conventional methods. 
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The method of immobilizing enzymes onto the surface of a microreactor have 
been shown to be advantageous as they use the large surface area present in a 
microreactor system (Asanomi et al., 2011; Schwarz, Thompson and Nidetzky, 
2009). An example of this method is using fused silica to immobilize the enzyme 
required onto the surface of the microreactor via Ni-complex (Miyazaki et al., 
2005). In the research by Miyazaki et al., (2005) enzymes were immobilized on 
microcapillary walls. This was found to be an efficient methodology for 
immobilization. Whilst covalent immobilization of enzymes to silanised walls of 
PDMS microchannels by coupling with glutardialdehyde (Thompson, Polt and 
Nidetzky, 2007) has also been described. Using this method a reaction 
conversion of 60 % was achieved and although not high it presents an 
alternative method of immobilization. 
 
The final method of immobilizing enzymes in a microreactor is with the use of a 
membrane within a microchannel. This method has shown to be easy to 
prepare but less efficient than other methods of immobilization (Asanomi et al., 
2011). In a previous study a functional polymer membrane was produced in a 
microreactor via a interfacial polycondensation reaction. The research showed 
that creating this membrane allowed horseradish peroxidase to be immobilized 
on one side of the surface allowing chemical transformations to take place.  
 
Each of the methods discussed, can produce more efficient and cost effective 
reactions and also allow a greater level of safety than reactions performed in 
batch models. The use of enzymes in microreactors can also lead to a higher 
degree of reaction control and a continuous-flow output (Haswell and Skelton, 
2000). 
 
4.1.4 Antibacterial testing and monitoring cell viability and metabolites 
4.1.4.1 Polyphenol metabolites 
Polyphenols have been shown to have strong antimicrobial effect against many 
different bacteria. However, as bacteria can metabolise polyphenols, studies 
into their metabolites are of great interest. A large amount of polyphenol 
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metabolism occurs in the gut where bacteria produce enzymes, which lead to 
their hydrolysis (Bokkenheuser, Shackleton and Winter, 1987). Enzymes such 
as alpha-rhamnosidase and beta-galactosidase produced by bacteria hsuch as 
Bacteriodes spp have been reported to hydrolyse polyphenols such as naringin 
and hesperidin. This metabolism has been reported to alter their bioavailability 
and thus can reduce or increase their beneficial effects (Rooks and Garrett, 
2001). Previous research has also shown these metabolites to be more 
effective than their parental compounds giving rise to greater anti-platelet 
activity and cytotoxicity (Kim et al., 1998). 
 
Using a labelled theaflavin would therefore allow clear identification of 
metabolites and give an indication to how the polyphenol was metabolised. 
Previous studies have used labelled polyphenols to determine metabolites. An 
examples of this is in the research study by Kohri et al., (2001) where labelled 
epigallocatechin gallate (EGCG) was synthesized in batch to discover its 
metabolic rate in rats. In this study is was discovered that the major excretion 
route of EGCG was in bile within 4 hours of dosing with polyphenol. Metabolites 
in this investigation were identified by HPLC where 4‘,4‘ ‘-di-O-methyl-EGCG 
was found to make up 14.7% of the administered EGC.  
 
4.1.4.2 Antibacterial testing  
Antibacterial testing is used to identify new antibacterial agents and the 
susceptibility to pathogens to antibacterial agents. Determining the minimum 
inhibitory concentrations (MICs) of antimicrobials is very important in order to 
judge their effectiveness. MICs are considered as the ‘gold standard’ for 
determining antimicrobial susceptibilities (Andrews, 2001) and methods range 
from the disc diffusion method to the microtiter assay. 
 
New methods include assays in microfluidic devices for detection of bacteria 
(Qiu et al., 2009) and determining susceptibilities (Chen et al., 2010). These 
methodologies are more rapid and cost efficient that traditional methods with a 
greater range of control. Using a microreactor, antibiotic susceptibilities of 
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bacterial biofilms can also be monitored. In a recent study (Kim et al., 2010) 
minimum biofilm eradication concentrations were determine against biofilms of 
Pseudomonas aeruginosa and were reported as higher than those for the 
minimum inhibition of planktonic cells. In a different study the use of plug-based 
microreactor technology for the rapid detection antibiotic susceptibilities 
(Boedicker et al., 2008) has been described. In this investigation droplets with a 
volume of nano litres were created to isolate individual bacteria and where 
confinement increases bacterial cell density eliminating any incubation step 
usually required. Due to this and the high throughput multiple tests were 
performed simultaneously giving a more rapid result.  
 
These new microfluidic methodologies could generate data regarding 
antimicrobial susceptibilities significantly faster than current methods. 
 
4.1.5 Monitoring cell viability 
There are a variety of methods to determine bacteria cell viability. The detection 
of biomarkers for cell viability related to transcriptional activity is one method of 
determining bacterial cell death (Kort et al., 2008). In the investigation by Kort et 
al., (2008) indentification of transcriptional biomarkers and the rapid expression 
of small numbers of competence genes were monitored after lethal heat stress. 
These competence genes are known to be active in the stationary growth 
phase of bacteria. The presence of living cells was indicated due to the 
expression of these genes after the heat treatment. 
 
Another simple method of monitoring bacterial cell viability is the use of 
resazurin (Borra et al., 2009). Resazurin is a blue dye with the ability to show 
cell viability as in the presence of NADPH + H+ it is reduced to resorufin 
compound pink in colour (Figure 96). As the transfer of elections from NADPH 
to resazurin occurs due to the presence of mitochondrial enzymes, it can 
indicate active metabolism and the presence of living cells. Its use was first 
described in 1963 by Moyer and Campbell, to show bacterial counts in milk. 
This method has been used in several studies to show the presence of living 
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bacteria. In a investigation by Perrot et al., (2002) resazurin was successfully 
used to indicate living bacteria on the cornea of pigs.  
 
Figure 96. Breakdown of resazurin to resorufin 
 
 
In another study using resazurin the dye was found to provide a good indication 
if living cells in a biofilm (Sandberg et al., 2009). However, it was also 
mentioned that the quality of the stains was dependant on the biofilm 
concentration and the length of the staining procedure. 
 
4.1.6 Links between synthesis and antimicrobial testing 
Microreactor synthesis of antimicrobial agents could be potentially linked to 
bioreactors for the determination of antimicrobial susceptibility. This would offer 
a rapid method of reporting antibacterial activities of newly synthesized 
compounds. Not only would this increase the speed of determining 
susceptibilities but also the amount of control would be greater. 
  
A proposed link between synthesis of labelled theaflavin and antimicrobial 
testing/monitoring of bacterial metabolites can be seen in figure 97. In this 
proposed methodology, a 3 step process of producing deuterium labelled 
theaflavin or 1 step process of synthesizing non-labelled theaflavin is linked to a 
bioreactor containing bacteria trapped on a matrix/filter to enable antimicrobial 
testing, monitoring of the markers of cell death/cell viability or the determination 
of polyphenol metabolites. 
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Figure 97. Proposed integration between microreactor synthesis and antimicrobial testing/monitoring of bacterial metabolites  
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4.2 Aims 
The aims of this investigation are to produce theaflavin and deuterated 
theaflavin in a biochemical microreactor. A further aim of this study was to link 
the deuterium synthesis with immobilized bacteria to monitor 
metabolites/markers of cell death and to create a method linking synthesis to 
antibacterial testing. 
 
4.3 Methods 
4.3.1 Method 1 for the microreactor synthesis of theaflavin  
4.3.1.1 Preparation of substrates 
It was decided that a 10 mM solution of epicatechin and epigallocatechin would 
be suitable, as this concentration was found to be a good balance between 
sufficient quantity of reactants and their solubility in 10% methanol. To prepare 
the substrates 0.0291 g of epicatechin and 0.0304 g of epigallocatechin were 
weighed out and then dissolved in 1mL of methanol in a 15 mL tube. To this 9 
mL of distilled water was added and then vortexed for 5-10 minutes to mix. The 
tube was then wrapped in aluminium foil to prevent light degradation and was 
kept in the fridge. The catechins prepared were used within 1 day of production 
to minimise any risk of degradation/oxidation. 
 
4.3.1.2 Tea leaf catalyst preparation 
1.5 mL of H2O was added to 0.1 g of fresh green tea leaf in a pestle and then 
ground for 30 seconds using a mortar. When the leaf was ground into a paste 
the mixture including any liquid was transferred to an Eppendorf tube. The tube 
was placed in a centrifuge and spun at 4000 rpm for 1 minute. Excess 
supernatant was then removed from the tube using a syringe and disposed off 
leaving a pellet. To remove as many natural catechins naturally found in the tea 
leaf the pellet was washed with distilled water three times by adding 1.5 mL of 
distilled water to the tube, vortexing and centrifuging at 4000 rpm before 
removing the excess water. The remaining cleaned residue was stored at 4°C 
and used within 24 hours. 
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4.3.1.3 Microfluidic reactor design and preparation 
A specific chip was designed and produced in glass, which would take in to 
consideration various factors including loading of a green tea catalyst and also 
adequate flow of catechins across the catalyst giving sufficient time for their 
reaction and oxidation. 
The chip designed had a reservoir to allow the green tea catalyst to be added 
which can be seen in figure 98. The channels in the microreactor had a 
diameter of 60 µm 
 
Figure 98. Microreactor design used for the synthesis of theaflavin 
 
 
Capillary tubes were attached to the 1.5 mm inlet and outlet holes using an 
adhesive epoxy resin. These were left to dry for approximately 1 hour. When 
dry, 1 mL of H2O was pushed through each capillary to check for any 
blockages. After this, 0.01 g of green tea catalyst was added to the reservoir via 
its inlet using a micro spatula and a needle. It was important that the catalyst 
covered the whole width of the reservoir to ensure reactants would pass across 
it. A PDMS plug was then placed into the reservoir inlet and sealed in place with 
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an adhesive epoxy resin and left to dry for at least 1hr. The PDMS bung allowed 
gas exchange to occur which was required for the reaction. 
 
4.3.1.4 Experimental setup 
Before any reaction took place the microreactor channels were washed with 1 
mL of methanol and 1 mL of H2O. This was to allow any residual catechins or 
potential theaflavin naturally in the leaf to be washed away. The 
epicatechin:epigallocatechin stock solution was then flowed across the fresh 
green tea catalyst in the microreactor at either 1, 2, 5 or 10 µL/min using a 
BabyB syringe pump. A photograph showing the reaction setup can be seen in 
figure 99. All products were collected into a syringe and using a separating 
funnel washed and extracted into ethyl acetate. The ethyl acetate layers were 
dried over MgSO4 and concentrated under reduced pressure. 
 
Figure 99. Experimental setup for the microreactor synthesis of theaflavin  
 
 
To determine if theaflavin had been produced, product samples were analysed 
using MS. MS was set to look at compounds in the range of 150 – 800 m/z. The 
elutants used were acetonitrile and water in a 50:50 ratio flowing at 800 µL/min. 
Each sample was analysed within 1 hour of the completed experiment and 
chromatographs were produced from the data acquired using LCQ tune 
software. 
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4.3.2 Method 2 for the microreactor synthesis of theaflavin 
4.3.2.1 Preparation of substrates 
A 10 mM solution of epicatechin and epigallocatechin was prepared by 
dissolving 0.0291 g of epicatechin and 0.0304 g of epigallocatechin in 1 mL of 
acetone in a 15 mL tube. To this 9 mL of distilled water was added then 
vortexed for 5 minutes to mix. The tube was then wrapped in aluminium foil to 
prevent light degradation and was kept in the fridge. The catechins prepared 
were used within 1 day of production to minimise any risk of 
degradation/oxidation. 
 
4.3.2.2 Crude polyphenol oxidase preparation 
Into a pestle, 1 g of tea leaves were added and then ground for 30 seconds 
using a mortar. The leaf paste created was transferred to a Büchner funnel 
containing filter paper were it was washed with acetone (5 mL x 5) to remove 
any polyphenols (Sharma, Bari and Singh, 2009). The remaining powder was 
resuspended in 5 ml of PBS (phosphate buffered saline) and centrifuged at 
10000 rpm for 20 minutes. The clear supernatant was removed and washed 
with ice-cold acetone (Jhoo et al., 2004). The solution was centrifuged again at 
10000 rpm for 20 minutes to precipitate out the proteins. The pellet was washed 
with PBS and the crude polyphenol oxidase (PPO) extract was dried under 
reduced pressure for 1 hour to give a beige powder. This was stored at 4°C and 
used within 24 hours. The PPO extract was mixed with silica gel 40 purchased 
from SigmaAldrich, UK (particle size 75-150 µm, pore size 40 Å) prior to loading 
into the microreactor. 
 
4.3.2.3 Experimental setup for method 2 
For this reaction a single inlet/outlet glass microreactor was used with a central 
reservoir (Figure 98). To prepare the microreactor the side of the reservoir next 
to the outlet channel was packed with a piece of moist cotton wool and the side 
nearest the inlet channel was packed with the crude polyphenol oxidase power. 
The cotton wool was used to eliminate the risk of any crude polyphenol power 
being washed out of the reservoir. The reservoir opening was then sealed with 
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a PDMS bung. The bung was kept in place using epoxy resin, which was 
allowed to harden for up to 1 hour before the reaction took place.  
 
In the reaction 1 mL of the 10 mM epicatechin:epigallocatechin stock solution 
was flowed across the through the microreactor at room temperature. The 
reaction was controlled by a syringe pump at a flow rate of 5 µL/min. All 
products were collected into a syringe. Using a separating funnel, products 
were washed and extracted into ethyl acetate (4 x 5 mL). The ethyl acetate 
layers were dried over MgSO4, filtered and concentrated under reduced 
pressure. The resulting brown/orange oil was weighed before being analysed 
via MS and 1H-NMR.  
 
4.3.3 The microreactor synthesis of deuterium labelled theaflavin 
In this reaction 0.0292 g of deuterium labelled epicatechin produced via the 2-
step method described in chapter 3 (Figures 20 and 21) and 0.0304 g of 
epigallocatechin was dissolved in 10 mL of water in a 10 mL tube and vortexed 
for 5-10 minutes to mix.  
 
To prepare the microreactor (Figure 98) the reservoir was packed with crude 
polyphenol oxidase as in method 2 of theaflavin production and was sealed with 
a PDMS bung with was glued in place with epoxy resin. 
 
In the reaction 2 mL of the 10 mM epicatechin-d:epigallocatechin stock solution 
was flowed across the through the microreactor at room temperature. The 
reaction was controlled by a syringe pump at a flow rate of 5 µL/min. All 
products were collected into a syringe. Using a separating funnel, products 
were washed and extracted into ethyl acetate (4 x 5 mL). The ethyl acetate 
layers were dried over MgSO4, filtered and concentrated under reduced 
pressure. The resulting brown/orange oil was weighed before being analysed 
via MS and 1H-NMR. 
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4.3.4 Method for linking microreactor synthesis products to a method for 
antibacterial testing  
4.3.4.1 Experimental setup 
The setup for the synthesis was the same as method 2 for the synthesis of 
theaflavin, with the exception that the outlet tube was connected to a second t-
shaped microfluidic device (Figure 100). In the second device the theaflavin 
products were passed with iso-buffer, also controlled by a syringe pump at a 
flow rate of 5 µL/min increasing the overall flow rate to 10 µL/min. The outlet of 
this device was connected to a membrane filter, which had been inoculated with 
100 µL of a 0.5 MacFarland solution of Acinetobacter baumannii NCTC 13485 
in 900 µL of nutrient broth. Acinetobacter baumannii was prepared based on the 
method by Moosdeen et al., (1988) by taking 1 large colony of A. baumannii 
using a flamed loop and adding to 2 mL of peptone water. This was vortexed 
and turbidity was measured using a spectrophotometer. A reading of 0.345 nm 
was recorded and using the dilution chart 25 µL of the broth was added to 5 mL 
of sterile distilled water giving a 0.5 MacFarland solution. The reaction products 
were flown across the cell membrane for 1, 2, 4 or 6 hours. This meant bacterial 
cells were exposed to either 600 µL (0.15 mg), 1200 µL (0.3 mg), 2400 µL (0.6 
mg) or 3600 µL (0.9 mg) of theaflavin.  
 
The setup was repeated but a solution of sterile water containing no 
epicatechin:epigallocatechin was flowed through microreactor 1. This acted as a 
control. All apparatus/reagents were sterilized with ethanol/autoclaved prior to 
use. 
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Figure 100. Microreactor - microbial filter setup 
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4.3.4.2 Cell viability testing 
After treatment with synthesized theaflavin at each time period, the filter 
containing the bacteria was washed with sterile PBS buffer. The cells were then 
back flushed out of the filter into an Eppendorf tube containing 1 mL of PBS 
buffer. The tube was centrifuged at 4000 rpm for 5 minutes (Sarker et al., 2007). 
The supernatant was removed and the pellet was re-suspended in 1 mL of PBS 
buffer before the sample was centrifuged again at 4000 rpm for 5 minutes. The 
supernatant was removed and the pellet was again re-suspended in 1 mL of 
peptone water.  This procedure was repeated for the control samples for each 
time period used.  
 
To each well of a 24 well pate 500 µL of PBS buffer was added. To each of the 
first 8 wells 100 µL of the bacterial suspension from the 20 minutes theaflavin 
treatment was added. To each of the next 8 wells 100 µL of the bacterial 
suspension from the 20 minutes treatment with water was added. To the final 8 
wells 100 µL of sterile peptone water was added. To test the viability of the 
bacteria, 100 µL of resazurin (0.05 %) was added. Any colour changes in the 
wells were noted and photographs were taken at 0, 3 and 10 minutes post 
resazurin addition.  
 
4.4 Results and discussion 
4.4.1 Results of method 1 for the microreactor synthesis of theaflavin  
The results from this reaction show that the crude leaf catalyst was successful 
in producing theaflavin, although it was unsuccessful at producing the 
polyphenol alone. From the MS data (Figure 101) the peak from theaflavin can 
be seen at 566.02 m/z. Whilst the mass of theaflavin is 564.13 g, the higher 
reading is likely to occur due to an interaction with 2 hydrogen atoms from the 
elutant. From the MS spectra it can be clearly seen that multiple peaks not 
associated with theaflavin exist. These could be from polyphenols and other 
compounds from the leaf catalyst that were not originally washed away during 
preparation. It is clear that the polyphenol oxidase catalyst required for this 
reaction should be extracted from the tea leaves to avoid multiple peaks from 
other compounds present. This would increase the purity of the theaflavin 
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produced enabling the continuous flow microreactor to be directly linked to a 
bioreactor for antimicrobial/metabolic testing. 
 
 
Figure 101. MS spectra for method 1 products of microreactor theaflavin 
synthesis 
 
 
4.4.2 Results method 2 for the microreactor synthesis of theaflavin 
The results from method 2 of the microreactor synthesis of theaflavin show that 
the reaction was successful in producing theaflavin. The brown/orange oil (0.05 
g) collected was a good indicator that theaflavin was present in the product. 
From the MS spectra peaks can be seen at 292.2 m/z, 566.09 m/z and 567.21 
m/z. The peak at 292.2 m/z represents epicatechin that has not been used up in 
the reaction, the peaks at 566.09 and 567.21 represent theaflavin. The peaks 
values for these compounds are slightly higher than their mass values, which 
could be due to proton interaction from the elutant or the presence of a natural 
carbon/oxygen/hydrogen isotope e.g. Carbon13. Due to the relevant abundance 
of the peak at 566.09 m/z it is clear that the reaction was very successful and 
that almost all epicatechin was used up. However, as a small peak for 
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epicatechin is present one might have expected that a peak for epigallocatechin 
also to be present. Its absence suggests it was either completely oxidised 
during the reaction or decomposition has taken place. When the products were 
analyzed by 1H’NMR they appeared to be of high purity due to the absence of 
any peaks from epicatechin or epigallocatechin.  
 
Figure 102. MS spectra for method 2 products of microreactor theaflavin 
synthesis
  
 
The 1H’NMR data below compares well with previous data (Peng and Yao, 
2009; Tu et al., 2005; Jhoo et al., 2004) with variations most likely being due to 
the different deuterated solvents used in the 1H’NMR method. 
 
1H’NMR (400 MHz, CD3CD) 7.97 (1H, s), 7.84 (1H, s), 7.21 (1H, d, J=8.4Hz, H-
5’), 7.33 (1H, s), 6.05 (1H, d, J=2.2 Hz), 6.02 (1H, d, j=2.2 Hz),  5.99 (1H, d, 
j=2.2 Hz), 5.96 (1H, d, J=2.2 Hz), 5.63 (1H, s), 4.90 (1 H, s), 4.46 (1H, m), 4.37 
(1H, m), 2.89 (2H, d, J=3.4 Hz), 2.81 (1H, s), 2.79 (1H, s). 
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From this data it is clear that the production of theaflavin in a microreactor is 
successful using a crude polyphenol oxidase on silica gel. The estimated yield 
from this reaction is approximately 88% with this being higher than previous 
batch reactions from the production of theaflavin (Jhoo et al., 2004). It is 
believed this is the first occasion where theaflavin has been produced in a 
microfluidic system. The result also shows that the reaction is successful 
enough to use products directly from the continuous flow system to a biological 
system for metalbolic/antibacterial testing.  
 
4.4.3 Results for the microreactor synthesis of d-labelled theaflavin 
From the results of this reaction it is clear that the synthesis of deuterium 
labelled theaflavin was not successful. From the MS spectra one major product 
peak was visible at 566.09 m/z, which was the same as in the production of 
non-labelled theaflavin. This indicates that the addition of a deuterium did not 
occur. Results from the 1H’NMR shows an almost identical spectra to that of 
non-labelled theaflavin. This confirmed that the reaction was unsuccessful. The 
possible reason for this is that proton transfer occurred during the enzymatic 
reaction resulting in the loss of deuterium from the labelled epicatechin 
substrate.  
 
1H’NMR (400 MHz, CD3CD) 7.97 (1H, s), 7.85 (1H, s), 7.21 (1H, d, J=8.4Hz, H-
5’), 7.33 (1H, s), 6.05 (1H, d, J=2.2 Hz), 6.01 (1H, d, j=2.2 Hz),  5.99 (1H, d, 
j=2.2 Hz), 5.96 (1H, d, J=2.2 Hz), 5.63 (1H, s), 4.90 (1 H, s), 4.46 (1H, m), 4.37 
(1H, m), 2.89 (2H, d, J=3.4 Hz), 2.81 (1H, s), 2.79 (1H, s). 
 
From this result it can be concluded that the labelled epicatechin produced in 
chapter 1 (Figures 20 and 21) is not stable enough to be used in the synthesis 
of deuterium labelled theaflavin. Future studies could investigate the synthesis 
of a more stable deuterium labelled theaflavin.  
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4.4.4 Results for monitoring bacterial metabolites from deuterated 
theaflavin 
As the reaction to synthesize deuterium labelled theaflavin was unsuccessful it 
was decided to carry out metabolic studies due to time restraints. Further 
investigations could use a more stable deuterium labelled theaflavin to monitor 
bacterial metabolites or those produced by labelled epicatechin. 
 
4.4.5 Results for linked microreactor theaflavin synthesis-cell viability 
testing 
The results from this investigation indicate that the continuous flow reactor and 
antibacterial testing has been successful. Acinetobacter baumannii isolates 
collected after 1 hour of treatment with theaflavin from the continuous flow 
reactor turned from blue at 0 minutes post resazurin addition to light purple after 
10 minutes to purple/pink after 15 minutes (Figure 103). This indicates that the 
amount of theaflavin the bacteria were exposed to (0.15 mg in 600 µL over 1 
hour), from the microreactor, was insufficient to cause cell death. The control 
isolates exposed to no theaflavin turned pink after 10 minutes post reazurin 
addition indicating, metabolism of the resazurin to resorufin by live bacterial 
cells. The control wells containing no cells remained blue indicating no 
metabolism of resazurin. 
 
The bacterial isolates collected after 2 hours of treatment with theaflavin from 
the continuous flow reactor also turned from blue at 0 minutes post resazurin 
addition to light purple after 10 minutes to dark purple/pink after 15 minutes 
(Figure 104). This is also evidence to suggest that the amount of theaflavin the 
bacteria were exposed to (0.3 mg in 1200 µL over 2 hours), from the 
microreactor, was insufficient to cause cell death. The control isolates exposed 
to no theaflavin also turned pink after 10 minutes post reazurin addition, 
indicating metabolism of the resazurin to resorufin by live bacterial cells. The 
control wells containing no cells remained blue indicating no metabolism of 
resazurin. 
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A. baumannii isolates collected after 4 hours of treatment with theaflavin from 
the continuous flow reactor remained blue from 0 minutes post resazurin 
addition to 15 minutes post resazurin addition (Figure 105). This is evidence to 
suggest that the amount of theaflavin from the microreactor that the bacteria 
were exposed to (0.6 mg in 2400 µL over 4 hours) was sufficient to cause cell 
death. However, the control isolates exposed to no theaflavin turned pink after 
10 minutes post reazurin addition indicating metabolism of the resazurin to 
resorufin by live bacterial cells. The control wells containing no cells remained 
blue indicating no metabolism of resazurin.  
 
A. baumannii isolates collected after 6 hours of treatment with theaflavin from 
the continuous flow reactor remained blue from 0 minutes post resazurin 
addition to 15 minutes post resazurin addition (Figure 105). This is evidence to 
suggest that the amount of theaflavin from the microreactor that the bacteria 
were exposed to (0.9 mg in 3600 µL over 60 minutes), was sufficient to cause 
cell death. However, the control isolates exposed to no theaflavin turned pink 
after 10 minutes post reazurin addition indicating metabolism of the resazurin to 
resorufin by live bacterial cells. The control wells containing no cells remained 
blue indicating no metabolism of resazurin. 
 
From the results of this investigation a minimum concentration of theaflavin to 
cause inhibition of A. baumannii NCTC 13485 was found to be 0.6 mg/2400 µL 
over 4 hours. The continuous exposure to theaflavin most likely accumulated in 
the bacterial cells leading to their inhibition after 4 hours. It is believed that this 
study demonstrates for the first time the link between enzymatic synthesis and 
antibacterial testing and unlike traditional methods such as the disc diffusion 
and the microtiter assay, is a faster and less expensive methodology. 
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Figure 103. Resazurin assay to test for cell viability for A. baumannii treated for 1 hour with synthesized theaflavin. Photographs taken at 
0, 3, 10 and 15 minutes after the addition of resazurin. In each image the first 8 wells contain treated cells (T), the second 8 wells contain 
untreated cells (U) and the last 8 wells contain no cells (N). 
         T          U             N              T        U              N 
 
         T             U     N    T        U              N 
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Figure 104. Resazurin assay to test for cell viability for A. baumannii treated for 2 hours with synthesized theaflavin. Photographs taken 
at 0, 3, 10 and 15 minutes after the addition of resazurin. In each image the first 8 wells contain treated cells (T), the second 8 wells 
contain untreated cells (U) and the last 8 wells contain no cells (N). 
        T          U              N     T        U       N 
 
          T              U     N    T        U            N 
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Figure 105. Resazurin assay to test for cell viability for A. baumannii treated for 4 hours with synthesized theaflavin. Photographs taken 
at 0, 3, 10 and 15 minutes after the addition of resazurin. In each image the first 8 wells contain treated cells (T), the second 8 wells 
contain untreated cells (U) and the last 8 wells contain no cells (N). 
          T            U               N    T        U           N 
 
      T           U                N    T      U          N 
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Figure 106. Resazurin assay to test for cell viability for A. baumannii treated for 6 hours with synthesized theaflavin. Photographs taken 
at 0, 3, 10 and 15 minutes after the addition of resazurin. In each image the first 8 wells contain treated cells (T), the second 8 wells 
contain untreated cells (U) and the last 8 wells contain no cells (N). 
         T           U               N     T        U           N 
 
         T             U     N                T      U           N 
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4.5 Conclusions 
In conclusion it has been shown in this study that the synthesis of theaflavin in a 
microreactor is not only possible, but produces high yields of pure product when 
compared to batch methods. It is believed that this is the first occasion that the 
microreactor enzymatic synthesis of theaflavin has been reported.  
 
Due to the stability of deuterium labelled epicatechin during the enzymatic 
synthesis of theaflavin is has been shown that this methodology although 
successful for producing theaflavin, could not produce labelled theaflavin and 
thus metabolic investigations did not take place. Future methodologies to 
produce more stable deuterium labelled epicatechin in a microreactor should be 
investigated to hopefully lead to a stable microreactor synthesized deuterium 
labelled theaflavin for use in metabolic studies. 
 
In this study it has also been shown that microreactor synthesis and 
antimicrobial susceptibility methodologies can be linked to produce more rapid 
chemical production to antimicrobial testing times. It is believed it is the first 
occasion where methods for continuous flow microreactor synthesis and 
antimicrobial testing have been linked together.  
 
In future research the bacterial filter will be integrated into a microfluidic device 
and linked to the microreactor for compound synthesis. This would give a fully 
integrated system to conduct antibacterial testing. There is also potential for 
linking the system for microreactor synthesis with other rapid antimicrobial 
determining methods such as bioluminescence. 
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Chapter 5 
Overall conclusions and future research 
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5.1 Overall PhD conclusions 
Overall the research conducted in this PhD was very successful. The direction 
of the PhD changed from the original goal of monitoring human metabolites 
from polyphenols into something more clinically important, involving the 
antibacterial actions of polyphenols and how they can interact with current 
antibiotics.  
 
The results proved that microreactors are an important tool in chemical 
synthesis. Using a microreactor system the research in this thesis has shown 
for the first time that not only could epicatechin could be labelled with 
deuteratium, but this could be achieved efficiently, producing very high yields.  
 
Research from this thesis has also shown for the first occasion that the 
enzymatic synthesis of theaflavin could be achieved in a microreactor. This 
method could be a cost effective alternative for producing small quantities of 
theaflavin for laboratory testing. The method developed is a more rapid 
approach of acquiring small quantities of theaflavin that of extracting theaflavin 
directly from tea leaves.  
 
Antimicrobial results in this thesis show the potential use of polyphenols as 
antimicrobial agents against clinical isolates of antibiotic resistant bacteria. For 
the first occasion the antimicrobial synergy between polyphenols against 
problematic bacteria has been observed. The research here has also shown, 
that synergy can occur between polyphenols and antibiotics. This results in the 
resistance of bacteria to specific antibiotics being reversed and the antibiotic 
again having some clinical use. 
 
The major difficulties encountered, concerned the labelling of epicatechin and 
theaflavin using a microreactor. Difficulties included blocking of the microreactor 
from precipitating products and bubbles, solvent selection, which needed to be 
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carefully chosen as compound solubility and reaction yields were massively 
effected by the solvent and stability of materials produced. 
 
5.2 Future work 
Future research projects might investigate the production of epicatechin with a 
more stable deuterium label, which can withstand the coupling reaction with 
epigallocatechin to form deuterium labelled theaflavin. A possible reaction 
scheme could be based on that used in figure 24, with the use of different 
protecting groups to allow for a more stable reaction when using Dess-Martin 
reagent. The production of stable, labelled theaflavin is still an important task 
that should be undertaken to discover more about how it is metabolised in the 
human body and how its toxicological effects differ between human and 
bacterial cells. 
 
Future work might investigate the immobilization of polyphenol oxidase on a 
monolith for the microreactor synthesis of theaflavin. This might increase the 
efficiency of the reaction and also enable a more commercial system. 
 
Futher work concerning the antimicrobial effects of polyphenols might 
investigate the mechanisms behind the synergism between polyphenols and 
polyphenols and antibiotics. Future work might also investigate if the synergism 
between polyphenols occurs when they are used purely as antioxidants.  If this 
is the case they could be used as additives into various products including 
suncreams, to prevent DNA damage caused by free radicals resulting from sun 
exposure. 
 
Further work might continue to develop the system to link a chemical synthesis 
microreactor and a bioreactor for the growth of bacteria. The end goal would be 
to produce a commercial system for rapid antimicrobial testing. 
